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Abstract 
Topical glucocorticoids (GCs), such as hydrocortisone (HC), are the main drugs used 
to treat inflammatory skin conditions including eczema and psoriasis, but their long-
term use is limited by the onset of side effects such as skin thinning, impairment of 
wound healing and systemic metabolic dysfunction. For this reason, there is a 
substantial need for new compounds with the same anti-inflammatory effects but 
fewer adverse effects. Previous studies have suggested 5-tetrahydrocorticosterone 
(5-THB) as a new, more selective anti-inflammatory compound; this steroid is a 
metabolite of the major endogenous GC in rodents, corticosterone (B). Preliminary 
data indicated that 5-THB may be as effective as HC in reducing mouse irritant 
dermatitis, but without the local or systemic side effects of HC. The aim of this thesis 
is to investigate the mechanisms through which 5-THB delivers more selective 
anti-inflammatory effects, with the hypothesis that 5-THB influences distinct 
signalling pathways from those of B. 
A mouse model of irritant dermatitis induced by topical application of croton oil on 
the ear was developed, and the anti-inflammatory properties of 5-THB were 
analysed, in comparison with those of B, after 6 and 24 hours of treatment. In 
inflamed tissue, B reduced tissue oedema and cell infiltration at both time points; in 
contrast, 5-THB did so at 24 but not 6 hours, at a dose five-fold higher than B. 
Real-time analysis at 24 hours showed that B and 5-THB similarly reduced the 
croton oil-induced increase of transcripts of genes encoding vascular and cellular 
adhesion molecules. Interestingly, while B did not affect the abundance of transcripts 
of the anti-inflammatory gene Dusp1, 5-THB increased it in croton oil-treated ears, 
suggesting a different mechanism of action between 5-THB and B. The experiment 
was repeated with the injection of the glucocorticoid receptor (GR) antagonist 
RU486; RU486 relieved the effect of B on swelling but did not attenuate the anti-
inflammatory effects of 5-THB, indicating a further important difference between 
the two steroids. 
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Angiogenesis is fundamental for the healing process, and it is known that topical 
GCs impair wound healing in part by inhibiting angiogenesis; for this reason, the 
effects of 5-THB on the formation of new vessels, in comparison with B, were 
tested in a mouse model of inflammatory angiogenesis induced by sub-cutaneous 
implantation of polyurethane sponges. 5-THB, at equipotent doses to B for the 
reduction of macrophage infiltration, inhibited angiogenesis to a lesser extent than its 
precursor. In addition, B had systemic effects in that it lowered adrenal gland 
weights, whereas 5-THB did not. Histological analysis suggested that while B 
inhibits formation and maturation of new vessels, 5-THB may affect only the 
former process. Molecular analysis showed that B reduced the abundance of 
transcripts of the majority of the tested genes involved in inflammation, angiogenesis 
and tissue remodelling, but 5-THB had more selective effects. 
Ex vivo studies in mouse bone marrow-derived macrophages stimulated with LPS 
showed that 5-THB inhibited release of pro-inflammatory cytokines in a weaker 
manner compared with B. This inhibition was partially prevented by co-incubation of 
RU486 with B but not with 5-THB. In in vitro studies, molecular pathways 
activated by B and associated with adverse side effects were only weakly activated 
by 5-THB. In particular, 5-THB only weakly induced phosphorylation of GR, and 
activation of expression of GC-responsive reporter plasmids and endogenous 
metabolic genes. Interestingly, 5-THB reduced B-induced trans-activation of some 
of these genes.  
In summary, 5-THB effectively reduces skin inflammation, but, unlike B, has only 
moderate anti-angiogenic properties, and weakly activates molecular mechanisms 
associated with adverse metabolic side effects. Most importantly, its action may not 
be due to activation of GR. This work opens the intriguing possibility that GCs work 
through mechanisms not yet investigated, and this may be of pivotal importance in 
the search for new safer anti-inflammatory compounds.  
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ELISA Enzyme-linked immunosorbent assay 
FACS Fluorescence-activated cell sorting 
FBS Fetal bovine serum 
FKBP51 FK506 binding protein 51 
GC/GCs Glucocorticoid/s 
GGT1 Gamma-glutamyltransferase 1 
GILZ Glucocorticoid-induced leucine zipper 
GR Glucocorticoid receptor 
GRE Glucocorticoid response element 
GRE1/2s Glucocorticoid response element half sites 
GRU Glucocorticoid responsive unit 
h Hour 
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H2O2 Hydrogen peroxide 
HEK293 Human embryonic kidney cell line 
HSD Hydroxysteroid dehydrogenase 
HSP Heat shock protein 
ICAM-1 Intercellular adhesion molecule-1 
IFN Interferon 
IGFBP Insulin-like growth factor-binding protein 1 
IL Interleukin 
INF Interferon 
IκB Inhibitor of NF-κB 
JNK c-Jun N-terminal kinases 
KD Knocked down 
kDa kilo Dalton 
KO Knock-out 
LBD Ligand-binding domain 
LPS Lipopolysaccharide 
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MAPK Mitogen-activated protein kinase 
MCP Monocyte chemoattractant protein 
MCP-1 Monocyte chemoattractant protein-1 
MKP MAPK phosphatase 
MMP Matrix metalloproteinase 
MMTV Mouse mammary tumour virus 
MW Molecular weight 
NaOH Sodium hydroxide 
NF-κB Nuclear factor-kappa B 
NO Nitric oxide 
PBS Phosphate buffered saline 
PCR Polymerase chain reaction 
PDGF Platelet-derived growth factor 
PECAM-1 Platelet endothelial cell adhesion molecule-1 
PNMT Phenylethanolamine N-methyltransferase 
POMC Pro-opiomelanocortin 
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RT-PCR Reverse transcriptase polymerase chain reaction 
STAT Signal transducer and activator of transcription 
TAT Tyrosine aminotransferase 
TAT Tyrosine aminotransferase 
THBS Thrombospondin 
TIMP Tissue inhibitor of metalloproteinase 
TLR Toll-like receptor 
TNF Tumor necrosis factor 
Tris Trisma base 
VCAM-1 Vascular cell adhesion molecule-1 
VEGF Vascular endothelial growth factor 
VEGFR2 Vascular endothelial growth factor receptor 2 
WT Wild-type 
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Ring the bells that still can ring  
Forget your perfect offering  
There is a crack in everything  
That's how the light gets in.  
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Chapter 1: Introduction 
1.1 Glucocorticoids 
1.1.1 General considerations 
Glucocorticoids (GCs) are steroid hormones produced by the adrenal cortex, and the 
name glucocorticoid (glucose + cortex + steroid) derives from their role in the 
regulation of the metabolism of glucose, their synthesis in the adrenal glands and 
their steroidal structure. They are necessary for the maintenance of the body’s 
homeostasis, and their production is controlled by the hypothalamic-pituitary-adrenal 
(HPA) axis in a circadian and ultradian manner; furthermore, their synthesis and 
release is increased in response to a variety of emotional or physical stress (Oakley 
and Cidlowski 2013). GCs have a wide range of functions, including the regulation 
of metabolism, cell growth and differentiation; they also affect mood and cognitive 
function and exert potent anti-inflammatory and immunosuppressive actions (Blum 
and Maser 2003; Ismaili and Garabedian 2004). Because of their role in suppression 
of the inflammatory response, synthetic derivatives of GCs, such as 
prednisone/prednisolone, dexamethasone and budesonide, are among the most 
effective anti-inflammatory drugs in use and they are widely prescribed to treat acute 
and chronic inflammatory diseases, autoimmune diseases, organ transplant rejection 
and malignancies of the lymphoid system (McDonough, Curtis et al. 2008; Revollo 
and Cidlowski 2009; Oakley and Cidlowski 2010; Oakley and Cidlowski 2013). In 
addition, their anti-proliferative and anti-angiogenic properties have also been 
exploited for the treatment of cancer (Vilasco, Communal et al. 2011; Oakley and 
Cidlowski 2013). Unfortunately, due to their broad range of physiological actions, 
the therapeutic benefit of glucocorticoids is limited by severe side effects such as 
osteoporosis, abdominal obesity, glaucoma, growth retardation in children, 
hypertension, muscle wasting, impairment of wound healing and skin thinning 
(Walker 2007; Lowenberg, Stahn et al. 2008; Oakley and Cidlowski 2010). An aim 
of the pharmaceutical industry is to develop safer drugs with anti-inflammatory 
effects and, at the same time, fewer side effects. 
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1.1.2 Glucocorticoid structure and synthesis 
Glucocorticoids have a common structure made up of 21 carbon atoms, and each 
carbon is numbered in a standard way. Like other steroids, they are derived from the 
cyclopentanoperhydrophenanthrene structure which is formed by three cyclohexane 
rings and a single cyclopentane ring, labelled A, B C and D respectively (Figure 1.1). 
GCs, together with mineralocorticoids and some sex steroids, belong to the group of 
hormones called adrenocorticosteroids; they are synthesized by and released from the 
zona fasciculata of the adrenal cortex. They derive from the same precursor, the lipid 
cholesterol, which is produced by the adrenal gland or taken from the blood stream. 
Cortisol (F) is the main active GC in humans, while in rodents it is corticosterone (B) 
since the enzyme 17-hydroxylase is not present in the adrenal gland (Luu-The, 
Pelletier et al. 2005). Pathways involved in the synthesis of F, B and the main 
mineralocorticoid hormone aldosterone, are shown in Figure 1.2 and take place in 
mitochondria. Their synthesis begins with the conversion of cholesterol to 
pregnenolone by the enzyme 20, 22-desmolase located in the inner mitochondrial 
membrane; subsequently, reactions of dehydrogenation and hydroxylation take place 
and form deoxycorticosterone (DOC) through the intermediate production of 
progesterone. In the zona fasciculata of the adrenal cortex, some of the progesterone 
is hydroxylated via the action of 17-hydroxylase and therefore converted to 
cortisol. In humans, both the zona fasciculata and glomerulosa can convert DOC to 
B; formation of aldosterone from B occurs exclusively in the zona glomerulosa 
thanks to the presence of the enzyme aldosterone synthase (Freel and Connell 2004). 
 
Figure 1.1 Structure of glucocorticoids. A, B and C, cyclohexane rings; D, cyclopentane 
ring; 1-21, standard numbering for the carbon atoms. 
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Figure 1.2 Common pathways of synthesis of glucocorticoids and aldosterone. 17-OH 
= 17-hydroxylase, 3-HSD = 3-hydroxysteroid dehydrogenase. Adapted from (Freel and 
Connell 2004). 
1.2 The glucocorticoid receptor (GR) 
Natural and synthetic GCs exert their actions via the glucocorticoid receptor (GR), a 
steroid hormone receptor that belongs to the nuclear receptor superfamily of 
transcription factors. Consistent with the wide-ranging effects of GCs, the receptor is 
ubiquitously expressed and necessary for life (Cole, Blendy et al. 1995). GCs can 
also bind the mineralocorticoid receptor (MR) with a similar affinity to aldosterone; 
however, the presence of the enzyme 11-hydroxysteroid dehydrogenase type 2 
(11-HSD 2) in tissues targeted by aldosterone (such as the kidney) prevents the 
binding of GCs to MR by converting the active form (F or B) into the inactive one 
(cortisone or 11-dehydrocorticosterone) (Seckl and Walker 2001). 
1.2.1 GR isoforms   
GR is derived from a single gene (NR3C1) (Evans 1988) found in the chromosome 5 
in humans and composed of nine exons, but alternative splicing gives rise to different 
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isoforms (Figure 1.3, page 30) The exons 2-9 represent the protein-coding exons, 
whilst exon 1 is the 5’ untranslated region; exons 2-8 are always present in the GR 
messenger RNA (mRNA), while the exon 9 has two isoforms,  and , alternative 
splicing of which give rise to two mature isoforms of transcripts: splicing of exon 9 
produces the major GR isoform, GR which is translated to generate a protein with 
a unique sequence of 50 amino acids (aa) at its C-terminus; splicing of exon 9 gives 
rise to the variant GR, which is translated to assemble a protein with a distinct 15 
aa-long tail at the C-terminus. GR (777 aa-long) is the main active isoform as it 
binds GCs, it translocates to the nucleus and it regulates gene expression (Rhen and 
Cidlowski 2005; Oakley and Cidlowski 2013). GR (742 aa-long) does not bind 
GCs, and it seems to function as an inhibitor of GR; however, in recent years, 
evidence has been accumulated in favour of a role of this isoform in regulating 
directly gene expression; in effect, despite agonists not being reported to bind GR, 
the antagonist RU486 does bind this GR isoform and regulates its transcriptional 
activity (Lewis-Tuffin, Jewell et al. 2007; Kelly, Bowen et al. 2008; Kim, Oh et al. 
2008; Kino, Manoli et al. 2009). Other minor isoforms derived from alternative 
splicing are also present, for example GR which contains an insertion of a single 
arginine, binds GCs and DNA to a similar extent to GR but its gene regulation 
profile is different. Its expression is associated with glucocorticoid resistance in 
many cancers (Thomas-Chollier, Watson et al. 2013). Two others are GR-A and GR-
P which lack the region of the receptor responsible for ligand binding and, as a 
consequence, lack the ability to bind GCs. While little is known about GR-A, GR-P 
seems to be the main variant expressed in GC-insensitive cancers (Gaitan, DeBold et 
al. 1995; Krett, Pillay et al. 1995; de Lange, Segeren et al. 2001). This scenario is 
made even more complex considering that GR exists in 8 different isoforms (A, B, 
C1, C2, C3, D1, D2, D3) produced by alternative translation initiation sites in exon 
2; all these isoforms bind GCs and interact with target genes, however GR-C 
isoforms are the most biologically active, while GR-D isoforms are the least 
(Kadmiel and Cidlowski 2013). It is predicted that 8 translational isoforms may exist 
also for GR (Kino, Su et al. 2009). The above-mentioned diversity in GR 
transcription and translation give rises to differential responses to GCs; indeed, their 
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effects also depend on which isoforms are present, and in which proportion, in a 
particular cell type. 
1.2.2 GR localization and structure 
In the absence of its ligand, GR resides in the cytoplasm forming a complex with 
chaperonic molecules composed of heat shock protein Hsp90, 70, 23 and other 
regulatory factors (Pratt and Toft 2003; Baschant and Tuckermann 2010). Upon 
ligand binding the chaperonic complex is dissociated and the exposure of specific 
nuclear localization sequences triggers its translocation to the nucleus, where it 
regulates gene expression. All members of the nuclear receptor superfamily, 
including GR, are modular proteins composed of an N-terminal trans-activation 
domain (NTD), a central DNA-binding domain (DBD), and a C-terminal ligand-
binding domain (LBD). Moreover, a flexible region called the “hinge region” 
connects the DBD and LBD (Figure 1.3). The most conserved region in the family is 
the DBD that contains two zinc finger motifs that recognize and bind DNA 
sequences, called glucocorticoid-responsive elements (GREs). The NTD domain 
possesses a strong transcriptional activation function (AF1) which binds several co-
regulators and components of the transcription machinery. The LBD forms a 
hydrophobic pocket for binding glucocorticoids and it consists of 12 -helices and 
four -sheets (Bledsoe, Montana et al. 2002). Another activation function that 
interacts with co-regulators in a ligand-dependent way is present in the LBD; 
moreover, two nuclear localization signals termed NL1 and NL2 are localised at the 
border DBD/hinge region and within the LBD respectively. 
1.2.3 Post-translational modification of GR 
Functional diversity in GR activity is achieved by alternative splicing taking place at 
the transcriptional level, as mentioned above, but also by modifications occurring at 
post-translation level. Among the latter, phosphorylation of serine and threonine 
residues is one of the most important in determining GR activity, influencing nuclear 
translocation and GR degradation. The most characterised GR phosphorylation sites 
in humans are serines (S113, S134, S141, S143, S203, S211, S226 and S404). Some 
of these sites (i.e. S211) are phosphorylated in a ligand-dependent manner, while for 
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others this modification is ligand-independent; indeed, it has been recently 
demonstrated that S134 is phosphorylated by p38 MAPK in a hormone-independent 
fashion (Rhen and Cidlowski 2005; Galliher-Beckley, Williams et al. 2011). In the 
past few years it has become clear that the outcome of GR phosphorylation in terms 
of gene expression is residue- and cell type-dependent, and it is likely due to the fact 
that phosphorylation of different sites induces differential conformation changes and 
recruitment of co-activators (Webster, Jewell et al. 1997; Wang, Frederick et al. 
2002). In effect, phosphorylation of sites such as S211 and S203 has been 
demonstrated to stimulate the GC-induced up-regulation of target genes, while 
phosphorylation of S226 and S404 has been shown to inhibit it. One example of the 
former is the induction by GCs of the gene Igfbp1, which is dependent on 
phosphorylation of S211 and consequent recruitment of the co-activator MED14 
(Poolman, Farrow et al. 2013). Other types of post-translational modifications are 
binding of ubiquitin induced by GCs such as cortisol, which promotes the 
degradation of GR via the proteasome, and sumoylation which refers to the 
attachment of small molecules similar to ubiquitin (Rhen and Cidlowski 2005). 
Recent studies suggest that the latter increases the transcriptional activity of GR (Le 
Drean, Mincheneau et al. 2002; Holmstrom, Van Antwerp et al. 2003). Furthermore, 
acetylation has also been reported on lysines 494 and 495 with consequent 
impairment of the ability of GR to inhibit the action of the transcription factor NF-
B (Barnes 2009). In figure 1.3 a simplified representation of the characteristics and 
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Figure 1.3 Schematic representation of the transcriptional origin of the human 
glucocorticoid receptor (hGR), its isoforms and modular structure. DBD = DNA-
binding domain; H = hinge region; LBD = ligand-binding domain; AF = activation function; 
P, Ub, Sumo = phosphorylation, ubiquitinilation and sumoylation sites; mRNA = messenger 
RNA. In the representations of the hGR gene and mRNA numbers identify exons, while in 
hGR protein they refer to the amino-acidic residues. Adapted from (Rhen and Cidlowski 
2005). 
1.2.4 GR signalling 
GR modulates gene expression and cellular behaviour via several genomic and non-
genomic mechanisms. The former refers to modulation of gene expression by 
interaction of GR with DNA, and is dependent on GR translocation to the nucleus 
and is observable within 15-150 min from cellular exposure to GCs (Haller, Mikics 
et al. 2008). The classical model is based on binding of a hormone-bound GR dimer 
to GREs in the regulatory regions of target genes. However, in spite of the fact that 
GRs are expressed in most tissues, the set of regulated genes differs in each tissue; 
this observation gave rise to the necessity for a revision of this classical model, and 
to the discovery of different mechanisms through which GR achieves selective, 
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differential control of gene expression, including recruitment of co-regulators and 
chromatin remodelling (Biddie 2011; Biddie, John et al. 2011). 
1.2.4.1 Activation of gene transcription  
Ligand-bound GR can activate gene transcription by direct binding to so-called 
simple GRE. Based on studies of a number of GREs, a consensus GRE has been 
defined as a 15-bp imperfect palindrome, 5’-GGTACAnnnTGTTCT-3’ (Nordeen, 
Suh et al. 1990), in which the 3’ half is the most conserved and the 5’ one is highly 
variable (Barnes 1998). The base positions are numbered as -6,-5,-4,-3,-2,-
1,nnn,1,2,3,4,5,6, where n is any nucleotide; it has been shown that only certain 
nucleotides are critical, and these are found at position -3, -2, +2, +3 and +5. GR 
forms dimers as two GR monomers bind in turn to the 3’ and then 5’ half sites 
allowing interactions of the dimerisation domains in the DBD (Tsai, Carlstedt-Duke 
et al. 1988; Dahlman-Wright, Siltala-Roos et al. 1990; Hard, Dahlman et al. 1990; La 
Baer and Yamamoto 1994). The 3-bp spacer between the two half-sites is a 
requirement for cooperative binding of the two monomers (Dahlman-Wright, Wright 
et al. 1991). Such simple GREs were found in a number of genes, such as 
Serine/Threonine protein kinase (Sgk1) and 2-adrenergic receptor, and they are a 
good match to the consensus. However, GC induction of these genes is only 
moderate. In several genes, binding of GR to GREs is not sufficient, and recruitment 
of other transcription factors (TFs) to adjacent binding sites is required. These 
composite regulatory sequences are often referred to as glucocorticoid responsive 
units (GRUs), as the different elements are spatially and functionally clustered. 
These units differ as the identity of recruited TFs varies in a cell and gene-specific 
manner (De Bosscher, Beck et al.; So, Chaivorapol et al. 2007; Baschant and 
Tuckermann 2010), and also in the number of elements in each unit, ranging from 4 
to 10. Examples of TFs are C/EBP, FoxA, CBP/p300, P/CAF and steroid receptor 
co-activator (SRC)-1 (Smoak and Cidlowski 2004). In contrast to simple GREs, 
induction of genes can be increased up to 23-fold in response to GCs, as in the case 
of the carbamoylphosphate-synthetase (CPS) gene. More modest induction is 
obtained for metabolic genes such as Phenylethanolamine N-Methyltransferase 
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(Pnmt), tyrosine aminotransferase (Tat) and phosphoenol pyruvate carboxykinase 
(Pepck) in the liver. 
GR can also bind the DNA as a monomer at so-called GRE half-sites (GRE1/2) 
(Segard-Maurel, Rajkowski et al. 1996); however, additional elements are required to 
mediate a glucocorticoid response. These elements may be represented by other TFs, 
by multiple GRE1/2s or classical GRE. An example of the first case is the induction 
of the phenylalanine hydroxylase gene, while for the activation of the hCYP3A gene, 
GR binds to two GRE1/2s which enable GCs responsiveness. In the mouse 
mammary tumour virus (MMTV) there are four GRE1/2s, and GR binds as 
homodimer to the two proximal ones. Interestingly, it is suggested that this kind of 
dimerisation, happening on directly repeated GRE1/2s, is mediated by the 
dimerisation function found in the LBD (Aumais, Lee et al. 1996). In the case of the 
thyrotropin-releasing hormone gene, however, a combination of a GRE and a 
GRE1/2 operates (Hovring, Matre et al. 1999).  
Induction of transcription by GR mainly targets genes controlling metabolism (e.g. 
gluconeogenesis), however, this mechanism also explains the increased expression of 
anti-inflammatory genes. An example is induction of the anti-inflammatory cytokine 
IL-10. It is known that GR binds as a monomer to the transcription factor STAT3 
(Signal Transducer and Activator of Transcription 3) increasing its transcriptional 
activity to promote expression of IL-10 in human B cells (Unterberger, Staples et al. 
2008), while transcription of the anti-inflammatory protein IkB results from GR 
dimers interacting with specific sequences within its promoter. In addition, studies 
have shown that GCs can modulate the rate of degradation of mRNAs through trans-
activation of key genes involved in the process, therefore decreasing the expression 
of pro-inflammatory cytokines in an indirect manner; for example, in the case of 
TNF there is some evidence that GR may act by inducing expression of the protein 
tristetraprolin (TTP), which in turn causes TNF mRNA destabilization and 
degradation (Smoak and Cidlowski 2004; Clark 2007). 
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1.2.4.2 Repression of gene transcription 
GR is also able to inhibit transcription, and this behaviour has long been regarded as 
the reason behind the majority of the anti-inflammatory properties of GCs. The main 
mechanism involved is called “trans-repression” where GR hinders the action of pro-
inflammatory DNA-bound transcription factors, such as Nuclear Factor-kB (NF-B) 
and Activator Protein-1 (AP-1), thus preventing transcription of pro-inflammatory 
genes. NF-B is a complex of several units, in which the heterodimer formed by the 
proteins p65/p60 is the predominant. GR binds to the p65 subunit resulting in the 
inhibition of gene transcription mediated by NF-B. AP-1 instead, is formed by a 
member of the Jun family (c-Jun, v-Jun, Jun-B or Jun-D) homodimerised with 
another member from the same family or heterodimerised with a Fos protein (c-Fos, 
Fos-B, Fra-1 or Fra-1), and GR interacts with the Jun member inhibiting its action to 
promote pro-inflammatory gene transcription (Smoak and Cidlowski 2004). Another 
trans-repression mechanism involves GR competing with co-activators of NF-B, 
such as cAMP response element binding protein (CREB)-binding protein (CBP) and 
steroid receptor co-activator (SRC)-1, required for NF-B maximal activity 
(Schoneveld, Gaemers et al. 2004); furthermore, GR has been reported to recruit co-
repressors, for example GRIP, and this represents another mechanism whereby the 
receptor can down-regulate gene expression (Uhlenhaut, Barish et al. 2013). Another 
way in which GR inhibits transcription is by binding to so-called negative GREs 
(nGREs) which harbour sequences more variable than those of classical positive 
GREs (Schoneveld, Gaemers et al. 2004). Examples of this mechanism are inhibition 
of genes such as the Corticotropin Releasing Hormone (CRH), 
ProOpioMelanoCortin (POMC) and osteocalcin, where GR binds mainly as 
monomer on the promoter of the former, and as trimer on the latter (Drouin, Sun et 
al. 1993). This mechanism is associated with some of GC-induced side effects. 
While this description of how GR can interact with the DNA and regulate gene 
expression is based on experimental data, the story might be much more complex. 
Indeed, a recent paper claims that while up to 20% of GR-mediated repression is 
accounted for by GR found at tethered and nGREs sites in lipopolysaccharide (LPS)-
stimulated macrophages, around 20% of GR-induced genes contain the same DNA 
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motifs; this makes predictions about GR effects on gene expression based on the 
classification of these motifs unreliable (Uhlenhaut, Barish et al. 2013). As our 
knowledge of the DNA sequences targeted by GR deepens, an even more complex 
scenario is emerging, and this scenario seems to suggest that GR itself may not be 
the central player when it comes to determining the fate of its own actions. Indeed, 
GR may be more of a co-actor than the protagonist of what happens at gene level; for 
instance, epigenetic regulators and chromatin context may be other players as 
important as GR itself (Uhlenhaut, Barish et al. 2013). 
1.2.4.3 Non-genomic glucocorticoid actions 
GR also regulates cell physiology via non-genomic mechanisms, which are mediated 
by cell signalling proteins and do not involve gene transcription (Stojadinovic, 
Sawaya et al. 2013). While genomic actions of GR are relatively slow, the non-
genomic effects take place in a shorter time frame, within 5 minutes or even seconds 
from cell exposure to GCs (Haller, Mikics et al. 2008). Among them, the interaction 
of GR with signalling pathways such as JNK and the T cell receptor signalling 
complex, may explain the modulation of pro-inflammatory gene expression 
(Baschant and Tuckermann 2010), while the release of chaperone proteins, such as 
SRC, upon ligand binding, are shown to contribute to other rapid glucocorticoid 
effects (Croxtall, Choudhury et al. 2000). Indeed, SRC interacts with lipids in the 
plasma membrane blocking the production of one of the precursors to inflammatory 
molecules (prostaglandin and leukotrienes), namely arachidonic acid (Croxtall, 
Choudhury et al. 2000); this is therefore a non-genomic mechanism that contributes 
to the anti-inflammatory effects of GCs (Alangari 2010). Some other signalling 
pathways influenced by GCs are those involving MAPKs, cAMP-PKA, PI3K and 
PLC-PKC proteins, in a variety of tissues such as neuronal and erythroid cells 
(Croxtall, Choudhury et al. 2000; Song and Buttgereit 2006; Stellacci, Di Noia et al. 
2009; Stojadinovic, Sawaya et al. 2013). Some other non-genomic effects are 
thought to be mediated by interactions with G protein-coupled receptors (GPCRs) 
and the membranous GR (mGR), distinct from the classical cytosolic GR (Orchinik, 
Murray et al. 1991; Gametchu, Chen et al. 1999; Bartholome, Spies et al. 2004; Song 
and Buttgereit 2006; Roozendaal, Hernandez et al. 2010; Stojadinovic, Sawaya et al. 
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2013). Furthermore, GCs have been shown to bind other receptors associated with 
membranes such as the gamma-aminobutyric acid (GABA) receptors (Majewska 
1987) and the low affinity glucocorticoid receptors (LAGs) (Roszak, Lefebvre et al. 
1990). GCs also alter the fluidity of the plasma and mitochondria membrane by 
interacting with lipids. At high concentrations they have been shown to be 
incorporated into membranes and, as a consequence, to influence the activity of 
proteins associated with them, such as cation channels (Stahn, Lowenberg et al. 
2007); these effects may explain in part the anti-inflammatory properties of GCs in 
that they may lead to inhibition of production of ATP (Song and Buttgereit 2006).  
1.3 Glucocorticoid metabolism 
The concentration of circulating and local GCs within tissues, and reaching GR, is 
regulated by several mechanisms. The release into the blood stream and the 
availability of GCs is controlled mainly by the HPA axis and by the corticosteroid-
binding globulin (CBG) in serum, while locally, within tissues and cells, the presence 
of metabolizing enzymes (such as 11-hydroxysteroid dehydrogenases) is the major 
factor influencing the ratio between the amount of active and inactive GCs (Kadmiel 
and Cidlowski 2013). 
The principal pathway responsible for the metabolism of glucocorticoids takes place 
in the liver. Here, F and B, and their inactive forms cortisone and 11-
dehydrocorticosterone, are metabolised via A-ring reductions by A-ring reductases, 
including 5- and 5-reductases and 3-hydroxysteroid dehydrogenase (3-HSD).  
5- and 5-reductases catalyse the irreversible trans or cis reduction of the double 
bond at position 

, forming trans 5- and cis 5- dihydro-glucocorticoids. These 
reactions are followed by another reduction by 3-HSD to produce 5- and 5- 
tetrahydro metabolites. This two-step A-ring reduction is common to other steroids 
including aldosterone, progesterone and androgens (e.g. testosterone). As the main 
interest of this PhD project is the compound 5-tetrahydrocorticosterone (5-THB), 
which is the product of the activity of 5-reductases, Figure 1.4 gives a 
representation of these metabolic reactions without including the 5-metabolites or 
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enzymes. Furthermore, I will focus my attention principally on describing the 
characteristics of the 5-reductase enzymes, and introduce here some important 
findings regarding mice in which the activity of one of the isoforms of 5-reductases 
has been disrupted. 
 
Figure 1.4 The A-ring reduction pathways for cortisol and corticosterone. 5Rs = 5-
reductases, 3HSDs = 3-hydroxysteroid dehydrogenase. Adapted from (Nixon, Upreti et 
al. 2011). 
1.3.1 5-Reductases 
There are two isozymes of 5-reductases that catalyse 5-reduction of steroids: the 
type I isozyme (5-R1) is expressed principally in the liver of mice, and in the liver, 
kidney and skin of humans; the type II isozyme is expressed principally in the genital 
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tract, including prostate, of mice, and in the liver, prostate and skin of humans. The 
genes encoding these enzymes (SRD5A1 and SRD5A2) are members of a larger 
family of genes containing -reductase domains, one of the other members being 
encoded by the gene SRD5A3, which has a less clear role. Conservation in the C- and 
N-terminal regions between it and 5-R1 and 5-R2 supports a role for resultant 
SRD5A3 protein in the metabolism of steroids. However, to date, this has not been 
demonstrated for GCs (Nixon, Upreti et al. 2011). 
1.3.2 5-Reduced glucocorticoids 
Many studies have demonstrated that 5-reduced metabolites of other hormones 
such as testosterone, aldosterone and progesterone, are potent agonists of the same 
receptor as their precursor (Siiteri and Wilson 1974; Rapkin, Morgan et al. 1997). 
Recently, McInnes et al. showed that 5-reduced GCs are able to bind to and 
activate GR, while the 5-reduced metabolites are inactive as agonists of GR 
(McInnes, Kenyon et al. 2004). In addition, there is evidence suggesting that the 5 
and 5-reduction of GCs is increased in human obesity (Andrew, Phillips et al. 
1998), and that 5-R1 expression and activity is increased in obesity in rodents and 
humans (Fraser, Ingram et al. 1999; Rask, Olsson et al. 2001; Livingstone, McInnes 
et al. 2005). As a result, the rates of glucocorticoid inactivation are increased in the 
liver in obesity and this may be a compensatory protective mechanism ameliorating 
metabolic risk factors. My supervisors’ group recently has shown that mice 
harbouring a disrupted 5-R1 enzyme have an adverse metabolic phenotype 
(Livingstone, Barat et al. 2014). However, although one might expect that increased 
glucocorticoid action in the liver as a result of 5-R1 deficiency would reduce 
susceptibility to intrahepatic inflammation in these mice, 5-R1 knockout mice had 
an exaggerated response to liver injury with carbon tetrachloride. The explanation for 
this disassociation between metabolic and inflammatory effects may lie in the 
intrinsic properties of the 5-reduced glucocorticoid product of 5-R1.  
My supervisors’ group has shown that the product of the 5-R1 pathway, 5-THB, 
possesses selective actions. Indeed, this compound can bind to GR with equivalent 
affinity to B (McInnes, Kenyon et al. 2004) and stimulate nuclear translocation of the 
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receptor (Yang 2009); however, it activates metabolic genes (requiring conventional 
GR dimerisation) only very weakly in vitro and not at all in vivo, while retaining the 
ability to potently suppress cytokine release (believed to be executed via GR 
monomers) from activated macrophages and also to invoke immune suppression 
(McInnes, Kenyon et al. 2004; Yang, Nixon et al. 2011). Furthermore, 5-THB is 
able to reduce skin inflammation (irritant eczema, also known as dermatitis) induced 
by croton oil in mice with a potency comparable with that of hydrocortisone (HC); 
most importantly though, 5-THB does not cause skin thinning or systemic 
metabolic changes (e.g. increase of circulating insulin) triggered instead by 
application of HC (Livingstone, Sykes et al. 2014). Therefore 5-THB has the 
properties of an attractive anti-inflammatory drug, and dissection of the distinct 
pathways activated by B or 5-THB may provide further opportunities for selective 
modulation of inflammatory versus metabolic processes. 
1.4 The effects of glucocorticoids on the immune 
system 
Inflammation is a vital response of the organism to infection, injury and tissue stress 
aimed to restore and maintain body homeostasis. In the past few decades it has been 
recognised that, in addition to already well-characterised inflammatory diseases, for 
instance asthma, dermatological manifestations (dermatitis, psoriasis) and 
inflammatory bowel disease just to name a few, a greater number of pathological 
conditions than previously thought are characterised by persistent and unresolved 
inflammation, such as obesity, type II diabetes, atherosclerosis and cancer. As a 
consequence, the quest for anti-inflammatory agents has intensified (Uhlenhaut, 
Barish et al. 2013). Importantly, this search is characterised by the need to find safer 
compounds than those available on the market. Among the most effective and 
prescribed anti-inflammatory drugs in use are synthetic derivatives of GCs. As 
mentioned above, the anti-inflammatory effects of these compounds are mediated 
largely, but not exclusively, through regulation of gene expression in a variety of 
ways; however, to truly understand why they are so powerful and important anti-
inflammatory agents, both from a physiological and a clinical point of view, we need 
to consider how broadly they affect the immune response and its cellular 
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components. Below, a summary is given of their effects on the different cell types of 
the immune system. 
GCs act by influencing the behaviour of nearly all immune cells (reviewed in Zen, 
Canova et al. 2011). Regarding their effects on the T cell population, they inhibit the 
production of the cytokine IL-2 through a mechanism affecting the activity of 
transcription factors involved in its expression. In addition, they also work through 
non-genomic mechanisms and inhibit signalling pathways by binding to membrane 
GR rather than the cytoplasmic form; as an example they block the transduction of 
important signals through the T-cell receptor (TCR) by inhibiting the protein kinase 
Scr and causing its dissociation from TCR. Furthermore, they interfere with 
pathways required for proliferation of T cells by disrupting calcium-dependent 
signalling cascades. They also induce pro-apoptotic effects in T helper cells 1 and 2 
by binding to GC receptors in the mitochondria. However, on a subpopulation of T 
cells identified as regulatory T cells they have pro-survival effects, highlighting how 
GCs are not merely inhibitors of the immune response, but more controllers of this 
complex system that ought to be kept in balance in order to maintain body 
homeostasis. Despite a lack of intense investigation of the effects of GCs on B cells, 
it is known that they exert some moderate actions on this population by influencing 
cell survival, proliferation and activity. For instance, they trigger pro-apoptotic 
signals by reducing the expression of the anti-apoptotic protein B-cell lymphoma 
(Bcl)-2. Another example of the complexity of the interaction between the immune 
system and GCs comes from the study of their effects on the macrophage population. 
Indeed, low concentrations of GCs stimulate their function by affecting adhesion, 
chemotaxis, phagocytosis and cytokine production; on the other hand though, high 
concentrations of GCs exert immunosuppressive effects on the same population, 
most of all on activated macrophages. They also increase the phagocytic activity of 
these cells, for example towards neutrophils. Another important group of cells 
affected by GCs are dendritic cells (DC), which act as messengers between the innate 
and the adaptive immune system as their main function is to process and present 
antigenic material to T cells. GCs disturb their maturation and function; for instance, 
stimulated DC pre-treated with dexamethasone display a reduced ability to activate T 
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cells, with a consequent decrease in their proliferative response and in the production 
of interferon (INF). Furthermore, granulocytes are targeted by GCs in that the 
maturation and the production of cytokines, chemokines and arachidonic acid 
derivatives are inhibited by these hormones in mast cells. They also inhibit the 
release of histamine from basophils and reduce their number, and induce apoptosis of 
eosinophils and neutrophils. 
The picture drawn above of the broad spectrum of effects of GCs on the immune 
system is of course only a simplification; however, it shows why these compounds 
have become one of the most widely used classes of drugs in clinical practice, since 
they are able to affect all the players involved in the immune response. 
1.5 The use of glucocorticoids as anti-inflammatory 
drugs 
The first GC introduced in clinical practice was cortisone which was employed for 
the treatment of rheumatoid arthritis in 1948 by Dr Philip Hench (McDonough, 
Curtis et al. 2008; Kadmiel and Cidlowski 2013), revolutionising the medical field. 
Since then numerous derivatives with GC activity have been synthesized and 
employed. A few examples are: hydrocortisone (cortisol, Murray 1952), 
prednisolone (Nobile 1958), prednisone (Oliveto 1959), methylprednisolone (Sebek 
1959), dexamethasone (Muller 1961), betamethasone (Taub 1962), budesonide 
(Brattsand 1975) and fluticasone (Philips 1982). The clinical potency of these 
different GCs depends on factors such as the rate of absorption, the concentration in 
target tissues, the rate at which they are metabolised and cleared, and also the affinity 
with which they bind the main target receptor, GR. To mention just some of the 
differences between the most commonly prescribed steroids, hydrocortisone (HC) 
has a lower GR activity and higher MR affinity compared with prednisolone, while 
dexamethasone possesses a particularly high GR activity and a lower MR activity. 
These differences impact on the use of the various drugs, with HC used mostly 
topically, for short periods of time to avoid off-target side effects. Regardless of their 
clinical differences, GCs are the standard therapy for a myriad of inflammatory 
conditions such asthma, allergies, autoimmune diseases, dermatological condition 
Mechanisms of action of 5-tetrahydrocorticosterone 
  42 
(dermatitis, psoriasis) and inflammatory bowel disease. This represents a very 
limited list though as their use has been reported in approximately 200 conditions 
(Zetterstrom 2008), and the number of prescriptions for these drugs has been 
increasing over the years; in the United States alone about 10 million of them are 
written for oral GCs each year, with the total annual market worth around 10 billion 
US dollars (Schacke, Docke et al. 2002). 
Despite the widespread use of these drugs, they are strongly associated with a myriad 
of adverse side effects, especially in the case of long-term and/or high-dose therapy 
regimes. It is estimated that long-term therapy with GCs represents between 1% and 
3% of the adult population worldwide, with 20% of patients using the medication for 
more than 6 months, and 5% taking daily GCs for more than 5 years (van Staa, 
Leufkens et al. 2000). In the UK, a third of the patients taking GCs for more than 2 
years receive a high dose, defined as more than 7.5 mg of prednisone daily (Wei, 
MacDonald et al. 2004; McDonough, Curtis et al. 2008). Among the most common 
and troublesome side effects are osteoporosis, glaucoma, weight gain, muscle 
atrophy, diabetes and impairment of wound healing (Bungard, Hartman et al. 2011). 
A large population study identified weight gain as the side effect with the greatest 
prevalence, followed by skin bruising or/and thinning and sleep disorders (Angeli, 
Guglielmi et al. 2006). Another study conducted in France found that 71% of patients 
undergoing systemic therapy reported the onset of side effects in the first three 
months of therapy, with 46.2% of them experiencing skin abnormalities (Fardet, 
Flahault et al. 2007). In the US alone it is estimated that 14% of people take GCs for 
skin or musculoskeletal conditions (Steinbuch, Youket et al. 2004). Factors 
determining the occurrence and severity of the side effects are duration, dosage, 
potency of the GC administered and individual susceptibility (Schacke, Docke et al. 
2002). 
Previous in vivo data from my supervisors’ group demonstrated that the 5-reduced 
GC, 5-THB, is an effective anti-inflammatory compound in a murine model of 
dermatitis. For this reason, an overview of the topical treatments with GCs and their 
side effects is given below. 
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1.5.1 Topical glucocorticoids and their side effects 
GCs are the most widely used therapy employed to treat dermatological conditions 
(Schacke, Docke et al. 2002). They were used topically for the first time in 1952, 
when HC was employed to treat dermatoses (Sulzberger and Witten 1952); soon 
after, in 1955, the first adverse side effects caused by topical GCs were reported 
(Fitzpatrick, Griswold et al. 1955). Despite the fact that topical application of 
steroids is a safer route of delivering steroids, this route is not devoid of side effects. 
When they are administered topically on the skin only 1% of the applied amount is 
absorbed and is therapeutically effective, while 99% is removed from the skin by 
actions such as rubbing, washing and exfoliation (Robertson and Maibach 1982). 
Despite this, the small absorbed amount is sufficient to cause systemic side effects, 
while local ones can also be triggered by the transitory presence of local GCs 
(Hengge, Ruzicka et al. 2006). Among them the most common is skin atrophy, which 
is seen with every topical GC administered (Steinberg, Hudson et al. 2006; Franklin, 
Lunt et al. 2007). This phenomenon is characterised by an increase in skin 
transparency and the appearance of striae (Doran, Crowson et al. 2002; Lee, Oran et 
al. 2006). The severity of atrophy depends on different factors, among which is the 
potency of steroids and age, with infants and children being the most at risk due to 
their delicate skin. The mechanisms responsible for this side effect are suppression of 
cell proliferation, but also inhibition of collagen synthesis. Delayed wound healing is 
another serious side effect of topical steroidal therapy and is attributed to 
deregulation of different physiological processes, such as keratinocyte proliferation, 
fibroblastic activity and angiogenesis, impairment of which causes delayed formation 
of granulation tissue (Schacke, Docke et al. 2002; Hengge, Ruzicka et al. 2006; 
McDonough, Curtis et al. 2008). 
The prevalence of skin diseases in the UK, and the widespread use of topical steroids 
for their treatment, makes the frequency of the side effects a matter of concern. 
According to the National Eczema Society (www.eczema.org), in the UK alone 5 
million people suffer from some form of eczema (also known as dermatitis), with 
one in five children, and one in twelve adults affected. As a consequence, the search 
for new more selective compounds is relevant to topical conditions and their 
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treatments. Ideally, a better topical compound for skin diseases would lack the ability 
to cause systemic side effects should any be absorbed, and not cause local side-
effects such as skin thinning and impairment of wound healing. The unpublished in 
vivo experiments mentioned earlier, and conducted by my supervisors, showed that 
treatment with 5-THB did not affect skin thickness. The next step would be to 
study its effects on wound healing. Since one of the processes involved in the repair 
of injured skin is the formation of new vessels, this thesis will investigate the effects 
of 5-THB on angiogenesis. As a consequence, an overview of what angiogenesis is 
and how GCs affect it is provided below. 
1.6 Angiogenesis and glucocorticoids 
1.6.1 Angiogenesis 
Historically, angiogenesis has been defined as the multi-step process by which new 
vessels are formed from pre-existing ones (Moura, Lima et al. 2011), and it mainly 
refers to the post-natal remodelling of the vasculature; the formation of vessels 
during embryogenesis is instead referred to as vasculogenesis, and involves in situ 
differentiation of undifferentiated precursors originating from the bone marrow or 
residing in the wall of already formed vessels (Carmeliet and Collen 2000; Welti, 
Loges et al. 2013). Vasculogenesis can also take place in adults, even though the 
process does not give rise to a fully functional vasculature (Carmeliet and Collen 
2000). The formation of new vessels is a highly regulated phenomenon that, during 
post-natal life, occurs in healthy individuals during wound healing, endometrial 
regeneration in women, muscle growth and adipose tissue espansion; while 
conditions such as cancer growth, diabetic retinopathy, psoriasis and rheumatoid 
arthritis are considered states in which pathological, dysregulated angiogenesis 
occurs, lasting for months or years (Andrade, Fan et al. 1987; Hadoke, Macdonald et 
al. 2006). 
Different types of angiogenesis have been described including sprouting 
angiogenesis, bridging and intussusception; however, sprouting angiogenesis is the 
most studied and characterized, and it will be the focus of this introduction 
(Carmeliet and Collen 2000). The first event characterizing angiogenesis is dilation 
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of pre-existing vessels, caused by the release from endothelial cells of factors such as 
VEGF (vascular endothelial growth factor). VEGF production causes formation of 
the downstream effector nitric oxide (NO), which in turn leads to increased vascular 
permeability; as a consequence, proteins from the blood stream are able to cross the 
vessel wall and reach the extracellular matrix (ECM) to form a temporary scaffold 
that allows the migration of endothelial cells (ECs) (Carmeliet and Collen 2000). In 
order for ECs to migrate through the basement membrane (BM), their intercellular 
connections need to loosen and the ECM needs to be partially degraded to free space. 
These two events are coordinated by the dynamic rearrangement of proteins forming 
intercellular junctions, such as the platelet endothelial cell adhesion molecule 1 
(PECAM-1) and the vascular endothelial cadherin (VE-cadherin), and by the activity 
of proteinases, including matrix metalloproteinases (MMPs), which degrade a variety 
of matrix constituents. MMPs also help orchestrate the angiogenic process by 
activating or freeing growth factors sequestered in the ECM under resting conditions 
(Carmeliet and Collen 2000); their activity is tightly regulated by other enzymes such 
as the tissue inhibitors of matrix metalloproteinases (TIMPS), which help to prevent 
excessive damage to the tissue. The migration and proliferation of endothelial cells 
gives birth first to solid cords that subsequently acquire a lumen to give rise to proper 
vessels. The final steps of the process involve the recruitment of non-endothelial 
cells which give structural and functional support to the newly formed vessels, 
followed by pruning and regression of the new network. A more refined description 
of sprouting angiogenesis, taking into consideration detailed molecular pathways, has 
been published recently (Welti, Loges et al. 2013); in this review, the endothelial 
cells involved in the process are divided into two types, tip cells and stalk cells. The 
former initiate and lead the angiogenic sprout throughout the process by responding 
to signals such as VEGF, and by interacting with the surrounding environment in a 
dynamic and complex fashion; the latter are proliferative cells that allow the 
extension of the sprout and formation of the lumen (Welti, Loges et al. 2013). 
Successful angiogenesis is the result of the complex interplay of pro- and anti-
angiogenic factors, and of the intervention of cells from the immune system as well 
(i.e. macrophages). A representative image of the process is showed in Figure 1.5. 
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Figure 1.5 Sprouting angiogenesis. According to recent studies, two kinds of cells can be 
identified, tip cells and stalk cells, with the former initiating and leading the process, and the 
latter responsible for the elongation and formation of the tubular structure. The recruitment 
of peri-endothelial cells, such as pericytes, will give functional and structural stability; cells 
of the immune system, for example macrophages, also contribute to the process. BM = 
basement membrane, ECs = endothelial cells. Adapted from (Welti, Loges et al. 2013). 
1.6.2 Glucocorticoids and the inhibition of angiogenesis 
Cortisone and hydrocortisone, given at pharmacological concentrations (millimolar), 
were the first glucocorticoids to be shown to inhibit angiogenesis when given 
together with heparin in studies performed using the chick chorioallantoic membrane 
(CAM) in vivo assay (Folkman, Langer et al. 1983). Subsequently, other steroids 
were found to possess anti-angiogenic properties (Crum, Szabo et al. 1985) and, soon 
afterwards, an extensive investigation of a panel of steroidal molecules showed the 
existence of a wide group of compounds displaying the same properties; this new 
class of steroids was termed “angiostatic steroids” as they affected angiogenesis but 
were devoid of any glucocorticoid or mineralocorticoid activity. Among them was 
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5-tetrahydrocortisol, which was found to be twice as potent as hydrocortisone in 
inducing regression of growing capillaries at pharmacological doses in the CAM 
assay; the compound could also inhibit, but not regress, the growth of capillaries in 
intracorneal tumours (Folkman and Ingber 1987). In 1996, an in vivo study using the 
subcutaneous sponge insertion model in rats revealed that dexamethasone, 
hydrocortisone and some of the newly discovered angiostatic steroids were inhibitors 
of angiogenesis without the presence of heparin (Hori, Hu et al. 1996). Soon after, it 
was shown that steroids were anti-angiogenic also in humans (Hasan, Tan et al. 
2000). The first evidence that endogenous glucocorticoid regulation by 11β-
hydroxysteroiod dehydrogenases regulates angiogenesis came from research using ex 
vivo and in vivo models of angiogenesis (Small, Hadoke et al. 2005; Rae, Mohamad 
et al. 2009) employing pathophysiological doses of the steroid. 
The mechanisms by which GCs inhibit angiogenesis are not yet fully understood, and 
the role of GR is still controversial (Hadoke, Macdonald et al. 2006). GCs affect 
many of the processes taking place during angiogenesis, but the relative significance 
of these different influences is not yet clear. For instance, GCs inhibit the 
expression/activity of MMPs, and stimulate that of certain TIMPs (Perretti and 
Ahluwalia 2000; Pitzalis, Pipitone et al. 2002; Shikatani, Trifonova et al. 2012); 
furthermore, they inhibit both the expression and post-translational modifications of 
collagen (Kucharz 1988), and in particular they reduce the deposition of collagen IV, 
which is the main constituent of the basement membrane, which supports vessels 
during growth and maturation (Ingber, Madri et al. 1986; Maragoudakis, Sarmonika 
et al. 1989). As mentioned earlier, vasodilation is the initial step required for 
angiogenesis to begin, and it involves VEGF-induced production of NO; GCs are 
known to both decrease abundance of VEGF (Nauck, Roth et al. 1997; Shikatani, 
Trifonova et al. 2012) and inhibit the enzyme responsible for NO release, nitric oxide 
synthase (NOS) (Duckles and Miller 2010). In addition, some angiogenic stimuli 
work in concert with the inflammatory response (Leibovich, Polverini et al. 1987), 
and GCs are strong inhibitors of the latter. For instance, prostaglandin E2 (PGE2) 
and thromboxane A2 (TxA2) are factors shared by both angiogenesis and 
inflammation, and are also inhibited in vitro and in vivo by GCs (Herschman 1994; 
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Masferrer and Seibert 1994; Leahy, Koki et al. 2000; Bloomer, Kenyon et al. 2003); 
furthermore, MMPs are regulated by pro-inflammatory cytokines (Lohmann, 
Krischke et al. 2004) which are inhibited by GCs. Steroids are also known for having 
a negative effect on proliferation of endothelial and smooth muscle cells 
(Longenecker, Kilty et al. 1984; Sakamoto, Tanaka et al. 1987; Versaci, Gaspardone 
et al. 2002), and there are reports showing that they stimulate apoptosis of pericytes 
(Katychev, Wang et al. 2003). While it is still unknown which of these effects 
represent the major mechanism explaining why GCs inhibit angiogenesis, their broad 
inhibitory influences are bound to have detrimental consequences on this finely 
regulated process, with negative physiological repercussions; for instance, when they 
are used topically for the treatment of inflammatory skin conditions, at high doses 
and/or for a long time, they cause impairment of wound healing, a process that relies 
on angiogenesis. For these reason, an alternative anti-inflammatory compound that 
does not inhibit angiogenesis, or inhibit it to a lesser extent than the currently 
prescribed GCs, would be preferable.   
1.7 Selective agonists of the glucocorticoid receptor 
Because GCs used in clinics have an unfavourable risk/benefit ratio, over the years 
clinicians and researchers have tried different approaches in order to reduce the risk 
of adverse effects; some of these approaches have included lowering the dose, 
shortening the length of the treatment (e.g. several shorter periods in place of longer 
ones) and using GCs in combination with other drugs. However, the first two ways 
are not ideal because of the reduction in the effectiveness of the therapy; the last 
approach has been developed during the past decade with some encouraging results, 
for example in the treatment of rheumatoid arthritis (Zimmermann, Avery et al. 
2009). Despite these newer interventions though, the search for safer compounds 
continues, and most of it has focussed on finding molecules using approaches based 
on the way in which GCs work, as outlined below.  
In spite of the recognition of several mechanisms of action of the GR-GCs complex, 
anti-inflammatory actions of GCs are still widely thought to be mediated by DNA 
binding- and GR dimerisation-independent trans-repression mechanisms. This 
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predominant view took hold when a knock-in mouse carrying a dimerisation-
deficient version of GR (called GR
dim
) was created. This mouse model has a 
mutation (A458T) affecting the dimerisation domain contained in the DBD, thus 
preventing binding of GR dimers to the GREs of GC-responsive target genes. When 
GR
dim
 mice were injected with dexamethasone, GR failed to activate GRE-dependent 
genes in vivo in the liver, such as Tat and Pepck, but trans-repressed AP-1-dependent 
genes, such as collagenase 3 and gelatinase B, and NF-B-dependent transcription 
(Reichardt, Kaestner et al. 1998; Tuckermann, Reichardt et al. 1999). These and 
other observations have led to the hypothesis that the side effects and anti-
inflammatory properties of GCs can be uncoupled from one another, and so-called 
“dissociated compounds” retaining the anti-inflammatory profile but lacking the 
capacity to prompt adverse effects, could be generated. However, the fact that GCs 
can lead to expression of anti-inflammatory genes by trans-activation makes it 
unclear to what extent anti-inflammatory effects are independent from gene 
induction or to what extent therapeutic properties can be dissociated from deleterious 
effects (Newton 2000; Rogatsky, Wang et al. 2003; Schacke, Rehwinkel et al. 2005; 
Abraham, Lawrence et al. 2006). Recently, for example, it has been shown that 
expression of some prednisolone-induced genes was still present in the GR
dim
 mouse 
(Frijters, Fleuren et al. 2010), while another group reported the existence of 
dimerisation-independent loss of osteoblast differentiation, accounting for at least a 
part of GC-induced osteoporosis (Rauch, Seitz et al. 2010). In addition, the metabolic 
gene phenylethanolamine N-methyltransferase (Pnmt) has been found to be more 
strongly induced by GR
dim
 than by wild-type GR (Adams, Meijer et al. 2003). In this 
case, the mutant GR formed multimeric complexes with other regulatory factors and 
proteins. Nevertheless, many studies have been performed in order to identify 
steroidal and non-steroidal molecules with such dissociated characteristics.  
These alternative anti-inflammatory compounds are, among other things, called 
“selective glucocorticoid receptor modulators”, or SGRMs, to point out that these 
drugs are supposed to work selectively by inhibiting inflammatory processes while 
not influencing other unrelated physiological functions, as opposed to the 
indiscriminate behaviour of classical GCs. At present, prescriptions of synthetic GCs, 
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such as dexamethasone, betamethasone, triamcinolone, prednisone, prednisolone and 
methylprednisolone, are estimated to number about 40 million just in the UK, 
highlighting the vast proportion of the population in danger of suffering the powerful 
GCs-induced side effects, and the importance of the quest for alternative drugs. 
These molecules have been identified historically by drug library screenings, and 
tested in vitro for capacity to bind GR and trans-activation and trans-repression 
properties. Trans-activation is studied by investigating the capacity of these 
compounds to induce transcription of GRE-containing genes, such as Tat, or 
luciferase reporters, such as MMTV-Luc and PNMT-Luc. Trans-repression instead is 
investigated by studying NF-B/AP1-dependent expression of constructs after 
stimulation with inflammatory stimuli. In addition, some screening for dissociated 
GR ligands has included the study of the inability to induce S211 phosphorylation as 
a read-out of their dissociated properties (De Bosscher, Vanden Berghe et al. 2005). 
The characteristics of the drugs under investigation are compared to those of 
dexamethasone, B or prednisolone, and if they are promising, they are further studied 
in vitro and in vivo for anti-inflammatory and side effects. 
Here, I will review some of the compounds that have emerged from such a quest; 
Figure 1.6 gives a representation of the structures of the SGRMs described below, 
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Figure 1.6 Molecular structures of selective glucocorticoid receptor modulators 
(SGRMs). The structures of the naturally occurring glucocorticoid corticosterone, its 5-
reduced metabolite, 5-tetrahydrocorticosterone (5-THB), and the synthetic glucocorticoid 
prednisolone, are included for comparison. 
1.7.1 RU24858 
This compound has a steroidal structure and was one of the first dissociated GR-
ligands discovered (Vayssiere, Dupont et al. 1997; Chivers, Gong et al. 2006). Its 
trans-repression properties in vitro were similar to those of dexamethasone, while its 
trans-activation activity was weaker. However, in vivo it did not show an improved 
effects/side effects profile (therapeutic index) (Belvisi, Wicks et al. 2001). This 
molecule was useful though in the discovery of new genes with a potential role in the 
anti-inflammatory effects of GCs, as it was shown that it could trans-activate genes 
such as glucocorticoid-induce leucine zipper (Gilz), dual specific phosphatase 1 
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(Dusp1), and annexin 1 to the same extent as dexamethasone (Janka-Junttila, 
Moilanen et al. 2006). 
1.7.2 AL-438 
The compound Abbott-Ligand 438 (AL-438) does not have a steroidal structure, and 
it has been identified analysing a range of molecules for their affinity to GR, their 
ability to induce a reporter containing the MMTV promoter (multiple GRE sites) and 
to repress an E-selectin construct (containing AP-1 and NF-B binding sites). AL-
438 had a similar affinity for GR to prednisolone, a weak activity on MMTV-Luc, 
but strongly activates the E-selectin reporter. In addition, AL-438 was not able to 
inhibit the expression of osteocalcin, a marker of bone formation, as opposed to 
prednisolone (Coghlan, Jacobson et al. 2003). This drug was also shown to have an 
improved effects/side effects profile in an in vivo rat model of acute inflammation, 
having reduced side effects on glucose and bone metabolism (Humphrey, Williams 
et al. 2006), however these are present. Interestingly, it was shown that AL-438 
promotes recruitment of different cofactors compared to prednisolone, indicating a 
possible explanation for its dissociated behaviour (Owens and Keyse 2007). 
1.7.3 LGD-5552 
LGD-5552 was recently discovered, and it is also a non-steroidal drug. After 
encouraging results from in vitro tests, it was studied in in vivo rat models of 
rheumatoid arthritis and multiple sclerosis, showing potent anti-inflammatory effects, 
the capacity for inducing the expression of the anti-inflammatory cytokine IL-10 and 
fewer side effects than prednisolone (Lopez, Ardecky et al. 2008). 
1.7.4 ZK 216348 and ZK 245186 
ZK 216348 and ZK 245186 were reported by Bayer Schering Pharma, and they are 
also non-steroidal drugs. The former was shown to be 300 times less potent than 
dexamethasone at inducing Tat in liver cells, and being able, on the other hand, to 
repress LPS-induced IL-8 expression in a monocyte cell line, but with lower potency 
and efficacy than dexamethasone and prednisolone. In in vivo models of skin 
inflammation in mice, ZK 216348 had comparable anti-inflammatory effects to 
prednisolone, but fewer side effects on skin and glucose levels, showing it to be a 
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potentially promising molecule (Schacke, Schottelius et al. 2004). The other drug, 
ZK 245186, after encouraging results in in vitro tests against MMTV promoter and 
AP1-dependent transcription, was tested in vivo in rodent models of irritant and 
allergic contact dermatitis, giving similar positive outcomes. However, the 
compound still caused skin thinning in rats after long-term (19 days) topical 
application to a similar extent to medium-potency GCs routinely used in clinical 
practice (Schacke, Zollner et al. 2009). Other studies by Bausch & Lomb 
investigated the molecule in ocular inflammatory conditions, gaining promising 
results on human corneal epithelial cells (Cavet, Harrington et al. 2010), and showing 
strong anti-inflammatory effects with reduced side effects in a rabbit model of ocular 
disease (Shafiee, Bucolo et al. 2010). After further studies in rabbits and monkeys, 
ZK 245186 is under clinical investigation as a topical agent in ocular inflammation 
after cataract surgery (phase III), allergic conjunctivitis (phase II), dry eye syndrome 
(phase II) and atopic dermatitis (phase II) (Ayroldi, Macchiarulo et al. 2014). 
1.7.5 Compound A (CpdA) 
One the most intensively studied SGRMs is a stable analogue of a molecule derived 
from a Namibian desert shrub, called compound A, or CpdA, first reported in 2005 
(De Bosscher, Vanden Berghe et al. 2005). The drug showed higher affinity for GR 
than dexamethasone in vitro, and, moreover, it did not activate GRE-dependent 
constructs, such as MMTV, while it repressed E-selectin, IL-6 and IL-8 reporters to a 
similar extent to dexamethasone. In the same study as the compound displayed 
completely dissociated behaviour, phosphorylation of GR at ser211 was also 
investigated since it had been correlated with the transcriptional activity of the 
receptor. Interestingly, while dexamethasone enhanced the phosphorylation status of 
the residue by 10-fold over background levels, CpdA did not lead to a similar 
increase, correlating therefore with the lack of induction of GR-mediated 
transcription. Further in vivo studies were performed by the same group, using a 
murine zymosan-induced inflamed paw model. Decreased paw swelling was used as 
a read-out for the anti-inflammatory properties of the drug, and CpdA was shown to 
be as effective as dexamethasone. Analysis of the side effects revealed that CpdA did 
not affect blood sugar levels. Also in other in vivo models this compound has been 
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shown to be an effective anti-inflammatory drug, such as in collagen-induced 
arthritis and multiple sclerosis murine models. In these latter studies CpdA-treated 
animals were shown to have a reduced hyperglycaemia/hyperinsulinaemia, HPA axis 
suppression and a more positive bone marker profile (Rauner, Goettsch et al.; 
Dewint, Gossye et al. 2008; Gossye, Elewaut et al. 2009; Wust, Tischner et al. 2009; 
Rauner, Goettsch et al. 2010; van Loo, Sze et al. 2010). More recently, an 
investigation demonstrated that CpdA inhibited GR dimerisation, giving a potential 
explanation for its dissociated behaviour (Robertson, Allie-Reid et al.). Some 
observations though are not as positive as these results would suggest. Some authors 
have indeed reported that the drug causes toxic to lethal effects in vivo, due to its 
conversion into pro-apoptotic agents (Wust, Tischner et al. 2009). Moreover, it is 
worth noting that in all studies, the dose of CpdA used to obtain similar effects to 
dexamethasone was 5 to 15 times higher. This highlights the fact that this compound 
may not really be the “holy grail” of the quest for alternative anti-inflammatory 
molecules, and demonstrates the challenges posed by this field of research. 
1.7.6 5-THB 
My supervisors’ group identified a potential SGRM from studies of endogenous 
steroid metabolites. As seen earlier in this chapter, the principal metabolic clearance 
of GCs takes place in the liver by steroid A-ring reductases (McInnes, Kenyon et al. 
2004). These enzymes catalyse a two-step A-ring reduction, which is common to 
other steroid hormones. GR binds preferentially steroids with a ketone rather than a 
hydroxyl at C3 position (Bledsoe, Montana et al. 2002), however, my supervisors’ 
group has shown that 5-THB can displace dexamethasone from GR binding sites in 
rat hepatocytes, and induce transcription of the GRE-containing, GR-responsive 
promoter MMTV in transiently transfected HeLa cells (McInnes, Kenyon et al. 
2004). Furthermore, when 5-THB was given to adrenalectomised rats, it suppressed 
circulating adrenocorticotrophic hormone (ACTH) levels (McInnes, Kenyon et al. 
2004), a response normally triggered by B to mediate negative feedback on the HPA 
axis to lower GC production. More recent investigation carried out by my 
supervisors’ group, showed that 5-THB suppressed release of pro-inflammatory 
proteins from bone marrow-derived macrophages stimulated by LPS (Yang, Nixon et 
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al. 2011). In particular, at equivalent doses, 5-THB was about three times less 
effective in suppressing the release of TNF and IL-6 than B and dexamethasone, 
while it was as effective as B and dexamethasone in inducing secretion of the anti-
inflammatory cytokine IL-10 from unstimulated macrophages. The suppressive 
effects of GCs on TNF and IL-6 are mediated through binding of GR to 
transcription factors such as NF-B and AP-1 (Smoak and Cidlowski 2004), while 
induction of IL-10 expression is due to interactions of GR with STAT3 (Unterberger, 
Staples et al. 2008); the data obtained by my supervisors’ group indicate that 5-
THB may exert its effects by the same mechanisms (Yang, Nixon et al. 2011). 
Effects of 5-THB were also investigated in vivo using acute and chronic models. 
Acute administration of 5-THB significantly lowered the recruitment of 
inflammatory cells into the peritoneum in thioglycollate-induced peritonitis, and 
suppressed peritoneal IL-6 levels, albeit with a lower efficacy than B (Yang, Nixon 
et al. 2011). Chronic infusion of 5-THB for two weeks could suppress LPS-induced 
secretion of TNF and IL-6 in the blood to a similar extent to B (Yang, Nixon et al. 
2011). More importantly, despite having similar anti-inflammatory actions at 
equivalent doses, 5-THB did not affect glucose metabolism, in contrast to B. The 
drug did not induce hepatic activity of TAT, and following chronic administration, 
the deleterious side effects seen with B (increased blood pressure and insulin 
resistance) were not seen when using 5-THB (Yang, Nixon et al. 2011). Based on 
these promising results, our group decided to further investigate the molecular 
mechanisms underlying the dissociated behaviour of 5-THB, and this investigation 
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1.8 Hypotheses 
Given the data my supervisors’ group has collected on the properties of 5-THB, the 
hypotheses of this PhD are: 
- 5-THB acts as an anti-inflammatory compound by modulating molecular 
pathways in a different manner than its precursor B 
- 5-THB does not inhibit angiogenesis 
- 5-THB does not trans-activate conventional GC target genes 
- The effects of 5-THB are mediated by GR  
1.9 Aims 
To test the hypotheses, the aims of this thesis are: 
- To investigate the effects of 5-THB in in vivo and in vitro models of 
inflammation, and their dependency on GR 
- To analyse the effects of 5-THB on angiogenesis, a process taken as 
representative of the potential side effects of the compound 
- To compare the effects of 5-THB on trans-activation of genes conventionally 
targeted by GCs in a GR-dependent fashion 
This will allow an understanding of how this compound compares with the precursor 
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Chapter 2: Materials and Methods 
Room temperature (RT) is defined as 18-22°C; the concentration of phosphate buffer 
solution (PBS) is 1X unless otherwise stated. Time is abbreviated as follow: sec = 
second/s; min = minute/s, h = hour/s, ON = overnight, n = biological replicates, N = 
experimental replicates. 
2.1 Cell biology 
2.1.1 Materials 
2.1.1.1 Outsourced reagents and chemicals 
Dextran-coated charcoal, ethanol (vehicle) and dimethylsulfoxide (DMSO) were 
from Sigma-Aldrich (Dorset, UK). All reagents for the preparation of cell culture 
media were from Lonza (Berkshire, UK) unless otherwise stated. Cell culture plates 
and all consumables were from Fisher Scientific (Loughborough, UK), with the 
exception of sterile syringes, needles and cell strainers which were from BD 
Biosciences, Oxford, UK. The provenance of other materials is specified. 
2.1.1.2 Sources of cultured cells 
2.1.1.2.1 Cell lines 
The two murine cell lines RAW264.7 (macrophages) and L292 (fibroblasts), and the 
human alveolar carcinoma cell line, A549, were from the European Collection of 
Cell Cultures (ECACC; distributor Sigma-Aldrich). The murine hepatoma cell line, 
BWTG3, was a gift from Prof. Guy Haegeman, University of Ghent (Ghent, 
Belgium). 
2.1.1.2.2 Murine bone marrow-derived macrophages (BMDMs) 
Bone marrow-derived macrophages (BMDMs) were isolated from murine tibia and 
femur as follows, according to a protocol revised from the literature (Weischenfeldt 
and Porse 2008): 
Bone retrieval: the mouse (inbred strain C57BL/6, male, 8-10 week old) was 
sacrificed by asphyxiation with CO2 and the lower body was sprayed with ethanol 
(70% v/v in milliQ water). Both femurs were dislocated from the hip joints, and skin 
was removed from the posterior limbs. Both femurs and tibias were detached and 
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cleaned of soft tissues. Isolated bones were then immersed in sterile, ice cold PBS 
and transferred to a laminar flow cabinet where, under sterile conditions, cells were 
isolated.  
Isolation of bone marrow-derived cells: each end of the femur and tibia were 
removed using a scalpel so that the marrow inside was exposed. The bone was held 
using sterile forceps at one of the extremities on top of a tube and, using a syringe 
containing F-12 medium (5 mL) attached to a needle (22 G), the marrow was flushed 
out until the bone looked transparent. The suspension obtained was gently passed 
three times through a bigger needle (18 G) in order to break cell clumps, and then 
transferred to a clean tube through a cell strainer (40 m) in order to trap bone 
fragments and debris. The suspension was diluted in order to obtain a concentration 
of 5 x 10
3
 cells/mL, and cells (1 mL) were plated in 12-well cell culture plates. Cells 
that were precursors of macrophages were allowed to attach to the surface of the 
plates until the next day (day 2) when the medium was removed, wells washed with 
PBS and fresh medium added. Cells were left to differentiate into macrophages for 6 
days before the start of any experiment. The cell culture medium (section 2.1.1.3.2) 
was replaced every second day. 
2.1.1.3 Preparation of reagents and solutions 
2.1.1.3.1 Foetal bovine serum (FBS) 
Heat inactivated (HI)-FBS: serum was incubated for 30 min at 56 °C in a water bath. 
Stripped HI-FBS: in order to remove steroid hormones naturally present in serum, 
HI-FBS (500 mL) was incubated under constant agitation (ON, 4 °C) with dextran 
coated-charcoal (5 g) and subsequently sterilised by filtration (0.22 m, Merck 
Millipore Ltd, Cork, IRL). Aliquots (50 mL) were stored at -20°C. 
2.1.1.3.2 Cell culture media 
Normal-serum medium: RAW264.7, A549 and BWTG3 cell were cultured in 
Dulbecco’s modified Eagle’s medium (DMEM) supplemented with a high 
concentration of glucose (4.5 g/L glucose), HI-FBS (10% v/v), penicillin (100 
IU/mL), streptomycin (100 g/mL) and L-glutamine (2 mM). L292 cells were 
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cultured in DMEM/Nutrient Mixture F-12 (DMEM/F-12) supplemented with HI-
FBS (10% v/v), penicillin (100 IU/mL) and streptomycin (100 g/mL). For BMMs, 
the same medium was employed with addition of L292 fibroblast-conditioned 
medium (15% v/v) (2.1.1.3.3). 
Stripped-serum medium: the media for the different cell types were prepared as 
above with the exception of the addition of stripped HI-FBS instead of complete HI-
FBS. 
2.1.1.3.3 L292 fibroblast-conditioned medium for BMDMs 
L292 cells were cultured in T75 cell culture plates until fully confluent and then left 
for 10 days without the medium being changed. The medium was then collected, 
sterilised by filtration (0.22 m) and frozen (-20 °C) for subsequent use for the 
culture of BMMs. 
2.1.2 Cell thawing, maintenance and freezing 
With the exception of BMDMs which were freshly isolated when needed, the culture 
of the other cells was always instigated from a frozen aliquot stored in liquid 
nitrogen. Frozen cells were thawed in a water bath maintained at 37°C and then 
transferred to a tube containing normal-serum medium and collected as a pellet by 
centrifugation (1000 x g, 5 min, RT). The cell pellet was re-suspended in normal-
serum medium and seeded in a 25 cm
3
 flask. The day after, cells were washed with 
sterile PBS and detached from the flask by mechanical treatment in the case of 
RAW264.7, or by addition of trypsin (5 min, 37 °C) in the case of A549, BWTG3 
and L292, re-suspended in normal-serum medium and plated on 75 cm
3
 flasks. 
Thawed cells were maintained at 37 °C in a 5% CO2 incubator, and passaged a 
maximum of 10 times until the appropriate cell density was achieved prior to the 
beginning of experiments. At this point, after two washes with sterile PBS, the 
medium was replaced with stripped-serum medium. The length of time in which the 
cells were maintained in this medium varied according to the cell type and 
experiment carried out, as specified. Cells were collected for protein extraction and 
analysis according to the protocols described in sections 2.3.3.1.2 and 2.3.3.2.2, or 
for RNA isolation as described in section 2.3.1.2. The medium was collected for 
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cytokines analysis as described in section 2.3.3.3.2. Cells not used for experiments 
were harvested, re-suspended with FBS containing DMSO (15% v/v), frozen (ON, -
80 °C) and then stored in liquid nitrogen. 
2.1.3 Experimental procedures 
2.1.3.1 Protein knock down by RNA interference (RNAi) 
2.1.3.1.1 Reagents 
Materials were from Insight Biotech (Middlesex, UK).  
2.1.3.1.2 Procedure 
Cells were seeded (3 x 10
5
) in 6-well plates and cultured overnight in antibiotic-free 
medium in order to reach 60-80% confluence. For transfection, two solutions per 
well were prepared: 
- Solution A: siRNA (2-8 L, 10 M) either targeted to the RNA of interested or not 
targeted to the human genome (control) in transfection medium (100 L). 
- Solution B: siRNA transfection reagent (2-8 L) in transfection medium (100L). 
Solution A was added to solution B, mixed gently by pipetting and incubated at RT 
(30-45 min). Subsequently, 0.8 mL of transfection medium was added to the tube 
and the mixture added to cells previously washed with transfection medium. Cells 
were then cultured for 24 h before medium containing 2X stripped FBS, glutamine 
and antibiotics was added (1 mL, section 2.1.1.3.2). After 24 h incubation, medium 
was replaced with fresh stripped-FBS medium, and after 24 h cells were harvested 
and protein abundance assessed using western blotting as described (section 2.3.3.1). 
2.1.3.2 Transfection of reporter plasmids in cultured cells 
2.1.3.2.1 Reagents 
Luria Bertani (LB) agarose and ampicillin were from Sigma-Aldrich. Other reagents 
were from various sources which are specified below. 
2.1.3.2.2 Amplification of plasmids 
Plasmid DNA (0.5 ng) was added to Escherichia coli cells (HB101, 50 L; Promega, 
Southampton, UK) on ice. The mixture was heat shocked (42 °C, 50 sec), incubated 
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on ice (3 min) before being plated and incubated (ON, 37 °C) on 1.5% w/v LB 
agarose (1.5% w/v in sterile PBS) with ampicillin (100 g/mL). A single colony was 
then selected and grown in LB with ampicillin for 7 h with vigorous shaking. This 
starter culture was subsequently diluted 1/1000 in 500 mL of the same medium and 
grown (overnight, 37 °C). Plasmid purification was carried out using a Plasmid Maxi 
Kit (Qiagen, West Sussex, UK) following manufacturer’s instruction. Briefly, 
overnight cultures were subjected to centrifugation (800 x g, 10 min, 4 °C) and the 
pellet formed re-suspended in Buffer P1 (10 mL), followed by addition of Buffer P2 
(10 mL) and mixed to ensure lysis of cells. After incubation (10 min, RT) the 
solution was added to Buffer P3 (10 mL), mixed thoroughly and incubated (10 min, 
4 °C) to precipitate plasmid DNA. The suspension was subjected to centrifugation 
(16000 x g, 30 min, 4 °C) and the supernatant added to a QIAGEN-tip, where DNA 
binds to the column. The QIAGEN-tip was washed twice with Buffer QC (30 mL 
each), before DNA was eluted with Buffer QF (15 mL). DNA was precipitated by 
addition of 0.7x volume of isopropanol and collected by centrifugation (15000 x g, 
30 min, 4 °C). The pellet was washed with ethanol (70% v/v) and subjected to 
centrifugation (15000 x g, 10 min, 4 °C). The pellet obtained was air-dried and re-
suspended in DNA/RNase free water. DNA was quantified with a NanoDrop 
Spectrophotometer (Thermo Fisher Scientific, Northumberland, UK) with 
absorbance recorded at 260 and 280 nm, and deemed acceptable if the ratio 260:280 
was approximately 1.7-2.1. 
2.1.3.2.3 Transient transfection 
Cells maintained in culture were seeded using stripped-serum medium on 6 well 
plates (4x10
5 
cells/well) 24 h prior to transfection. On the day of transfection, culture 
medium was replaced 1 hour before transfection with antibiotic-free medium. For 
each well to be transfected, a transfection complex containing the following 
components was prepared: 
- Plasmid DNA of interest (variable quantity according to the type of plasmid, 
control or experimental). Refer to table 6.2 in Chapter 6. 
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- Opti-MEM reduced Serum Medium (100 L, Invitrogen Life Technologies, 
Paisley, UK). 
- Lipofectamine 2000 Transfection Reagent (4 L, Invitrogen Life Technologies). 
The solution was then incubated (30-40 min, RT) before being added directly to the 
medium of each appropriate well, in triplicate. After 24 h, fresh antibiotic-free 
medium was added and experimental treatment started. At completion, proteins from 
cells were harvested and plasmid activity tested as described in section 2.3.3.2.  
2.2 In vivo physiology and pathophysiology 
2.2.1 Source of experimental animals 
Male mice (inbred strain C57BL/6, 8-10 week old) were purchased from Harlan 
Laboratories (UK) when needed.  
2.2.2 Maintenance 
Mice from commercial sources were allowed to acclimatise for one week after 
arrival prior to the start of each experiment. All mice were maintained under 
controlled conditions of light (lights on 0700-1900hs) and temperature (18-20 °C) 
and allowed free access to standard chow (RMI 801002; Special Diet Services, 
Witham, UK) and drinking water. All experiments were performed under the 
guidelines of the UK Home Office and the following project licences: JR Seckl, PPL 
No: 60/3962; KE Chapman, PPL No: 60/7874 and PW Hadoke, PPL No: 60/4523, 
and personal licence: A Gastaldello, PIL No: 60/13215). Animals were culled by 
decapitation for experiments studying angiogenesis and by asphyxiation with CO2 
for all the others. 
2.2.3 Collection of tissues and preparation of plasma 
Collection of solid tissues and implants was performed at cull as specified within 
experimental chapters. Plasma was obtained by centrifugation (10,000 x g, 5 min, 4 
°C) from blood collected as described in the appropriate chapters. Aliquots were 
stored at -80 °C until needed. 
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2.3 Laboratory protocols 
2.3.1 RNA analysis 
2.3.1.1 Materials 
All reagents were from Qiagen unless otherwise stated.  
2.3.1.2 Total RNA extraction from cells 
Cells were washed with cold PBS, and incubated on ice with QIAzol reagent (200 
L/well, 5 min). Subsequently, cells were released by scraping and the cell lysate 
transferred to cold RNase free-tubes. Total RNA was extracted by using an RNeasy 
mini kit according to the manufacturer’s instructions. Briefly, chloroform (40 L) 
was added, the tube’s contents were mixed by vortexing and subjected to 
centrifugation (12000 x g, 15 min, 4 °C). The upper layer containing the total RNA 
was removed and transferred to a tube containing ice-cold ethanol (70 L, 70% v/v). 
After brief mixing, the solution was transferred to an RNeasy spin column and buffer 
RWI added prior to centrifugation (12000 x g, 15 sec, RT). The flow-through was 
discarded and the column washed twice with RPE buffer (12000 x g, 15 sec, RT). 
After the last wash, the tube was subjected to centrifugation in order to remove any 
residual buffer (16000 x g, 1 min, RT), and RNase-free water (30 L) was added 
thereafter. To collect total RNA, the tube was subjected to a further centrifugation 
(12000 x g, 1 min, RT). The total amount of extracted RNA was quantified with a 
NanoDrop Spectrophotometer. 
2.3.1.3 Total RNA extraction from tissues and implants 
Total RNA was extracted using the RNeasy Fibrous Tissue Mini Kit and following 
manufacturer’s instruction. Briefly, tissue was immersed in RLT buffer (500l) and 
homogenised using MagNA lyser green beads and a MagNA lyser centrifuge (Roche 
Diagnostics, West Sussex, UK) (6000 x g, 40 sec followed by 6000 x g, 30 sec). 
Lysates were transferred in new tubes containing proteinase K solution (16.7 L/mL 
of RNase-free water), mixed and incubated (55 °C, 10 min) before being subjected to 
centrifugation (10000 x g, 3 min, RT). The supernatant was transferred to a new tube 
and ethanol added (100%, 0.5 volumes); after mixing, the solution was transferred to 
an RNeasy Mini spin column and subjected to centrifugation (8400 x g, 30 sec). The 
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column was washed with RW1 buffer (350 L; 8400 x g, 30 sec) before DNase I 
solution was added and samples incubated (RT, 15 min). One more wash with RW1 
buffer (350 L; 8400 x g, 30 sec) was followed by two washes with RPE buffer (500 
L; 8400 x g, 30 sec and 8400 x g, 2 min) and a dry centrifugation (16000 x g, 1 
min). Total RNA was eluted by adding RNase-free water (30 L) and subjecting the 
column to centrifugation (8600 x g, 1 min). The total amount of extracted RNA was 
quantified with a NanoDrop Spectrophotometer. 
2.3.1.4 Evaluation of RNA quality 
To evaluate RNA quality, RNA samples were analysed using an Agilent 2100 expert 
Bioanalyzer and Agilent RNA 6000 Nano LabChip kit (Agilent Technologies, 
Berkshire, UK). RNA 6000 Nano gel matrix (500 L) was pipetted into a spin filter. 
The tube was subjected to centrifugation (1500 x g, 10 min, RT) and aliquots (65 L) 
were stored at 4 °C and used within 4 weeks. Prior to the assay, each RNA sample 
was diluted with RNase-free water, in order to have a concentration of total RNA in 
the range 25-500 ng/L, which is the quantitative working range of the Bioanalyzer. 
Each RNA sample was then analysed according to manufacturer’s instructions. 
Briefly, to prepare the gel-dye mix, RNA 6000 Nano dye concentrate was allowed to 
equilibrate to RT for 30 min. The dye was vortexed (10 sec), subjected to a brief 
centrifugation and added (1 L) to an aliquot of filtered gel. After mixing well, the 
solution was subjected to centrifugation (13000 x g, 10 min, RT) and used within 24 
h. A new RNA 6000 Nano chip was placed on the priming station, the gel-dye mix (9 
L) and the RNA 6000 Nano marker (5 L) were added to the appropriate wells. 
Subsequently, the ladder and the samples were loaded in the remaining wells. After 
mixing the chip using a IKA vortex mixer (1 min), the run was initiated within 5 
min; once completed, the RNA Integrity Number (RIN) and electropherograms 
associated with each sample were analysed using the 2100 Expert software provided 
by Agilent Technologies. The samples with RIN between 7 and 10 were accepted for 
real-time PCR analyses. 
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2.3.1.5 Reverse Transcription 
First strand cDNA synthesis was performed using a QuantiTect Reverse 
Transcription kit. Any genomic DNA was removed during a first step where total 
RNA (250 ng) was treated with gDNA Wipeout buffer (42 °C, 2 min).  
Subsequently, reverse transcription was performed in a reaction mixture containing 
Quantiscript Reverse Transcriptase (1 L), Quantiscript RT buffer (4 L) and RT 
Primer mix (1 L) adjusted to a total volume of 20 L with RNase-free water. 
Negative controls were prepared in parallel: one mixture was prepared as above but 
in the absence of Quantiscript Reverse Transcriptase in order to identify samples 
contaminated with any remaining genomic DNA, and one mixture was prepared in 
the absence of RNA to identify contamination of the Reverse Transcriptase system 
reagents. Reverse transcription was carried out using an Eppendorf Mastercycler 
Gradient (Eppendorf, Stevenage, UK) with a heated lid. Samples were incubated at 
42 °C for 15 min, then at 95 °C for 3 min, finally reduced to 4 °C and stored at -20 
°C until needed.  
2.3.1.6 Real-time PCR 
Primers were from Invitrogen Life Technologies; UPL probes, Probes Master and 
LightCycler water were from Roche Diagnostics. 
For quantification by real-time PCR a LightCycler 480 (Roche Diagnostics) was 
used. Primers (Table 2.1) were designed to match intron-spanning probes within the 
Roche Universal Probe Library (UPL), using the online software Universal 
ProbeLibrary Assay Design Center (Roche: 
http://lifescience.roche.com/shop/CategoryDisplay?catalogId=10001&tab=Assay+D
esign+Center&identifier=Universal+Probe+Library&langId=-1). Each newly made 
cDNA (2 μL), previously diluted 1:20 in LightCycler water, was mixed with 
LightCycler 480 Probes Master (5 μL), LightCycler water (7 L), custom designed 
primers (10 M, .1 L each) and the corresponding UPL probe (10 M, 0.1 L). In 
parallel, for each gene tested, serial dilutions of a starting solution were prepared by 
pooling together all samples under analysis (2 L each) and used to generate a 
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standard curve. A negative control to assess for potential contamination of reagents 
was prepared by using LightCycler water instead of sample. 
Samples were heated for initial denaturation (95 °C, 5 min), followed by 50 cycles of 
PCR amplification, consisting of denaturation (95 °C, 10 sec), annealing (60 °C, 30 
sec) and elongation (72 °C, 1 sec). Once the PCR programme was complete, samples 
were cooled (40 °C, 30 sec). All samples were analysed in triplicate and 
amplification curves plotted (x axis = cycle number, y axis = fluorescence). 
Triplicates were deemed acceptable if the standard deviation of their crossing points 
(Cp) was lower or equal to 0.5 cycles. A standard curve was generated (x axis = 
concentration, y axis = crossing point), fitted with a straight line of best fit and 
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Gene symbol, full name, accession No Primers sequence UPL 
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Gene symbol, full name, accession No Primers sequence UPL 
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Gene symbol, full name, accession No Primers sequence UPL 









Pdgfrb (platelet-derived growth factor receptor, 































Mechanisms of action of 5-tetrahydrocorticosterone 
  72 
Gene symbol, full name, accession No Primers sequence UPL 
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Table 2.1 Details of primers and probes for real-time PCR analysis of murine genes 
using Roche Universal Probe Library (UPL). The reverse primer (3’ → 5’) for each gene 
is above the separation line, the forward primer (5’ → 3’) is below. 
2.3.2 DNA analysis 
2.3.2.1 Materials 
All materials for DNA extraction were components of a DNeasy® Blood and Tissue 
Kit from Qiagen. For PCR assay a Qiagen Multiplex PCR kit was used. Materials for 
agarose gel electrophoresis were from Sigma-Aldrich. The DNA ladder (1500-100 
bp) was from Promega (Southampton, UK). 
2.3.2.2 DNA extraction 
Samples were immersed in ATL buffer (180 L) added with Proteinase K (20 L) 
and incubated (56 °C, ON). To the mixture, buffer AL (200 L) mixed with ethanol 
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(200 L) was added and the solution was mixed thoroughly. The mixture was 
transferred into DNeasy Mini spin column and subjected to centrifugation (≥ 6000 x 
g, 1 min). The flow-through was discarded and the column washed with Buffer AW1 
(500 L) before being subjected to centrifugation (≥ 6000 x g, 1 min). The column 
was washed with buffer AW2, subjected to centrifugation (20000 x g, 3 min) before 
the DNA was eluted into a 1.5 ml tube by adding Buffer AE (200 mL) followed by a 
brief incubation (RT, 1 min) and centrifugation (≥ 6000 x g, 1 min). DNA was stored 
at -20 °C until PCR reactions were performed. 
2.3.2.3 PCR analysis 
Each sample (1 L) was added to a reaction mixture containing the following: 
mastermix (10 L), Sol
n 
Q (2 L), primer mix (2 pmol/L, 2 L) and Qiagen water 
(5 L). A negative control was included by adding Qiagen water to the mixture in 
place of any sample. DNA amplification was performed using a G-storm thermal 
cycler (G-Storm Ltd, Somerset, UK). At completion, the samples were removed and 
agarose gel electrophoresis performed. 
2.3.2.4 Agarose gel electrophoresis 
2.3.2.4.1 Solutions 
TBE (5X) solution: Tris-HCl 1.1 M, boric acid 900 mM, EDTA 25 mM (pH 8) in 
milliQ water; TBE 0.5X solution (1 L): 100 mL TBE 5X + 900 mL milliQ water.  
2.3.2.4.2 Procedure 
Samples were added with loading dye (5 L; 4 mg/mL cresol red in 40% w/v 
sucrose) and separated (80V, 4 h) on an agarose gel (2% w/v in TBE 0.5X). The gel 
was imaged using a UVITEC transilluminator and the UVIpro software (both 
UVITEC, Cambridge, UK). 
2.3.3 Protein analysis 
2.3.3.1 Western blotting 
2.3.3.1.1 Materials and buffers 
All reagents and chemicals were purchased from Sigma-Aldrich, unless otherwise 
stated. 
Mechanisms of action of 5-tetrahydrocorticosterone 
  74 
Lysis Buffer: 25 mM HEPES, 68.5 mM NaCl, 0.5 mM MgCl2, 0.5 mM CaCl2, 5 mM 
NaF, 1 mM EDTA, 1% NP40, 10% glycerol, Halt protease and phosphatase inhibitor 
cocktail (200 L, Thermo scientific, Northumberland, UK), one complete mini 
Protease inhibitor tablet (Roche Diagnostics). 
Running Buffer 1X: 1 M Tris Base, 0.035 M SDS, 1 M HEPES in distilled water. 
Transfer Buffer 1X: 0.025 M Tris Base, 0.2 M glycine, 10% methanol in distilled 
water. 
TBST: Tris-buffered saline (TBS) prepared with 50 mM Tris-HCl and 150 mM NaCl 
plus Tween-20 0.1% v/v, in distilled water 
2.3.3.1.2 Protein extraction 
Each well was washed with cold PBS and incubated (4 °C, 15 min) with cold lysis 
buffer (100 L). Cells were scraped and the lysate incubated with constant shaking 
(4 °C, 30 min) before being subjected to centrifugation (13000 x g, 20 min, 4 °C). 
The supernatant was utilised for protein quantification. 
2.3.3.1.3 Protein quantification 
Protein quantification was carried out in duplicate using a Bio-Rad Dc Protein Assay 
kit (Bio-Rad Laboratories, Hertfordshire, UK). A working reagent solution was 
prepared by adding reagent S (20 L) to reagent A (1 mL). A protein standard was 
prepared by making serial dilutions of a bovine serum albumin (BSA, fraction V) 
solution (1 mg/mL) using the same lysis buffer used for protein extraction. Samples 
and standards (5 L) were pipetted into wells of a 96-well plate microplate. The 
working reagent solution was added to each well (25 L) prior to addition of reagent 
B (200 L). The microplate was gently agitated to mix the reagents, incubated (15 
min, RT) and absorbance at 750nm was recorded using a “OPTImax” microplate 
reader operated by SoftMax Pro4.8 software (Molecular Devices Limited, Berkshire, 
UK). A regression line of best fit (x axis concentration, y axis absorbance) was 
deemed acceptable if r
2
 > 0.98 and the protein concentration of samples calculated. 
Data were deemed acceptable if duplicate differed from the mean by < 10%. 
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2.3.3.1.4 Gel electrophoresis and protein detection 
Protein lysates (30 g) were added to loading buffer (10:1, NuPage LDS sample 
loading dye:NuPAGE sample reducing agent; Invitrogen). Samples were heated (99 
°C, 5 min) prior to separation by gel electrophoresis on a 12% w/v Pierce Precise 
protein gel (Thermo Fisher Scientific, Northumberland, UK) using the XCell 
Surelock Mini-Cell apparatus (Invitrogen). The samples were then transferred to a 
nitrocellulose membrane (GE Healthcare, Buckinghamshire, UK; 2 h, 70V) using 
Mini Trans-Blot Electrophoretic Transfer Cell apparatus (Bio-Rad Laboratories). 
After transfer, the membrane was blocked with a solution of 5% w/v milk (Bio-Rad 
Laboratories) in TBST for one hour (RT). Primary antibody diluted in a BSA 
solution (5% w/v in TBST) was then added and incubated (ON, 4 °C). Thereafter, 
the membrane was washed three times with TBST and incubated with the secondary 
antibody (60 min, RT) diluted 1:10000 in a milk solution (5% w/v in TBST). After 
three more washes, the blot was developed using the 800 nm channel of the 
Odyssey® Imaging Systems (LI-COR Biosciences, Cambridgeshire, UK), and the 
intensity of fluorescence of the bands quantified. 
2.3.3.2 Luciferase and -galactosidase assays  
2.3.3.2.1 Materials 
Reagents were from Sigma-Aldrich.  
2.3.3.2.2 Preparation of cell lysate 
Cells were washed with cold PBS and incubated (4 °C, 15 min) with lysis buffer 
(100 L, 2 5mM Tris phosphate, 2 mM dithiothreitol (DTT), 1% Triton X100, 10% 
glycerol in distilled water). Cell lysates were transferred into 1.5 mL tubes and 
subjected to centrifugation (12000 x g, 1 min, 4 °C). Luciferase and -galactosidase 
activities were assessed in the supernatant. 
2.3.3.2.3 Luciferase Assay 
Luciferase activity is commonly assessed to test the degree by which a promoter is 
induced. The enzyme luciferase, the expression of which is under the control of the 
promoter being investigated, catalyses the reduction of luciferin to oxyluciferin in the 
presence of ATP Mg
2+
 producing light as a by-product. This reaction is energetically 
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very efficient therefore allowing, by recording the amount of light produced, a robust 
estimation of the relative amount of promoter activity compared to a control.  
Luciferase assays were carried out on 96-well plates with samples analysed in 
duplicate. To each well the following components were added: assay buffer (100 L, 
40 mM Tricine, 66 mM DTT, 0.2 mM EDTA, 2.14 mM MgSO4, 0.26 mM 
Coenzyme A in distilled water), 0.1 M ATP (5 L) and cell lysate sample (40 L). 
To assess the background signal two wells were prepared by replacing the cell lysate 
with lysis buffer. Subsequently, a Microplate Luminometer (Orion II, Hertfordshire, 
UK) was used to add the substrate luciferin (105 L; 1 mM) into each well, and the 
amount of chemi-luminescence was recorded at 560 nm.  
2.3.3.2.4 -Galactosidase Assay 
Galacton is a substrate used for sensitive quantification of β-galactosidase activity in 
reporter gene assays. Light emitted from the reaction is directly proportional to the 
number of β-galactosidase enzyme molecules. To assess -galactosidase activity, to 
each well of a 96-well plate, reaction mix (67 L, 1/100 dilution of Galacton in 
diluent, Tropix Kit, Applied Biosystems) and the cell lysate sample (10 L) were 
added immediately after the luciferase assay. To assess the background signal two 
wells were prepared by replacing the cell lysate with lysis buffer. The plate was 
incubated (15 min, RT) prior the addition of Accelerator II (100 L, Tropix Kit, 
Applied Biosystems) using the luminometer as above (section 2.3.3.2.3).  
2.3.3.2.5 Data management 
Data were recorded using the software Simplicity 4.1 (Orion II, Hertfordshire, UK). 
Samples were analysed in duplicate and data deemed acceptable if they differed from 
the mean by < 10%. 
2.3.3.3 Quantification of cytokines by Enzyme Linked Immuno- Sorbent 
Assay (ELISA) 
2.3.3.3.1 Reagents 
“ELISA READY-SET-GO!” kits were from eBioscience (Hatfield, UK). 
Mechanisms of action of 5-tetrahydrocorticosterone 
  77 
2.3.3.3.2 Medium collection 
Culture medium was pipetted into a tube and subjected to centrifugation (1000 x g, 
10 min, 4 °C). Supernatant was immediately used for ELISA assay or stored at -80 
°C. 
2.3.3.3.3 Assay procedure 
The amounts of cytokines released into the medium of cultured cells were quantified 
in duplicate according to the manufacturer’s instructions. A 96-well plate was coated 
overnight at 4 °C with appropriate capture antibody (100 L/well). The plate was 
then washed 5 times with wash buffer (PBS-0.05% Tween-20) before blocking with 
1X Assay Diluent (200 L/well, 1 h, RT). The plate was washed again as before, and 
the standards and samples added to the appropriate wells and incubated (ON, 4 °C). 
After 5 more washes, the detection antibody (100 L/well) was added and incubated 
(1 h, RT). The washes were repeated and Avidin-HRP added (100 L/well) and 
incubated (30 min, RT), followed by 7 more washes. Finally, the Substrate Solution 
(100 L/well) was added and incubated (15 min, RT) followed by Stop Solution (50 
l/well). The absorbance was quantified at 450 nm using a “OPTImax” microplate 
reader. A 4-parameter standard curve was fitted (x axis log concentration, y axis 
absorbance), deemed acceptable if r
2
 > 0.98, and the cytokine concentration of 
samples calculated. Data were deemed acceptable if duplicate differed from the mean 
by < 10%. 
2.3.3.4 Quantification of corticosterone in plasma by ELISA 
2.3.3.4.1 Materials 
ELISA kits containing all the reagents, corticosterone concentrated standard and 96-
well microplate were from ENZO Life Sciences (Exeter, UK); ethyl acetate was from 
Sigma-Aldrich; glass tubes and pipettes were from BD Biosciences. 
2.3.3.4.2 Steroid extraction from plasma samples 
Plasma was thawed from -80 °C in ice, and diluted 1:20 with sterile deionized water 
in glass tubes. An equal volume of steroid displacement reagent (SDR, diluted 1/100 
with the assay buffer from the kit) was added and the mixture incubated (5 min, RT). 
Reagent AB15 (280 L) and ethyl acetate (3 mL) were added to each sample; the 
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mixture was vigorously vortexed, allowed to stand (2 min) and then vortexed one 
more time. The upper, clear, organic layer was removed using a glass pipette and 
transferred to a fresh tube. Samples were reduced to dryness under oxygen-free N2 at 
60 °C, and thereafter the residues stored at -80 °C until quantification of 
corticosterone was performed. 
2.3.3.4.3 Assay procedure 
Reagents from the kit were allowed to warm up at RT for at least 30 min prior to 
beginning of the procedure. The samples were reconstituted with AB15 (500 μL) and 
vortexed vigorously. Standard curves were prepared by making serial dilutions of a 
concentrated solution provided in the kit (200,000 pg/mL) and using reagent AB15 
as the diluent. Standards (100 L) and samples were pipetted into the appropriate 
wells, before blue conjugate (50 L) was added, followed by yellow antibody (50 
L). The microplate was then incubated on a plate shaker (RT, 2 h, 500 rpm). 
Thereafter, the wells were washed (x3) using wash solution (400 L) before adding 
pNpp substrate (200 L) followed by incubation at RT (1 h). Stop Solution (50 L) 
was added to every well and absorbance read immediately at 405 nm using a 
“OPTImax” microplate reader. A 4-parameter standard curve was fitted (x axis log 
concentration, y axis absorbance), deemed acceptable if r
2 
> 0.98 and the 
concentration of corticosterone in samples calculated. Samples were analysed in 
duplicate, and data were deemed acceptable if they differed from the mean by < 
10%. 
2.3.3.5 Quantification of myeloperoxidase (MPO) activity in tissue 
2.3.3.5.1 Materials 
MPO activity was quantified using a Myeloperoxidase fluorometric detection kit 
from ENZO Life Sciences (Exeter, UK). Additional materials needed and not 
included in the kit were: DMSO, hexadecyltrimethylammonium (HTA-Br) and black 
96-well plates, all from Sigma-Aldrich 
2.3.3.5.2 Sample preparation 
Ear biopsies were placed in dry ice and weighed before homogenization. They were 
transferred into MagNA lyser green beads tubes containing 1X assay buffer and 
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homogenized using the MagNA lyser centrifuge (Roche Diagnostics) (6000 x g, 40 
sec followed by 6000 x g, 30 sec). Homogenate was transferred into 1.5 mL tubes 
and subjected to centrifugation (1000 x g, 4 °C, 20 min). Supernatant was removed 
and the pellet re-suspended in solubilisation buffer (1 mL, 0.5% HTA-Br (w/v) in 
assay buffer). Samples were sonicated (30 sec) and submitted to two cycles of 
freeze/thaw, before being subjected to centrifugation (8000 x g, 4 °C, 20 min). The 
supernatant was assayed immediately for MPO activity. 
2.3.3.5.3 Assay procedure 
A standard curve was prepared immediately before the assay was performed by 
making serial dilution of the enzyme using the assay buffer. Samples or standards 
(50 L) were pipetted to the bottom of a black 96-well plate, and Reaction Cocktail 
(50 L) added to each well. The plate was incubated (RT, 45 min, in the dark) and 
fluorescence measured using a Magellan Infinite M1000 plate reader (Tecan UK Ltd, 
Reading, UK) with excitation wavelength set to 570 nm, and emission to 600 nm. A 
linear standard curve was fitted (x axis concentration, y axis fluorescence) by Tecan 
I-CONTROL I.6 software and deemed acceptable if r
2
 < 0.98. Samples were 
analysed in duplicate and deemed acceptable if they differed from the mean by < 
10%. 
2.3.4 Histological analysis 
2.3.4.1 Materials 
Solutions for haematoxylin and eosin (H&E) staining were from Sigma-Aldrich. 
2.3.4.2 Sample preparation 
Tissue samples were fixed in formalin (10% v/v in PBS) for 24 h and then 
transferred to ethanol (70% v/v in milliQ water) prior to embedding in paraffin. 
Sections of 5 m were cut using a microtome, floated in a water bath at 45 °C and 
placed on positively-charged glass slides (VWR International Ltd., Leicestershire, 
UK) and oven dried (37 °C, ON). 
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2.3.4.3 H&E staining 
Paraffin was removed from samples by immersion in xylene (5 min, x2) before re-
hydration was performed by immersion in consecutive solutions containing 
decreasing concentration of ethanol (100%, 95% and 70% v/v in milliQ water). After 
rinsing in tap water, samples were stained first with haematoxylin (5 min) and then 
with eosin (13 sec) in order to differentiate between cell nuclei and other cellular 
structures. Samples were de-hydrated by immersion in consecutive solutions with 
increasing concentration of ethanol (70%, 95% v/v in milliQ water and 100%), and 
finally cleared by using two changes of xylene prior to application of a thin layer of 
mountant (D.P.X., Sigma-Aldrich) and covered with a glass cover slip.  
2.4 Data analysis 
All data were analysed using GraphPad Prism6 software, and presented as mean ± 
SEM. Data were analysed by the statistical tests described in the legend of each 
figure. A comparison was considered statistically significant when p < 0.05. When a 
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Chapter 3: Anti-inflammatory properties of 5-
THB in vivo 
3.1 Introduction 
Glucocorticoids (GCs) are the main topical drugs prescribed for the treatment of 
inflammatory skin conditions such as psoriasis and dermatitis. As with systemic 
administration, long-term topical application of GCs is restricted by the onset of 
serious side effects including skin atrophy, characterised by loss of skin thickness 
and elasticity, and impeded wound healing. In addition, variability in the response to 
the treatment and the onset of resistance to glucocorticoid therapy are two factors 
that sometimes make these drugs not as effective as clinically needed 
(McDonoughAK 2008; Schacke H 2002). It is, therefore, a priority for the scientific 
community to research and develop new, more selective anti-inflammatory drugs for 
topical use.  
Preliminary unpublished data from my supervisors’ laboratory showed that the 5-
reduced glucocorticoid 5-THB, originating from the reduction of the principal 
active glucocorticoid in rodents, corticosterone (B), represents a promising 
candidate. This compound reduced inflammatory swelling associated with irritant 
contact dermatitis in a murine model of the condition. The effect was comparable to 
that of hydrocortisone (HC), which is a steroidal drug prescribed for the treatment of 
inflammatory skin conditions in humans. Long-term topical application of 5-THB 
alone did not induce skin thinning or systemic metabolic effects, such as weight loss, 
nor did it increase insulin levels, even when given at a concentration eight times 
higher than its EC50 (25 g). In contrast, HC caused weight loss and increased insulin 
levels and also induced massive skin thinning. These and earlier results (Yang, 
Nixon et al. 2011) suggested that 5-THB is a more selective anti-inflammatory 
glucocorticoid. For these reasons, we proposed to determine the molecular 
mechanisms through which this steroid is exerting its anti-inflammatory action using 
the same murine model of irritant dermatitis.  
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The presence of the enzyme responsible for the formation of 5-THB, 5-reductase 
type 1 (5-R1), has been shown in human and rat skin (Nixon, Upreti et al. 2011). 
Consequently, the response of any steroid, which is a substrate for 5-R1 (e.g. 
hydrocortisone, corticosterone), may be modified by its presence. In addition, 5-
THB could be reversed to B, although the kinetics of the enzyme suggests this is 
unlikely (Nixon, Upreti et al. 2011). These concepts were explored in mice with 
genetic disruption of 5-R1.   
Hypotheses 
- Resolution of inflammation by 5-THB shares some but not all of the mechanisms 
of corticosterone (B) 
- Local formation of 5-THB plays a role in determining the local anti-inflammatory 
response to B 
Objectives 
To investigate: 
- How the anti-inflammatory properties and mechanisms of 5-THB compare with 
those of B 
- Whether the action of 5-THB is dependent on the glucocorticoid receptor (GR) 
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3.2 Materials and Methods 
3.2.1 Model of contact irritant dermatitis   
3.2.1.1 Materials    
Croton oil (CO), isopropyl myristate (IM), ethanol, DMSO and RNAlater® were 
from Sigma-Aldrich (Dorset, UK). B, 5-THB and the GR antagonist, RU486, were 
from Steraloids (Newport, RI, USA). 
3.2.1.2 Induction of dermatitis 
Male C57BL/6 mice (9-12 week old) were treated on the inner surface of the right 
ear with a solution containing the irritant compound croton oil (10 L, 3% v/v in a 
mixture of ethanol and IM 30:5), using a micropipette. The solution was prepared 
immediately prior to each experiment. The left ear of each mouse was left untreated 
and used as a control as preliminary experiments showed lack of effect of the 
vehicle. Treatments were performed between 10 a.m. and 3 p.m. in order to avoid the 
influence of circadian variation of steroid levels on the inflammatory response. 
Treatments lasted for a period of 6 or 24 h, as stated.  
3.2.1.3 Treatment with steroids and glucocorticoid receptor antagonist 
3.2.1.3.1 Topical treatments 
A mixture (10 L) of croton oil and steroids was applied to the inner surface of the 
right ear of each mouse, leaving the left ear untreated as a control. The mixtures were 
prepared as follows:  
Topical treatment with B and 5-THB: concentrated solutions (8 g/L) of B and 
5-THB in ethanol were stored at -80 °C. Working solutions were prepared before 
the beginning of each experiment by warming the stock solutions (RT, 1 h) and 
diluting them in the croton oil solution (3% v/v in a mixture of ethanol and IM 30:5). 
The concentration of B to be used and compared with 5-THB was determined by 
performing dose-response (swelling) experiments lasting 6 and 24 h. The doses of B 
tested were 0.3, 1, 3, 10 and 30 g per mouse (corresponding to approximately 0.09, 
0.29, 0.9, 2.9 and 9 mM). From the graphs generated from these experiments, the 
concentration of B able to reduce the inflammatory swelling by 50% (half maximal 
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effective concentration, also known as EC50) was calculated at each time point by 
fitting a “non-linear log(agonist) versus response (three parameters)” regression 
curve using GraphPad 6 software which uses the following equation: 
Y=Bottom + (Top-Bottom)/(1+10^((LogEC50-X))) 
The EC50s for B (10 g (2.90 mM), 6 h  and 5 g (1.45 mM), 24 h) so determined 
were employed in the subsequent experiments. 5-THB was used at final 
concentrations corresponding to 1, 3 and 5 times the EC50 of B. In previous studies, 
in which the treatment with 5-THB lasted 24 h, the EC50 was found to be 25 g 
(7.13 mM) (Livingstone, Sykes et al. 2014); no previous studies are available in 
which the treatment lasted 6 h. 
Topical treatment with RU486: RU486 was used at the same molar concentration 
corresponding to the EC50 of B at 24 h (5 g = 1.45 mM). To prepare it, RU486 (10 
g/L) was dissolved in DMSO prior to each experiment and diluted to 0.62 g/L 
in the croton oil solution (3% v/v in a mixture of ethanol and IM 30:5) before topical 
application of 6.20 g (1.45 mM) on the mouse ear for 24 h.  
3.2.1.3.2 Subcutaneous injection of RU486 
A concentrated solution was prepared by dissolving RU486 either in DMSO or 
ethanol to a concentration of 25 mg/mL or 20 mg/mL, respectively. The mixture (0.5 
mg/mouse) was then injected subcutaneously in the neck region 15 min prior to any 
topical treatment. The same amount of vehicle (DMSO or ethanol) was injected in a 
separate group of mice serving as control.  
3.2.1.4 Tissue collection 
At the end of each experiment, ears were collected at cull (section 2.2.2) and halved; 
each half was either preserved in 10% v/v formalin for histological analysis (section 
2.3.4), in dry ice or RNAlater® for real-time PCR analysis (sections 2.3.1.5 and 
2.3.1.6) or frozen in liquid nitrogen for myeloperoxidase activity assay (section 
2.3.3.5). 
Mechanisms of action of 5-tetrahydrocorticosterone 
  87 
3.2.1.5 Assessment of inflammatory swelling 
Inflammatory swelling (or oedema) of auricular tissues was evaluated by measuring 
the weight difference between treated (right) and untreated (left) ears (referred to 
also as control ears).  
3.2.1.6 Microscopic quantification of swelling and cell infiltration 
Pictures of ear tissues stained with H&E and magnified 100X under a microscope 
were captured using the software QCapture Pro 7 (QImaging, Canada). 
Quantification of swelling was performed by measuring the width (in m) of the 
dermis at both sides of the central cartilage layer. Total width was calculated by 
summing the two measurements for each section. Quantification of cell infiltration 
was performed by counting the nuclei on both sides of the cartilage and summing the 
numbers. In order to make measurements robust, for each image the widest part and 
the area most populated by inflammatory cells were always analysed. Help for these 
analyses was received from MSc student Amber Abernethie and Honour student 
Nicola Tsang. The person performing the measurements was blind to group 
allocations. 
3.2.1.7 Quantification of transcripts by real-time analysis 
3.2.1.7.1 Optimisation of the method for collecting and preserving auricular 
tissues  
Two methods for collecting and preserving ears were tested: (a) storage in dry ice 
upon collection and subsequent preservation at -80 ºC, and (b) storage in RNAlater® 
upon collection, followed by storage at 4 ºC ON and subsequent preservation at -20 
ºC. In order to evaluate the best approach, extraction of total RNA, RNA quality 
evaluation using an Agilent 2100 expert Bioanalyzer and Agilent RNA 6000 Nano 
LabChip kit, and real-time PCR analysis for the housekeeping genes TATA-binding 
protein (Tbp) and glyceraldehyde 3-phosphate dehydrogenase (Gapdh) were carried 
out as described in section 2.3.1. 
3.2.1.7.2 RNA isolation 
Total RNA was isolated from sponges as described in section 2.3.1.3. 
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3.2.1.7.3 Real-time PCR analysis 
Production of cDNA and subsequent real-time PCR analysis were performed as 
described in sections 2.3.1.5 and 2.3.1.6. 
3.2.1.8 Model of dermatitis in adrenalectomised mice 
3.2.1.8.1 Surgery 
Surgery was performed by Dr Dawn Livingstone. In summary, a bilateral 
adrenalectomy through dorsal incisions under isoflurane anaesthesia was performed. 
Buprenorphine pain relief was given peri-operatively and 16 h later. After surgery, 
animals were maintained on 0.9% saline drinking water and allowed to recover for 
one week before subsequent intervention.  
3.2.1.8.2 Topical treatment  
Contact irritant dermatitis was induced and steroid treatment applied (24 h) as 
described in sections 3.2.1.2 and 3.2.1.3, one week after surgery. 
3.2.1.8.3 Tissue collection and assessment of inflammatory swelling 
Ears were collected at cull as described in section 3.2.1.4, and swelling assessed as 
described in section 3.2.1.5. 
3.2.1.9 Model of contact irritant dermatitis in mice with genetic 
disruption of 5-R1 (5-R1-/-) 
3.2.1.9.1 Animals 
Homozygous 5-reductase type 1 knockout (5-R1
-/-
) mice were obtained by in-
house breeding of heterozygous mice (5-R1
+/-
) derived through backcrossing for 
>10 generations onto a C57BL/6 background. Embryos comprising the original 
colony (C57BL6/SvEv/129 mixed background; (Mahendroo, Cala et al. 1996; 
Mahendroo, Cala et al. 1997) were purchased from The Jackson Laboratory (Bar 
Harbor, Maine, USA).  
3.2.1.9.2 Maintenance 
Mice were maintained as described in section 2.2.2. 
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3.2.1.9.3 Genotyping of 5-R1-/- mice by PCR 
Materials: Ear punches for genotyping were collected at the MVM Biological 
Services (University of Edinburgh) by technical staff and stored at -20 °C until DNA 
extraction and genotyping were performed. The sources of all reagents are described 
in section 2.3.2. Primers were designed by Dr Dawn Livingstone (Table 3.2) and 
purchased from Invitrogen Life Technologies. 
Genotype Primer sequence 
5-R1
-/- gattgggaagacaatagcaggcatgc 
5-R1 WT atggagttggatgagttgtgc 
Common ccagacacgaacttccacgcttctg 
 
Table 3.1 Sequences of the primers (5´→ 3´) for the genotyping of mice with genetic 
disruption of 5-reductase type 1 (5-R1). 5-R1
-/-
 = mice homozygous for the genetic 
modification, WT = wild type mice. 
Procedure: DNA extraction and PCR analysis were performed as described (sections 
2.3.2.2, 2.3.2.3). The samples were amplified with the following program: 94°C, 15 
min; (94°C, 30 sec - 60°C, 1.30 min -  72°C, 1 min) x30 cycles; 72° 10 min. Products 
were separated by gel electrophoresis (section 2.3.2.4). The anticipated bands for 
genotype distinction were as follows: 5-R1 WT band = 400 base pairs (bp); 5-R1
-
/-
 band = 360bp. 
3.2.1.9.4 Topical treatment of 5-R1-/- mice 
Topical treatment with croton oil alone or in conjunction with steroids lasting 6 and 
24 h was performed on male 5R1
-/-
 mice (9-12 week old) as described (sections 
3.2.1.2, 3.2.1.3). As control, littermate wild type (5-R1 WT) male mice were used. 
3.2.1.9.5 Collections of tissues and assessment of inflammatory swelling 
Ears were collected at cull as described in section 3.2.1.4, and swelling assessed as 
described in section 3.2.1.5. 
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3.2.1.9.6 Collection of blood 
Blood was collected immediately after removal of the ears, in tubes treated with 
sterile EDTA solution (0.5M, pH 8) by puncture of the abdominal aorta using a 26G 
needle inserted onto a 1 ml syringe (both from BD Biosciences, Oxford, UK). 
Plasma was recovered as described in section 2.2.3. 
3.2.1.9.7 Quantification of B in plasma by ELISA 
B in plasma was quantified as described in section 2.3.3.4. 
3.2.2 Analysis of 5-reductases in murine skin by PCR  
3.2.2.1 Materials 
Sources of reagents are described in sections 2.3.1 and 2.3.2. Specific primers for 
5-R1 and 5-Reductase type 2 (5-R2) were designed by Dr Dawn Livingstone 
(Table 3.1) and purchased from Invitrogen Life Technologies (Paisley, UK). 
Gene symbol, full name, accession No Primers sequence 
Srd5a1 (steroid 5 alpha-reductase 1), NM_175283.3 
R ctgccatcaattccttggat 
F tttgctcttcctttgggcta 




Table 3.2 Sequences of the primers for PCR analysis of 5-reductases type 1 and 2. R = 
reverse, F = forward. 
3.2.2.2 PCR analysis 
Total RNA and cDNA from murine ears, liver and prostate were obtained as 
described in sections 2.3.1.3 and 2.3.1.5. Samples were amplified by PCR (section 
2.3.2.3) using the following protocol: initial denaturation = 95 °C, 5 min; (94 °C, 4 
sec – 55 °C, 45 sec – 72 °C, 1 min) x33 cycles; final extension 72 °C, 10 min. The 
products were separated by agarose electrophoresis (section 2.3.2.4). The anticipated 
bands were: 5-R1 = 240 bp; 5-R2 = 299 bp. 
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3.2.3 Data analysis 
3.2.3.1 General 
Data were represented as mean ± SEM, and analysed as described in section 2.4. 
3.2.3.2 Analysis of the inflammatory response in ear 
The effects of the application of steroids on ear swelling, cell infiltration and 
thickness are presented as percentage of the group that received CO alone; the mean 
weight difference in this group was set as 100% inflammation and efficacy of 
steroids on different parameters calculated accordingly. The inflammatory swelling 
was reported as weight difference in mg when the comparison did not involve 
steroidal treatment. 
3.2.3.3 Real-time PCR analysis 
For quantification of transcripts by real-time PCR, the abundance of each gene was 
represented in relation to the abundance of chosen housekeeping genes. For this 
chapter, the two housekeeping genes used were Tbp and Gapdh due to the lack of 
significant changes in the abundance of transcripts following treatment with croton 
oil or croton oil plus steroids. For each sample and each gene studied the values 
presented in the graphs were calculated as follow: value sample X/(mean values Tbp 
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3.3 Results 
3.3.1 Characterization of a model of irritant dermatitis  
3.3.1.1 Inflammatory swelling in response to croton oil  
Application of croton oil induced tissue swelling after both 6 h and 24 h (Figure 3.1); 





















5 0 * * *
d u ra tio n  o f c ro to n  o il tre a tm e n t
 
Figure 3.1 Ear swelling induced by croton oil was greater after treatment for 6 than 24 
hours (h). Weight difference (mg) between treated and untreated ears after treatment for 6 
and 24 h with croton oil. Data (mean ± SEM) were analysed by Student’s t-test; n=10/group, 
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3.3.1.2 Histological changes associated with inflammatory swelling  
Staining of auricular tissues with H&E showed an increase in the dermal thickness of 
ears treated with croton oil for 6 and 24 h compared with the matched untreated ears; 
the swelling appeared greater at 6 h (Figure 3.2 (6h) A,B,C; (24h) D,E,F). This 
confirmed measurements of ear weights at cull (Figure 3.1). At 24 h-post treatment, 
generalised cell infiltration was more abundant than at 6 h, seen clearly at higher 















Figure 3.2 Treatment of ears with croton oil for 6 hours (h) caused a greater dermal 
swelling, but less cell infiltration, compared with treatment lasting 24 h.  Representative 
images of tissues stained with haematoxylin and eosin from untreated (A, D) and croton oil-
treated (B, E) murine ears. Ears were collected after treatment for either 6 h (A, B) or 24 h 
(D, E). Selected fields in B and E were magnified (400x) in order to show cell infiltration (C 
and F, black arrow indicating purple nuclei). All other images were taken using a 10x 
objective. c = cartilage; d = dermis, which can be found at both sides of the ear cartilage; 
only one dermal layer has been highlighted for clarity; e = epidermis. 
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3.3.1.3 Evaluation of the method to collect and preserve tissues for 
real-time PCR analysis 
3.3.1.3.1 Collection in dry ice 
The RNA quality, as evaluated by gel electrophoresis (Figure 3.3 a), was poor for 
samples belonging to the croton oil-treated group (samples 9-12, 6 h; 13-16, 24 h) 
compared with samples of the control group (samples 1-4, 6 h; 5-8, 24 h), as shown 
by the low RNA integrity number (RIN) and the high number of bands indicating 
degradation of the RNA pool. This translated into poor quality data obtained by real-
time PCR analysis; indeed, the abundance of mRNAs of the housekeeping gene Tbp 
was lower in the treated group at both time points compared with the control group 
(Figure 3.3 b). Analysis of another housekeeping gene, Gapdh, showed that the 
amount of transcripts was not different between the treated and untreated group for 
both end points (Figure 3.3 c), however the treated group at 24 h showed a 
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Figure 3.3 Collection of auricular tissues in dry ice yielded poor quality RNA. (a) Gel 
electrophoresis of either untreated (1-4, 6 hours (h); 5-8, 24 h) or croton-oil treated ears (9-
12, 6 h; 13-16, 24 h) collected in dry and stored at - 80°C; nt = number of nucleotides, L = 
RNA ladder, RIN = RNA integrity number, 28s (5070 nt) and 18s (1869 nt) = sizes of the 
correspondent ribosomal RNAs in Svedberg units. (b) and (c) Abundance of transcripts of 
TATA-binding protein (Tbp) and glyceraldehyde 3-phosphate dehydrogenase (Gapdh) 
respectively in control (CTRL) and croton (CO)-treated ears quantified through real-time 
PCR at 6 and 24 h. Data (mean ± SEM) were analysed at each time point by unpaired 
Student’s t-test; ** = p < 0.001, ns = not significant; n = 4/group. A.U. = Arbitrary Unit.     
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3.3.1.3.2 Collection in RNAlater® 
The RNA quality, as evaluated by gel electrophoresis (Figure 3.4 a), was good for all 
samples analysed (croton oil-treated = 9-12, 6 h; 13-16, 24 h; untreated = 1-4, 6 h; 5-
8, 24 h), as shown by the high RNA integrity number (RIN) and the presence of only 
two predominant bands corresponding to the ribosomal RNAs 28s and 18s. This 
translated into good quality data obtained by real-time PCR analysis; indeed, 
quantification of the transcripts of Tbp and Gapdh in ears revealed no difference 
between untreated (CTRL) and croton oil-treated groups either at 6 or 4 h (Figure 3.4 
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Figure 3.4 Collection of auricular tissues in RNAlater® yielded good quality RNA. (a) 
Gel electrophoresis of either untreated (1-4, 6 hours (h); 5-8, 24 h) or croton-oil treated ears 
(9-12, 6 h; 13-16, 24 h) collected in RNAlater® and stored at - 20°C; nt = number of 
nucleotides, L = RNA ladder, RIN = RNA integrity number, 28s (5070 nt) and 18s (1869 nt) 
= sizes of the correspondent ribosomal RNAs in Svedberg units. (b) and (c) Abundance of 
transcripts of TATA-binding protein (Tbp) and glyceraldehyde 3- phosphate dehydrogenase 
(Gapdh) respectively in control (CTRL) and croton (CO)-treated ears quantified through 
real-time PCR at 6 and 24 hours (h). Data (mean ± SEM) were analysed at each time point 
by unpaired Student’s t-test; ns = not significant; n = 4/group. A.U. = Arbitrary Unit. 
Mechanisms of action of 5-tetrahydrocorticosterone 
  98 
3.3.1.4 Abundance of transcripts of pro-inflammatory genes in inflamed 
ears 
The abundance of transcripts of Il6, Il1andnf increased after treatment with 
croton oil for 6 and 24 h compared with untreated ears (Figure 3.5). This increase 
was more pronounced for Il6 compared with Il1 and Tnf, at both time points, and 
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Figure 3.5 Treatment with croton oil (CO) for 6 and 24 hours (h) increased abundance 
of transcripts of pro-inflammatory genes. Abundance of transcripts of (a) Il6, (b) Il1 and 
(c) Tnf represented as fold induction versus untreated ears. CTRL = control ears. Ref = 
average of two housekeeping genes. Data (mean ± SEM) were analysed using unpaired 
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3.3.2 Efficacy of B to suppress irritant dermatitis 
The next step was to test how the model would respond to applications of B. 
Increasing concentrations of B reduced the extent of swelling (Figure 3.6 a and b) in 
a dose-dependent manner after 6 and 24 h from induction. The EC50 for B at 6 h-post 
treatment was 10 g, while at 24 h it was 5 g. 
 
Figure 3.6 Corticosterone (B) reduced croton oil-induced inflammatory swelling in a 
dose-dependent manner. Reduction in inflammatory swelling by increasing concentration 
of B after (a) 6 and (b) 24 hours (h) of treatment with croton oil. 6 h, n=4/group; 24h, n=8-
12/group. Data are mean ± SEM. The graph was drawn as a semi-log plot; the log values 
were substituted with the real concentrations of B to give a clearer representation. 
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3.3.3 Efficacy of 5-THB to alleviate irritant dermatitis in mice 
Having established a suitable protocol to demonstrate the anti-inflammatory 
properties of glucocorticoids to suppress ear inflammation, the model was then used 
to explore the actions of 5-THB in comparison to B. 
3.3.3.1 Effect of 5-THB to alleviate inflammatory swelling  
The efficacy of 5-THB to reduce inflammatory swelling of the ear in comparison 
with B at 6 h was studied by applying a dose of B corresponding to the EC50 (10 g), 
whereas 5-THB was applied at 10, 30 and 50 g. In these conditions, B reduced 
inflammation to 35.5 ± 8.7% compared with the croton oil-treated group (set to 
100%), while an effect was not observed with 5-THB at any concentration tested 
(Figure 3.7 a).  
The efficacy of 5-THB to reduce swelling induced by treatment with croton oil 
lasting 24 h was studied by applying B at its EC50 (5 g), while 5-THB was applied 
at 5, 15 and 25 g (EC50 from previous studies (Livingstone, Sykes et al. 2014)). B 
reduced swelling to 57.0 ± 4.5%; 5-THB decreased it to 85.3 ± 11.3% at 5g, to 
64.3 ± 15.7% at 15 g and to 64.9 ± 7.9% at 25 g (3.7 b) compared with the croton 
oil-treated group (set to 100%). Only the effect induced by 25 g was statistically 
significant compared with the group treated with croton oil alone. At 15 g a trend 
toward significance was found.  
Subsequent analysis of samples treated with 5-THB was restricted to tissues 
harvested following treatment with the highest concentrations used (50 g at 6 h and 
25 g at 24 h). 
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Figure 3.7 5-Tetrahydrocorticosterone (5-THB) suppressed swelling induced by 
treatment with croton oil (CO) lasting 24 but not 6 hours (h). Efficacy of 5-THB and 
corticosterone (B) to suppress swelling induced by treatment with CO for (a) 6 and (b) 24 h. 
Data (mean ± SEM) were analysed by one-way ANOVA followed by Tukey’s post-hoc test; 
** = p < 0.001, * = p < 0.05, & = 0.05 < p < 0.1 vs CO; £££ = p < 0.0001; ns = not 
significant. 6h, n=4-8/group; 24h, n = 5-19/group.  
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3.3.3.2 Histological analysis of the effect of 5-THB to suppress 
swelling and cell infiltration 
Ear samples were analysed microscopically in order to compare the effect of co-
application of croton oil and steroids for 6 or 24 h on swelling and cell infiltration.  
3.3.3.2.1 Analysis of ears treated for 6 h 
Treatment with croton oil for 6 h caused swelling of the tissue as clearly seen by the 
increase in the width of the dermal layer (Figure 3.8 A, B). B (10 g), but not 5-
THB (50 g), reduced swelling as seen from the reduction of width of the dermal 
layer (Figure 3.8 C, D) and confirmed by the quantification of the dermal thickness 
(Figure 3.9 a). 
Counts of cell nuclei in the tissue (black arrows in Figure 3.8 A-D) revealed an 
increase in the number of cells infiltrating the ear after application of croton oil 
(Figure 3.9 b). B, but not 5-THB, decreased the number (Figure 3.9 b).  
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Figure 3.8 5-Tetrahydrocorticosterone (5-THB) did not reduce swelling induced by 
croton oil when applied for 6 hours (h). Representative images of ear tissue stained with 
haematoxylin and eosin showing changes in the width of dermal layer after treatment with 
croton oil alone or together with steroids for 6 h. (A) untreated ear, (B) ear treated with 
croton oil only, (C) ear co-treated with croton oil and B (10 g), (D) ear co-treated with 
croton oil and 5-THB (50 g). Arrows point to cell nuclei of infiltrating cells; c=cartilage; 
d = dermis, which can be found at both sides of the ear cartilage; only one dermal layer was 
highlighted for clarity. Magnification = 100x.  
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Figure 3.9 5-Tetrahydrocorticosterone (5-THB) did not reduce swelling and cell 
infiltration induced by application of croton oil (CO) for 6 hours (h). Quantitative 
measurement of (a) dermal thickness and (b) cell infiltration after treatment with CO alone 
or together with steroids for 6 h. CTRL = control ears; ### = p < 0.0001, # = p < 0.05 vs 
CTRL;*** = p < 0.0001, * = p < 0.05 vs CO; data (mean ± SEM) were analysed by one-way 
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3.3.3.2.2 Analysis of ears treated for 24 h 
Treatment with croton oil for 24 h caused swelling of the tissue as clearly seen by the 
increase in the width of the dermal layer (Figure 3.10 A, B). Both B (5 g) and 5-
THB (25 g) reduced swelling as seen from the reduction of width of the dermal 
layer (Figure 3.10 C, D) and confirmed by the quantification of the dermal thickness 
(Figure 3.11 a).  
Counts of cell nuclei in the tissue (black arrows in Figure 3.10 A-D) revealed an 
increase in the number of cell infiltrating the ear after application of croton oil 











Figure 3.10 5-Tetrahydrocorticosterone (5-THB) and corticosterone (B) reduced 
swelling induced by croton oil when applied for 24 hours (h). Representative images of 
ear tissue stained with haematoxylin and eosin showing changes in the width of dermal layer 
after treatment with croton oil alone or together with steroids for 24 h. (A) untreated ear, (B) 
ear treated with croton oil only, (C) ear co-treated with croton oil and B (5 g), (D) ear co-
treated with croton oil and 5-THB (25 g). Arrows point to cell nuclei of infiltrating cells; 
c=cartilage; d = dermis, which can be found at both sides of the ear cartilage; only one 
dermal layer was highlighted for clarity. Magnification = 100x.  
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Figure 3.11 5-Tetrahydrocorticosterone (5-THB) and corticosterone (B) reduced 
swelling and cell infiltration induced by application of croton oil (CO) for 24 hours (h). 
Quantitative measurement of (a) dermal thickness and (b) cell infiltration after treatment 
with CO alone or together with steroids for 24 h. CTRL = control ears; ### = p < 0.0001, # = 
p < 0.05 vs CTRL; *** = p < 0.0001 vs CO; data (mean ± SEM) were analysed by one-way 
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3.3.3.3 Effect of 5-THB on infiltration of polymorphonuclear (PMN) 
cells  
Qualitative analysis of samples collected after 6 and 24 h of treatment with croton oil 
and stained with H&E showed a pool of inflammatory cells in the tissue and blood 
vessels. The majority of these cells displayed a nucleus with a multi-lobulated shape 
(Figure 3.12 A and B, black arrows), a presentation which is typical of PMN cells of 
which neutrophils represent the highest percentage. In order to quantify this pool and 
to investigate the effect of co-application of steroids, the activity of the enzyme 
myeloperoxidase (MPO), which is most abundantly expressed in neutrophils, was 
assessed. 
Application of croton oil for 6 and 24 h increased MPO activity compared with 
untreated ears; this increase was bigger at 6 h compared with 24 h.  Co-application of 
B (10 and 5 g) reduced this increase at both time points while 5-THB (25 g) did 
so only when co-applied for 24 h (Figure 3.13 a-b). At this time point the effect of 
5-THB was stronger than that of B (Figure 3.13 b).  
BA 400x 1000x
 
Figure 3.12 Croton oil application stimulated infiltration of polymorphonuclear (PMN) 
cells in ears. Representative images of dermal tissue and vessels of ears treated with croton 
oil and stained with haematoxylin and eosin showing PMN cell infiltration (black arrow). In 
this particular example the treatment lasted for 6 h. Magnification: A = 400X; B = 1000X. 
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Figure 3.13 Croton oil (CO)-induced increase of myeloperoxidase (MPO) activity in 
ears was decreased by application of 5-tetrahydrocorticosterone (5-THB) for 24 but 
not 6 hours (h). Quantification of MPO activity in auricular tissues treated either with CO 
alone or in combination with corticosterone (B) or 5-THB at the concentration indicated; 
CTRL = control ears. ### = p < 0.0001, & = 0.05 < p < 0.1 vs CTRL; *** = p < 0.0001, * = 
p < 0.05 vs CO; $ = p < 0.05.  Data (mean ± SEM) were analysed with one-way ANOVA 









Mechanisms of action of 5-tetrahydrocorticosterone 
  109 
3.3.3.4 Effect of 5-THB on abundance of transcripts of genes involved 
in the local inflammatory response 
The effect of 5-THB on abundance of transcripts for pertinent genes was 
investigated by real-time PCR only using ears from mice treated for 24 h, as this was 
the time point at which the compound showed anti-inflammatory properties. 
Treatment with croton oil alone increased the abundance of transcripts of the pro-
inflammatory genes Il6, Tnf, Il1 and Inf compared with untreated ears (Figure 
3.14 a-d). Of these, only the increase in Inf transcripts was reduced by co-treatment 
with B or 5-THB (Figure 3.14 d). Application of croton oil alone increased also the 
transcripts for the anti-inflammatory gene Dusp1 compared with untreated tissues 
(Figure 3.14 e). Interestingly, 5-THB, but not B, increased further the abundance of 
Dusp1 transcripts compared with tissue treated only with croton oil (Figure 3.14 e). 
Treatment with croton oil did not affect the abundance of transcripts of the anti-
inflammatory gene Annexin A1; B and 5-THB increased the abundance compared 
with tissues treated only with croton oil (Figure 3.14 f). 
The abundance of transcripts of genes controlling the permeability of the vasculature 
and infiltration of inflammatory cells was also studied. Treatment with croton oil 
alone increased the abundance of transcripts of all genes compared with untreated 
ears (Figure 3.15 a-f). Both B and 5-THB decreased, to a similar extent, the amount 
of mRNAs of Vegf, Pecam1, Icam1 and VE-cadherin (Figure 3.15 a, c-e) compared 
with the croton oil-treated group, but did not affect E-selectin or Mcp1 (Figure 3.15 b 
and f).  
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Figure 3.14 5-Tetrahydrocorticosterone (5-THB) increased the abundance of 
transcripts of the anti-inflammatory gene Dusp1 in inflamed ears. Real-time analysis of 
the abundance of transcripts of the pro-inflammatory genes (a) Il6, (b) Tnf, (c) Il1 and (d) 
Inf, and the anti-inflammatory genes (e) Dusp1 and (f) Annexin A1. CTRL = control ears; 
CO = croton oil; Ref = average of two housekeeping genes. Data (mean ± SEM) were 
analysed with one-way ANOVA followed by Tukey’s post-hoc test; ### = p < 0.0001, ## = 
p < 0.001, # = p < 0.05 vs CTRL; * = p < 0.05 vs CO; n=10/group.  
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Figure 3.15 In inflamed ears 5-tetrahydrocorticosterone (5-THB) and corticosterone 
(B) similarly decreased the abundance of transcripts of genes involved in the control of 
vascular permeability. Real-time analysis of the abundance of transcripts of the vascular 
and inflammatory genes (a) Vegf, (b) E-selectin, (c) Pecam1, (d) Icam1, (e) Ve-cadherin 
and (f) Mcp1. CTRL = control ears; CO = croton oil; Ref = average of two housekeeping 
genes. Data (mean ± SEM) were analysed with one-way ANOVA followed by Tukey’s post-
hoc test; ### = p < 0.0001, ## = p < 0.001, # = p < 0.05 vs CTRL; ** = p < 0.001, * = p < 
0.05 vs CO; & = 0.05 < p < 0.1 vs CO; n=10/group. 
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During inflammation tissues go through a process of remodelling to allow the 
recovery of homeostasis and the healing process to take place. These processes are in 
part dependent upon enzymes such as metalloproteinases (MMPs) and tissue 
inhibitors of metalloproteinases (TIMPs). Treatment with croton oil increased the 
abundance of transcripts of Mmp2, Timp2, Mmp9 and Mmp10 compared with 
untreated ears (Figure 3.16 a-d). 5-THB did not affect the abundance of any of the 
transcripts, while B decreased the amount of mRNAs of Mmp9 compared with the 
group treated only with croton oil (Figure 3.16 c).  
In response to the action of MMPs and TIMPS, and to the inflammatory process 
itself, structural changes take place in the extracellular matrix to allow, for example, 
for the movement of inflammatory cells and for the recovery of the physiological 
architecture of the tissue after the damage. The abundance of transcripts of genes 
encoding structural proteins was, therefore, examined. Application of croton oil 
alone increased the abundance of transcripts for all genes investigated: keratin 6, 
actin and collagen 4a1 (Figure 3.17 a-c). B suppressed this increase for all of them 
(Figure 3.17 a-c), whereas 5-THB did so only for actin and collagen 4a1 (Figure 
3.17 b, c). 
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Figure 3.16 In inflamed ears 5-tetrahydrocorticosterone (5-THB) did not affect the 
abundance of transcripts of genes involved in remodelling of the extracellular matrix 
(ECM). Real-time analysis of the abundance of transcripts of (a) Mmp2, (b) Timp2, (c) 
Mmp9 and (d) Mmp10. CTRL = control ears; CO = croton oil; Ref = average of two 
housekeeping genes, B = corticosterone. Data (mean ± SEM) were analysed with one-way 
ANOVA followed by Tukey’s post-hoc test; ### = p < 0.0001, ## = p < 0.001, # = p < 0.05 
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Figure 3.17 In inflamed ears 5-tetrahydrocorticosterone (5-THB) decreased the 
abundance of transcripts of Col4a1 and Actin. Real-time analysis of the abundance of 
transcripts of (a) keratin 6, (b) actin and (c) Col4a1. CTRL = control ears; CO = croton oil; 
Ref = average of two housekeeping genes, B = corticosterone. Data (mean ± SEM) were 
analysed with one-way ANOVA followed by Tukey’s post-hoc test; ### = p < 0.0001, # = p 
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3.3.4 Are the anti-inflammatory effects of 5-THB dependent 
on the glucocorticoid receptor (GR)?  
3.3.4.1 Development of a model 
3.3.4.1.1 Topical application of RU486 
In order to investigate whether the anti-inflammatory effect of 5-THB on the croton 
oil model of irritant dermatitis is mediated by GR, the antagonist RU486 was used. 
Firstly, a working method to deliver the compound needed to be developed. To begin 
with, RU486 was applied topically on the ears of mice in conjunction with croton oil 
and B for 24 h. Attenuation of the effects of B was considered a positive control. 
As seen in Figure 3.18, croton oil application caused swelling of the ear, while B 
decreased it. Topical application of RU486 did not diminish the anti-inflammatory 















































Figure 3.18 Topical application of RU486 did not prevent the anti-inflammatory effect 
of corticosterone (B) on swelling induced by croton oil (CO). Quantification of the effect 
of B alone or together with RU486 (6.2 g) on the inflammatory swelling induced by the 
application of CO for 24 hours. Data (mean ± SEM) were analysed by one-way ANOVA 
followed by Tukey’s post-hoc test; * = p < 0.05 vs CO; n=6-10/group. 
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3.3.4.1.2 Subcutaneous injection of RU486 
Subcutaneous injection of a solution of RU486 in DMSO was tested as an alternative 
method to deliver the drug. As seen in Figure 3.19, injection of the vehicle (DMSO) 
alone reduced the swelling induced by application of croton oil for 24 h, 
independently from co-treatment with B, and injection of RU486 alleviated this 
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Figure 3.19 Subcutaneous injection of dimethyl sulfoxide (DMSO) reduced swelling in 
inflamed ears independently from treatment with corticosterone (B), and injection of 
RU486 alleviated this effect. Quantification of the inflammatory swelling in ears after either 
treatment with croton oil (CO) alone or injection of DMSO or RU486 prior to application of 
croton oil alone or together with B for 24 hours. Data (mean ± SEM) were analysed with 
one-way ANOVA followed by Tukey’s post-hoc test; ** = p < 0.001 vs CO; # = p < 0.05 vs 
CO+DMSO; $ = p < 0.05 vs CO + B 5g + DMSO; n=4/group. 
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3.3.4.1.3 Optimisation of the model 
The results above indicated that the injection itself caused a reduction in the swelling 
induced by croton oil. This may have been an effect due either to the release of 
endogenous corticosterone in response to stress, or to the intrinsic anti-inflammatory 
properties of the vehicle DMSO, which have been documented before in this model 
(Coruzzi, Pozzoli et al. 2011) and others within the department (Dr. Mark Miller, 
personal communication), or to a combination of these two factors. As a 
consequence, two simultaneous measures were taken to address these concerns, by 
performing the experiment in adrenalectomised (ADX) mice and administering 
RU486 dissolved in ethanol. 
Firstly, ADX mice were tested for their response to treatment with croton oil alone 
for 24 h in comparison with non-ADX mice. The extent of the inflammatory swelling 
between ADX and non-ADX mice was not different (Figure 3.20 a). When ADX 
mice were co-treated with croton oil and B, the steroid alleviated the swelling 
(Figure 3.20 b). These results showed that this was a suitable working model in 
which to test the effect of ethanolic RU486 on the anti-inflammatory properties of 
5-THB. 
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Figure 3.20 In adrenalectomised (ADX) mice croton oil (CO) caused ear swelling to a 
similar extent to non-ADX animals, and this inflammatory response was alleviated by 
corticosterone (B). (a) Quantification of inflammatory swelling (mg) after application of 
CO alone in ADX (CO ADX) and non-ADX (CO) mice. (b) Quantification of the anti-
inflammatory effect of B in ADX mice treated with CO. Data (mean ± SEM) were analysed 
with unpaired Student’s t-test; * = p < 0.05; n=4/group. 
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As shown in Figure 3.21, subcutaneous injection of ethanol alone or ethanolic 
RU486 did not have any effect on swelling induced by croton oil applied for 24 h, 


































Figure 3.21 Injection of ethanol (EtOH) or ethanolic RU486 did not affect swelling 
induced by croton oil (CO) in adrenalectomised (ADX) mice. Quantification of ear 
swelling (in mg) after application of either CO alone or after injection of either ethanol or 
ethanolic RU486 (6.2 g/mouse). Data (mean ± SEM) were analysed with one-way ANOVA 
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3.3.4.2 Effect of RU486 on the anti-inflammatory properties of 5-THB 
The developed model was used to test the effect of injection of ethanolic RU486 on 
the reduction of swelling caused by 5-THB after treatment for 24 h. As shown in 
Figure 3.22, B decreased croton oil-induced swelling, and the effect was attenuated 
by injection of RU486; 5-THB lowered inflammatory swelling but in contrast to B, 
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Figure 3.22 The anti-inflammatory effect of 5-tetrahydrocorticosterone (5-THB) on 
swelling was not attenuated by the subcutaneous injection of RU486. Quantification of 
ear swelling after injection of either ethanol (EtOH) or ethanolic RU486 prior to treatment 
with either croton oil (CO) alone or together with corticosterone (B) or 5-THB for 24 
hours. Data (mean ± SEM) were analysed using one-way ANOVA followed by Tukey’s 
post-hoc test; * = p < 0.05 vs CO + EtOH; # = p < 0.05 vs CO + B5 + EtOH; £ = p < 0.05 vs 
CO + RU486; n=5-7/group.  
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3.3.5 Is the physiological production of 5-THB important in 
the response to the treatment with croton oil and for the 
anti-inflammatory effects of steroidal substrates? 
3.3.5.1 Analysis of the transcripts encoding 5-reductase isozymes in 
ears 
The presence of mRNAs encoding the two enzymes 5-R1 and 5-R2 in the ear was 
investigated first by PCR analysis. As shown in Figure 3.23 (a), a DNA band was 
present for both enzymes in the positive controls (liver for 5-R1 and prostate for 
5-R2), while only 5-R1 was detected in the ear sample. Analysis of the influence 
of the treatment with croton oil alone and in combination with steroids on the 
abundance of transcripts of Srd5a1 (5-R1) was also performed by real-time PCR 
analysis (Figure 3.23 b). Application of croton oil decreased the abundance of 
mRNAs of Srd5a1, whilst treatment with B or 5-THB did not affect this change. 
 
Figure 3.23 Transcripts for 5-reductase type 1 (5-R1), but not 5-reductase type 2 
(5-R2), were present in ear tissue, and their abundance was decreased by the 
application of croton oil (CO) alone. (a) PCR analysis for 5-R1 (product = 240 base pairs 
(bp)) and 5-R2 (product = 299 bp) in ear (E), liver (L) and prostate (P) samples. Numbers 
represent the base pairs of the DNA ladder; the symbol (-) represents the negative controls. 
(b) Real-time analysis of transcripts of Srd5a1. CTRL = control ears; Ref = average of two 
housekeeping genes. Data (mean ± SEM) were analysed with one-way ANOVA followed by 
Tukey’s post-hoc test; # = p < 0.05, $ = 0.05 < p < 0.1 vs CTRL; n = 10/group. 
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Having verified the presence of transcripts for 5-R1 in ear tissues, the inflammatory 
response induced by application of croton oil was then tested in mice with genetic 
disruption of the enzyme. 
3.3.5.2 Effects of the genetic disruption of 5-R1 on the concentration 
of B in plasma after treatment with croton oil  
The concentration of B in plasma of mice with genetic disruption of 5-R1 (5-R1
-/-
) 
and wild type littermates (WT), treated with croton oil for 6 or 24 h, was measured. 
No differences were found between the two groups (Figure 3.24).  
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Figure 3.24 Plasma corticosterone (B) did not differ between mice with genetic 
disruption of 5-reductase type 1 (5-R1
-/-
) and wild type littermates after treatment 
with croton oil. Quantification of the concentration of B in plasma (nM) by ELISA in mice 
treated with croton oil for 6 or 24 hours (h). WT = wild type littermates. Data (mean ± SEM) 
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3.3.5.3 Analysis of the inflammatory response to application of croton 
oil in 5-R1 -/- mice 
The extent of the swelling was similar between 5-R1
-/-
 and WT mice, both after 6 
and 24 h (Figure 3.25). The oedema was greater at 6 than at 24 h for both groups, 
reproducing what was shown previously in C57BL6 wild type mice (compare Figure 
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Figure 3.25 Swelling induced by treatment with croton oil (CO) for 6 and 24 hours (h) 
was not affected by the genetic disruption of 5-reductase type 1 (5-R1). Quantification 
of ear swelling (mg) induced by application of croton oil for either 6 or 24 h. WT = wild type 
littermates. Data (mean ± SEM) at each time point were analysed by unpaired Student’s t-
tests; *** = p < 0.0001 vs -/- 6h, ** = p < 0.01 vs WT 6h; n=6-8/group. 
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3.3.5.4 Efficacy of B and 5-THB to suppress swelling in 5-R1-/- mice 
Both after 6 and 24 h of treatment, B (EC50, 10 and 5 g respectively) reduced the 
inflammatory swelling caused by croton oil application; the reduction was similar in 
the two genotypes (Figure 3.26 a, b).  
As there is the possibility that the anti-inflammatory effects of 5-THB could be due 
to its reversion back to B through the action of 5-R1, its anti-inflammatory 
properties was tested at 24 h in 5-R1
-/-
 mice. As shown in Figure 3.26 b, 5-THB 
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Figure 3.26 Genetic disruption of 5-reductase type 1 (5-R1) did not affect the ability 
of 5-tetrahydrocorticosterone (5-THB) and corticosterone (B) to reduce swelling 
induced by croton oil (CO). Quantification of swelling in 5-R1
-/-
 and wild type (WT) 
littermates mice after application of either CO alone or in combination with B or 5-THB 
for (a) 6 or (b) 24 hours (h). Data (mean ± SEM) were analysed with one-way ANOVA 
followed by Tukey’s post-hoc; *** = p < 0.0001, * = p < 0.05 vs CO; n=8-13/group. 
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3.4 Discussion 
In this chapter the ability of 5-THB to suppress inflammation was tested using the 
murine model of croton oil-induced irritant dermatitis through the analysis of a 
variety of molecular parameters. The main findings were that 5-THB is anti-
inflammatory, but compared with B is less potent and acts more slowly, being 
effective after 24 but not 6 h of treatment. At 24 h, 5-THB reduced total cell 
infiltration in ear tissues and swelling to a similar extent to B. Interestingly, when the 
effect on infiltration of polymorphonuclear cells was studied, 5-THB reduced the 
amount of this population more than B. At a molecular level, 5-THB and B affected 
the same transcripts, mainly those encoding molecules involved in the control of 
vascular permeability; however, the RNA abundance of the anti-inflammatory gene 
Dusp1 was induced significantly only by the 5-reduced steroid. The most intriguing 
difference concerned the putative receptor targeted by the two steroids. While the 
anti-inflammatory action of B was prevented by the GR antagonist RU486, this did 
not happen for 5-THB, suggesting that one the reasons for the selectivity of 5-
THB may be represented by the way it binds to GR, or by binding to a different 
receptor.  
The application of croton oil to induce contact irritant dermatitis represents a 
research model that has been widely used in the literature (Gahring, Osborne et al. 
2010), and it is a well-characterised steroid-responsive system. Croton oil is derived 
from the seeds of Croton tiglium, a tree originating from Asia. It is a mixture of 
lipids and contains irritant diester compounds that are derivatives of the diterpene 
phorbol, and that have both inflammatory and tumour-promoting activities (Hecker 
1967; Tragni, Tubaro et al. 1985). Concerning the inflammatory properties, the 
damage caused by the mixture of chemicals applied to the skin promotes the release 
of cytokines and other molecules (i.e. IL1 and ATP) from keratinocytes and other 
local cells, which in turn stimulates the release of pro-inflammatory cytokines such 
as IL1 and IL6 from epidermal and dermal cells (McKenzie and Sauder 1990; 
Barker, Mitra et al. 1991; Effendy, Loffler et al. 2000; Lee, Stieger et al. 2013) 
causing swelling and infiltration of leukocytes. Research investigating the kinetics of 
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this inflammatory response (Tonelli, Thibault et al. 1965; Tubaro, Dri et al. 1986; 
Towbin, Pignat et al. 1995; Baumgartner, Sosa et al. 2011) showed that the 
predominant effect at the early stages of the process is tissue oedema which is at its 
peak at 6 h-post treatment; this phase is followed by one characterised by cell 
infiltration (mainly neutrophils) which is at its highest between 12 and 24 h, 
depending on the study. Most studies though have evaluated the inflammatory 
responses after treatment for 6 or 24 h, and therefore it was decided to test the effects 
of the interventions at these two time points. The data presented in this chapter are in 
accordance with the literature, therefore the choice of 6 and 24 h was deemed a good 
strategy in order to test how 5-THB and B affected two different aspects of the 
inflammatory process. Furthermore, quantification of transcripts of pro-inflammatory 
genes showed a significant increase in groups treated with croton oil compared with 
untreated ears. The increase was greater at 6 compared with 24 h. In a preceding 
study (Towbin, Pignat et al. 1995), it was found that the abundance of IL1 protein 
was higher at 24 than 6 h, suggesting, as expected, that the kinetics of the production 
of the cytokine is slower than that of the transcripts. 
Studies investigating the anti-inflammatory effect of GCs in the croton oil model of 
dermatitis have mostly used dexamethasone and other steroidal pharmaceutical 
formulations (i.e. HC) as positive controls, showing their potent inhibitory effects 
both on swelling and cell infiltration (Muramoto, Goto et al. 2010; Baumgartner, 
Sosa et al. 2011; da Silva, Sperotto et al. 2013; Vassallo, De Tommasi et al. 2013; 
Pacheco, Pinto Nde et al. 2014). To our knowledge, B has never been tested in this 
model; as a consequence, its potency and efficacy in reducing swelling was 
investigated before comparison with 5-THB. Treatment with B induced a dose-
dependent reduction of ear swelling, confirming the powerful anti-inflammatory 
properties of this endogenous glucocorticoid. The half maximal effective 
concentration of B, or EC50, was calculated at 6 and 24 h and used in subsequent 
experiments. Using the EC50 allowed a more straightforward comparison between the 
two steroids as it is a measure of the potency of a drug. It was found that the EC50 at 
6 h was double the EC50 at 24 (10 g versus 5 g). As already mentioned, the acute 
inflammation at the early stage (6 h) is mainly due to oedema of the tissue, while at 
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the later stage (24 h) it is predominantly the result of cell infiltration. The fact that B 
is efficacious at both time points indicates that both stages are affected by its action; 
however the fact that it is less potent at the early stage would suggest a stronger 
effect on cell infiltration. In previous unpublished studies from my supervisors’ 
group, HC was used in the same model and the EC50 was found to be equivalent to 
approximately 13 g at 24 h. The data presented here indicate that B is 2.6 times 
more potent than HC in this model.  
Interestingly, 5-THB significantly reduced ear swelling at 24 but not 6 h. Although 
the use of both 15 and 25 g produced similar effects on oedema, only the higher 
concentration was statistically effective. The post-hoc comparison between the effect 
of the steroid at 15 g and the croton oil group returned a p value of 0.07. This may 
be due to the higher variability of the data at this concentration, as suggested by the 
bigger standard error associated to the mean at 15 compared with 25 g. This also 
indicates that because of this variability, the number of animals investigated should 
be increased in order to boost the statistical power of the analysis. Importantly 
though, at both concentrations, 5-THB was as efficacious as B in reducing ear 
swelling making it three to five times less potent than B in this model, and therefore 
comparable to HC. In previous abovementioned studies the EC50 of 5-THB was 
found to be 25 g, at 24h. In this chapter the reduction in swelling caused by 5-
THB applied at its EC50 was not 50% but approximately 35%. Observations made 
during the execution of the experiments suggested that this mouse model is very 
susceptible to external changes, and the inflammatory response could be alleviated 
by any stressor. It is therefore possible that the change in the operator may have 
played a role in the response to the treatments. Some variability was seen also 
between experiments carried out by the same researcher. Nonetheless, 5-THB was 
shown to be an effective anti-inflammatory agent. 
Histological analysis showed that B was effective in reducing both swelling and cell 
infiltration at both time points, while 5-THB reduced both parameters only at 24 h. 
The infiltration of polymorphonuclear (PMN) cells was analysed by performing the 
MPO activity assay. In the literature this measurement is taken to be representative 
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of the population of neutrophils infiltrating the tissue since they are the main cell 
type recruited to the site of injury in acute inflammation, and they represent the most 
abundant pool of cells among PMNs. More importantly, neutrophils have been 
shown to be the predominant cell type reaching the site of inflammation in this 
model (Gahring, Osborne et al. 2010). The results shown in this chapter confirmed 
what was seen microscopically and reported in the literature (Tubaro, Dri et al. 1986; 
Baumgartner, Sosa et al. 2011) in that these cells were barely detectable in control 
ears and increased in number following croton oil treatment, being more abundant at 
24 than at 6 h. Regarding the effect of the two steroids, the more powerful inhibitory 
effect of 5-THB at 24 h compared with B suggests that 5-THB may work 
predominantly by limiting the amount of PMNs, and therefore most likely 
neutrophils, recruited to the site of injury rather than influencing the onset of 
oedema. This would also be in accordance with the fact that the anti-inflammatory 
effect was seen at 24 but not at 6 h post-treatment. 
GCs have been shown previously to inhibit migration of neutrophils (Pitzalis, 
Pipitone et al. 2002), and promote their phagocytosis by macrophages therefore 
stimulating the resolution of inflammation (Heasman, Giles et al. 2003). The work 
presented in this chapter was limited in that it analysed only one cell population. 
Future work needs to address the issue of cell infiltration in a quantitative manner by 
using techniques such as fluorescence-activated cell sorting (FACS). In this way, the 
numbers of cells infiltrating the ear tissue in response to croton oil and steroids could 
be investigated; more importantly, analysis of the different populations of cells 
present would also be possible. 
Oedema and recruitment of inflammatory cells, including neutrophils, to the site of 
inflammation are processes that include many steps, from the release of 
inflammatory cytokines (i.e. IL1) from keratinocytes and resident cells (i.e. 
Langerhans cells) to changes in vascular permeability and the expression of adhesion 
molecules (Grabbe and Schwarz 1998; Tsunemi, Saeki et al. 2006). To understand 
which of these steps may be influenced by 5-THB and B, analysis of transcripts for 
a variety of genes was performed. Croton oil application significantly elevated 
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abundance of mRNAs of pro-inflammatory genes and of the anti-inflammatory gene 
Dusp1; B and 5-THB, compared with the croton oil group, significantly reduced the 
abundance of transcripts of Inf only, and increased that of Annexin 1A, whereas only 
5-THB increased significantly also that of Dusp1. Increase in the abundance of 
protein or transcripts of Il6, Il1 and Tnf following croton oil application has been 
reported before (Towbin, Pignat et al. 1995; Ku, Jeong et al. 2009; Chen, Li et al. 
2012; da Silva, Sperotto et al. 2013; Klose, Zigrino et al. 2013; Mo, 
Panichayupakaranant et al. 2013; Tian, Matsuo et al. 2013). INF is a pro-
inflammatory factor mainly produced by Th1 cells, belonging to the adaptive 
immune system. It is known that the inflammatory cells found in irritant contact 
dermatitis are mainly cells of the innate immune response, as opposed to those found 
in allergic contact dermatitis. However, there is some evidence indicating that cells 
of the adaptive immune response may also play a role in irritant dermatitis (Kawase, 
Hoshino et al. 2003; Tsunemi, Saeki et al. 2006). The reduction in the amount of 
transcripts of Inf seen with B and 5-THB may indicate that they reduce the 
recruitment of lymphocytes to the site of inflammation. As mentioned above, the use 
of techniques such as FACS would help to clarify the cellular targets of the two 
steroids. 
DUSP1, or dual specificity phosphatase 1, is an anti-inflammatory protein which, to 
our knowledge, has never been studied in models of irritant dermatitis, and therefore 
the findings presented here are new. Expression of DUSP1 is known to increase in 
response to a variety of inflammatory and irritant stimuli (Ryser, Massiha et al. 
2004), such as dinitrofluorobenzene (DNFB) (Ayush, Lee et al. 2012), representing a 
negative feedback mechanism through which the inflammatory response is 
controlled. In effect, DUSP1 is a negative regulator of the MAPK signal transduction 
pathways, activation of which leads to production of cytokines, chemokines and 
adhesion molecules (Ayush, Lee et al. 2012). Its abundance is increased by 
conventional glucocorticoids (Kassel, Sancono et al. 2001), by non-steroidal anti-
inflammatory compounds such as the non-essential amino acid l-glutamine (Ayush, 
Lee et al. 2012), and by new selective modulators of the glucocorticoid receptor 
(Joanny, Ding et al. 2012). The increase in transcripts abundance induced by 5-
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THB suggests that this may represent a mechanism through which this steroid works. 
Another anti-inflammatory gene tested was annexin A1, known also as lipocortin. 
The protein encoded by the gene was originally described as one of the molecules 
responsible for the anti-inflammatory properties of glucocorticoids (Oliani, Ciocca et 
al. 2008), and acts as a regulator of cells of the innate immune response. It has been 
shown that its expression on the surface of neutrophils inhibits their adhesion to 
endothelial cells diminishing their recruitment (Oliani, Ciocca et al. 2008). B and 5-
THB moderately increased abundance of transcripts of annexin A1 in inflamed ears 
indicating a possible molecular mechanism for the reduction in neutrophil infiltration 
seen with the two steroids.  
When a panel of transcripts of genes controlling the vasculature and adhesion of 
inflammatory cells was investigated, B and 5-THB were found to similarly 
decreased the abundance of those of Vegf, Pecam1, Icam1 and Ve-cadherin in 
inflamed ears. Disruption of the epidermal barrier leads to activation of endothelial 
cells (ECs) by factors such as VEGF. This factor has been previously shown to be 
highly expressed in response to croton oil application (Bae, Shim et al. 2010). This 
protein is a potent activator of the vasculature, increasing the expression of 
permeability and adhesion molecule (i.e. ICAM1) and representing one of the first 
molecules to be produced locally after injury, most likely by keratinocytes (Bae, 
Shim et al. 2010; Zeng, Zheng et al. 2013). Many studies have directly investigated 
croton oil-induced increases in permeability by use of Evans blue (Shin, Joo et al. 
2010; Chen, Li et al. 2012; Kobayashi, Tsubosaka et al. 2013; Sarashina, Tsubosaka 
et al. 2013), but only a few have analysed the process from a molecular point of view 
(Gahring, Osborne et al. 2010; Tian, Matsuo et al. 2013). Recruitment of 
inflammatory cells to the site of inflammation is a process involving different steps 
including tethering to and rolling on the endothelium, adhesion and paracellular 
migration (Hebeda, Teixeira et al. 2008). The process is coordinated by expression of 
adhesion molecules. E-selectin and ICAM1 are important in tethering, rolling and 
adhesion, while PECAM1 and VE-cadherin are involved in paracellular migration. It 
is know that glucocorticoids inhibit endothelium-leukocyte interaction (Cavalcanti, 
Lotufo et al. 2007; Hebeda, Teixeira et al. 2008). B and 5-THB seem to modulate 
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each of the steps, and they could do so either by affecting the transcription of these 
molecules, via for example inhibition of the NF-B pathway, which is known to be 
affected by steroids in endothelial cells (Brostjan, Anrather et al. 1996), or by 
inhibiting the expression of other permeability-promoting protein such as VEGF. 
Effective recruitment of inflammatory cells and tissue repair after injury are 
mechanisms dependent on tissue remodelling. Important molecules involved in this 
process belong to the family of metalloproteinases (MMPs); they cleave different 
kinds of extracellular matrix components, freeing space for cells to move and tissue 
to be re-built. Furthermore, complete recovery of the skin structure after injury is 
only possible if there is deposition of extracellular structural proteins, such as 
collagen. Disruption of the epidermal barrier by croton oil is a traumatic event that 
leads to activation and death of mainly keratinocytes. The combined action of 
MMPs, structural protein such as collagen 4a1, which forms the basement membrane 
beneath the epidermal and endothelial layers, and cytoskeletal proteins that allow 
proliferation and cellular migration, represents the response to the injury through 
which the skin heals itself. This is well represented in this chapter’s model by the 
increase induced by croton oil of the abundance of transcripts of genes involved in 
tissue remodelling. Both 5-THB and B similarly decreased that of Col4a1 and Actin 
in inflamed ears, while only B decreased that of Mmp9 and Keratin6. It is worth 
noting that the effect of 5-THB on Mmp9 and Keratin6, despite not being 
significantly different from the croton oil group, is not different from the group 
treated with B either. This indicates that the results of the statistical test have 
probably been influenced by a larger variability in the 5-THB group, and that also 
this steroid may be decreasing transcription of the two genes. 
Inhibition of transcription by GCs has been reported in the literature for all the genes 
mentioned, although mainly under non-inflammatory conditions and mostly in in 
vitro experiments targeted to specific cell types (keratinocytes and endothelial cells) 
(Dhabhar and McEwen 1999; Radoja, Komine et al. 2000; Stojadinovic, Lee et al. 
2007; Donet, Bosch et al. 2008; Shikatani, Trifonova et al. 2012). The protein 
keratin6 is a marker of activated keratinocytes and hyper-proliferative epidermis and 
is known to be repressed by glucocorticoids (Radoja, Komine et al. 2000; 
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Stojadinovic, Lee et al. 2007; Donet, Bosch et al. 2008), while actin is a cytoskeletal 
component universally present in cells. These factors, together with collagen, are 
important in tissue remodelling/scar formation which are processes involving cell 
proliferation (Stojadinovic, Lee et al. 2007). It is known that steroids cause skin 
thinning, and this side effect is likely due to their inhibitory action on MMPs, cell 
proliferation (i.e. of keratinocytes) and structural proteins (Stojadinovic, Lee et al. 
2007). The data presented here though do not necessarily suggest a negative impact 
on the healing process and skin thickness. Indeed, a likely possibility is that the 
decrease in abundance of the transcripts of these genes is an indirect effect of the 
reduction of inflammation caused by the two steroids. Previous unpublished data 
showed that 5-THB, in contrast to B, did not inhibit transcription of collagen genes, 
and did not cause skin thinning when applied to uninjured and non-inflamed skin. To 
better clarify the effects of this compound on structural molecules with an important 
role in maintaining skin integrity, wider approaches such as microarray or RNAseq 
analysis would be useful.  
It is worth taking into consideration that the results obtained from the study of 
abundance of transcripts may not reflect the abundance of protein in the tissue. GCs 
have been shown to inhibit translation rather than transcription for some molecules 
involved in inflammation (Clark 2003; Clark, Dean et al. 2003). As a consequence, 
while no significant effect of 5-THB and B was found on transcription of cytokines, 
it may well be possible that they may be affecting the translation of those transcripts. 
By the same token, any significant effect seen regarding adhesion molecules, 
vascular and remodelling factors should be further verified by analysis of protein 
abundance, either by ELISA, Western blotting or immunohistochemistry.  
In order to investigate the involvement of the glucocorticoid receptor in the anti-
inflammatory properties shown by 5-THB and B, the literature was reviewed for 
previous studies using the GR receptor antagonist RU486 in the croton oil model of 
irritant dermatitis. A small number of papers was retrieved (Iwasaki, Mishima et al. 
1995; Pinto, Morais et al. 2010) and adaptation of their methods was carried out in 
order to efficiently deliver the drug. The lack of an effect of topical application of 
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RU486 on the anti-inflammatory properties of B suggested that his method was not 
efficiently delivering the drug to GR in the skin. Previous work in literature (Iwasaki, 
Mishima et al. 1995) used creams containing RU486, and this indicates a possible 
issue with delivery from the vehicle used in the experiment presented here. It was 
also possible that the concurrent administration of RU486 and B has played a role, 
since routinely the antagonist is given before the agonist. The results obtained with 
subcutaneous injections of RU486 showed that the antagonist could partially relieve 
the action of B; however, injection of the vehicle DMSO also had anti-inflammatory 
effects that could be partially reversed by RU486. There is the possibility that DMSO 
may have had anti-inflammatory properties per se, as shown previously in this model 
(Coruzzi, Pozzoli et al. 2011); another plausible scenario is that a glucocorticoid-
dependent stress response was taking place as suggested by the effect of RU486 in 
mice injected with DMSO. It is worth noting that control groups were never included 
in the previous publications mentioned above, leaving one wondering about the true 
interpretation of the data published. 
In order to resolve the issue described above, two measures were adopted 
simultaneously: removal of the adrenal glands and change of the vehicle in which 
RU486 was dissolved from DMSO to ethanol. It could be argued that the best 
approach would have been to test first whether DMSO represented the main problem, 
and then, based on the results, proceed with the adrenalectomy. However, based on 
the experience of my supervisors’ group with the high variability of this model, 
applying the two measures together was judged as the best approach to tackle two 
possible issues while at the same time sparing important resources.  
From the experiments a surprising result emerged: while RU486 relieved the anti-
inflammatory effect of B this was not the case for 5-THB. This finding was 
unexpected because 5-THB has been shown to displace dexamethasone from rat 
GR (McInnes, Kenyon et al. 2004). However, 5-THB has never been tested in vivo 
in the presence of RU486 before, and these results indicate that binding to GR may 
not occur in this context in which many molecular and cellular players are involved, 
in contrast to the in vitro scenario. A novel selective glucocorticoid receptor 
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modulator, called Compound A, has shown a promising dissociated profile in 
different in vitro and in vivo models. However, some aspects of its action are not GR-
dependent (Beck, Drebert et al. 2013). In line with this, 5-THB’s behaviour may 
not be totally dependent on GR either, which may also explain the different time-
course, compared to B, of its anti-inflammatory effects in the dermatitis model.  
The fact that 5-THB, naturally produced in the body, shows anti-inflammatory 
properties, raises the intriguing possibility that it may have a role in the physiological 
response to inflammatory stimuli. Two enzymes are responsible for its production, 
5-R1 and 5-R2, and only transcripts for 5-R1 were detected in skin by PCR. 
Previous research has shown the expression of both in genital and non-genital skin 
(Nixon, Upreti et al. 2011), in human and rat samples. This is the first study, to our 
knowledge, that analysed the transcription of these enzymes in murine skin. 
Quantitative analysis of transcripts was also performed, and their abundance was 
decreased by treatment with croton oil. This pattern suggests a local regulation of the 
action of glucocorticoids and their metabolism by croton oil, or by a component of 
the response to croton oil which is not altered by GCs. This is possibly a mechanism 
put in place by cells in order to re-establish tissue homeostasis after injury by 
reducing metabolism of endogenous GCs and, therefore, promoting the anti-
inflammatory action of the substrate steroid. However, the data may also reflect a 
decrease in the proportion of 5-R1 expressing cells as a new inflammatory cell 
population not transcribing the gene may infiltrate the ears. Indeed, the PCR analysis 
presented here was performed in non-inflamed skin, containing virtually no cells of 
the circulating immune system; since a reduction in the amount of transcripts of 
Srd5a1 was seen after croton oil application, it seems unlikely that infiltrating 
immune cells express the gene. In humans and rats, 5-R1 seems more widely 
distributed than 5-R2 in the immune system, but previous work in mice  showed no 
transcripts in murine bone marrow-derive macrophages (Yang, Nixon et al. 2011). 
In physiological conditions, the HPA axis maintains the concentration of GCs in the 
circulation within certain values. Emotional or physical stress triggers the release of 
corticotrophin-releasing hormone (CRH) from the hypothalamus, which in turn 
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stimulates the production of adrenocorticotropic hormone (ACTH) from the anterior 
pituitary; this drives the release of cortisol (in humans) or B (in rodents) from the 
adrenal gland into the blood stream (Keller-Wood and Dallman 1984). This pathway 
is controlled by negative feedbacks in order to return the concentration of cortisol or 
B to basal levels once the stressful stimulus is no longer present. The concentration 
of B in plasma in wild type and 5-R1
-/-
 mice at cull, after treatment with croton oil, 
was higher than that measured in unstressed mice in previous studies (Livingstone, 
Di Rollo et al. 2014), but it was comparable to that measured under mild stress 
(handling stress). This suggests that the animals were stressed, probably because of 
cage disturbance, at the moment of cull. No differences were found between 
genotypes in the studies presented in this chapter, in contrast to the investigation 
mentioned above. This may have been due to differences between the two studies in 
the duration of the stressful stimulus, and in the way the stress was induced. It would 
be of interest to quantify plasma B in response to the handling stress induced by 
topical treatment. However, because the effects of croton oil and steroids were 
comparable in the two genotypes, any difference concerning B concentration in 
response to stress is unlikely to have played a role in this model.  
To test for a putative role of 5-R1 in inflammation and response to steroidal 
treatment, mice with genetic disruption of 5-R1 (5-R1
-/-
) were employed. The 
results obtained indicate that local metabolism of glucocorticoids in the ear tissue 
does not play an important role in either the physiological inflammatory response or 
in the anti-inflammatory properties of 5-THB or B. As mentioned above, previous 
studies (Livingstone, Barat et al. 2014) showed that 5-R1
-/-
 mice had a worse 
hepatic metabolic phenotype than wild type littermates, suggesting an important role 
for the production of 5-THB in controlling local physiology. Other reports showed 
that local metabolism is a central factor in determining the local availability of GCs 
and their effects, both on physiology and pathology (Tiganescu, Walker et al. 2011; 
Yau and Seckl 2012; Morgan, McCabe et al. 2014; Terao, Tani et al. 2014; 
Tiganescu, Hupe et al. 2014). The present study did not show a role of local A-ring 
metabolism of GCs in the response to irritation of the skin, suggesting perhaps that 
the physiological amount of GCs or/and the activity of the enzyme in adult mice skin 
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may be too low to be of any influence. A remark worth making is that even though I 
showed the presence of transcripts of Srd5a1 in ears, this may not correlate with the 
presence of a functional enzyme.     
In summary, 5-THB is anti-inflammatory, albeit in a less potent fashion than B, and 
shows a different time course of efficacy compared with the compound from which it 
derives. Investigation of the molecular mechanisms revealed that the two steroids 
influenced anti-inflammatory pathways in a similar manner. However, a couple of 
exciting differences were found. Firstly, 5-THB significantly increased abundance 
of the transcripts of Dusp1, a central anti-inflammatory gene. This result confirmed 
unpublished findings (Dr. Alastair Jubb, personal communication) which showed 
Dusp1 transcripts to be increased by 5-THB in human monocyte-derived 
macrophages. Secondly, the anti-inflammatory properties of 5-THB, in contrast to 
B, were not relieved by the GR antagonist RU486. This finding suggests that the 
reason behind the lack of side effects seen with the use of 5-THB may lay upstream 
of any molecular pathways investigated, specifically on the receptor to which it is 
bound. This is an exciting discovery that, while challenging the current knowledge 
about how GCs work, also opens new doors to a better scientific understanding of 
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Chapter 4: Anti-inflammatory properties of 5-
THB in vitro 
4.1 Introduction 
In Chapter 3, 5-THB was shown to possess anti-inflammatory properties in an in 
vivo model of inflammation. Surprisingly, these effects were not antagonised by the 
GR antagonist RU486. In order to complement these data, the ability of this 5-
reduced steroid to suppress the release of cytokines from macrophages in a GR-
dependent manner was investigated in simpler cellular in vitro models. 
Classically, macrophages in culture are activated by cytokines such as TNF or 
molecules such as lipopolysaccharide (LPS), a major component of the membrane of 
gram-negative bacteria. LPS stimulates macrophages by binding to the Toll-like 
receptor (TLR) 4, and triggering the activation of intracellular signalling pathways 
which leads to the production of pro-inflammatory cytokines (i.e. IL6, TNF and 
IL1 through the action of transcription factors such as NF-B and AP-1 (Nissen 
and Yamamoto 2000; Kracht and Saklatvala 2002; De Bosscher, Vanden Berghe et 
al. 2003; Fukao and Koyasu 2003; Fang, Pengal et al. 2004; Hayden and Ghosh 
2008; O'Neill 2008; O'Neill 2008). Despite monumental efforts to determine how 
GCs work to inhibit inflammation, the mechanisms involved are not yet fully 
understood. There is strong evidence, though, that the binding of GR monomers to 
NF-B and AP-1, with consequent blockage of their transcriptional activity, is one of 
the principal mechanisms involved (Schoneveld, Gaemers et al. 2004; Barnes 2006; 
De Bosscher and Haegeman 2009). This mechanism is referred to as trans-
repression. GCs also interfere with pro-inflammatory stimuli in a more indirect 
manner. For instance, they are known to suppress the activation of p38 MAPK by 
inducing the expression of the protein MAPK phosphatase 1 (MKP1), also known as 
DUSP1, and annexin 1 by a mechanism that is classically called trans-activation and 
is dependent mainly, but not only, on binding to DNA of GR homodimers (Barnes 
2006; Bhattacharyya, Brown et al. 2007; Ayroldi, Cannarile et al. 2012; Vandevyver, 
Dejager et al. 2012; Vandevyver, Dejager et al. 2013).  
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To shed light on the molecular mechanisms potentially involved in the anti-
inflammatory properties of 5-THB, the cell line RAW264.7 and murine bone 
marrow-derived macrophages were employed in the studies presented in this chapter.  
Hypothesis 
5-THB suppresses the release of pro-inflammatory cytokines from stimulated 
macrophages in culture through actions mediated by GR. 
Objective 
The objective of this chapter is: 
- To investigate the anti-inflammatory properties of 5-THB in comparison with B, 
in cell culture models of inflammation by biochemical and molecular analysis. 
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4.2 Material and methods 
4.2.1 General 
4.2.1.1 Materials 
Materials for general cell culture and experimental treatments were obtained as 
described in section 2.1.1.1. Steroids, including the GR antagonist RU486, were from 
Steraloids (Newport, RI, USA); lipopolysaccharide (LPS) was from Sigma-Aldrich 
(Dorset, UK). 
4.2.1.2 Preparation of steroids and LPS 
Steroids were dissolved in ethanol, and LPS diluted in sterile PBS, to obtain 
solutions 1000 times more concentrated than required. This allowed the addition of 1 
L of steroid or LPS solutions into each mL of medium at the time of treatment, 
minimising the effect of ethanolic vehicle. The solutions containing steroids were 
stored at -20 ºC for a maximum of one month before being replaced. LPS solutions 
were stored at 4 ºC. When needed, the solutions were allowed to stand at RT for 30 
min prior to use. 
4.2.1.3 General treatments 
Stimulation of macrophages was performed by treatment with LPS at the 
concentration and for the time indicated. A “vehicle group” was always included by 
treating the cells with PBS instead of LPS. When steroidal treatments were used, the 
cells were pre-incubated for 1 h with steroids or vehicle (ethanol) prior to stimulation 
with LPS. Details are given about specific adjustments made throughout the 
experiments. Each treatment was performed in triplicate, and each experiment 
repeated between three and eight times, as indicated. 
4.2.1.4 ELISA  
ELISA was performed as described in section 2.3.3.3. 
4.2.2 RAW264.7 cells 
4.2.2.1 Source of cells  
The cell line RAW264.7 was obtained as described in section 2.1.1.2.1. 
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4.2.2.2 Cell culture 
Cells were thawed as described in section 2.2.2. They were maintained in culture in 
T75 flasks in normal-serum medium (prepared as described in section 2.1.1.3.2), and 
passaged as described in section 2.1.2 When a confluence of approximately 80% was 
reached, they were passaged into 12-well culture plates at a concentration of 3-4 x 
10
5
 cells/well. Twenty four hours later, they were washed twice with PBS and the 
medium was replaced with stripped-serum medium, prepared as described in section 
2.1.1.3.2. After 24 h, the experimental treatments were started. 
4.2.2.3 Adjustment of the treatments 
Development of an in vitro model of inflammation 
To select the time at which to analyse the anti-inflammatory properties of 5-THB 
compared with B, RAW264.7 cells were pre-treated with the positive control B (1 
M) and stimulated with LPS for 4 and 24 h. The amount of LPS to use (30 ng/mL) 
was calculated in previous experiments performed in my supervisors’ group (Nixon 
2011) and represented a sub-maximal concentration of LPS. 
 
Optimization of the anti-inflammatory response with 5-THB 
The effect of 5-THB on the abundance of transcripts for cytokines was firstly 
investigated employing an equivalent concentration to B (1 M). Thereafter, to 
assess if the response obtained with the compound was maximal, cells were pre-
treated with steroid at a range of concentrations (1-10 M) before being stimulated 
with LPS for 24 h. 
 
Time-dependent variations of levels of pro-inflammatory cytokines  
To assess the time-course of response of pro-inflammatory cytokines, cells were 
stimulated with LPS for 1, 2, 4, 8, 16 and 24 h in the presence or absence of steroids, 
and transcripts for IL6 and TNF were quantified by real-time PCR as described in 
section 2.3.1.6. Production of IL6 after stimulation either with LPS alone or LPS and 
steroids for 4, 8, 16 and 24 h was performed using ELISA. 
Investigation of the causes for the lack of reproducibility  
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The results obtained showed that the in vitro model of inflammation based on the use 
of LPS-stimulated RAW264.7 cells was not reproducible with respect to the data 
obtained through real-time PCR and ELISA regarding pro-inflammatory cytokines. 
The following steps were taken to address this problem: 
1) comparison of different batches of 5-THB prepared at different times prior 
to the beginning of experiments 
2) utilisation of a new batch of RAW264.7 cells, purchased afresh 
The following outcomes were assessed: the abundance of transcripts for pro-
inflammatory cytokines was measured after 24 h treatment either with LPS or LPS 
plus steroids, using 5-THB at 1, 3 and 10 M. Production of cytokines was 
measured after treatment for 4, 8, 16 and 24 h using ELISA. 
4.2.2.4 Real-time PCR 
Total RNA was extracted and mRNA abundance quantified as described in sections 
2.3.1.2 and 2.3.1.6. The primers employed were as described in Table 2.1, Chapter 2. 
4.2.2.4.1 Data analysis of real-time PCR data 
For quantification of transcripts through real-time PCR, the abundance of mRNAs 
for each gene was represented in relation to the abundance of a chosen housekeeping 
gene. The housekeeping gene used was Tbp due to the lack of significant changes in 
the abundance of transcripts following treatment with LPS or LPS + steroids. For 
each sample and each gene studied the values presented in the graphs were calculated 
as follow: value sample X/value Tbp sample X. 
4.2.3 Murine bone marrow-derived macrophages 
4.2.3.1 Source of cells and materials 
Bone marrow-derived macrophages (BMDMs) were isolated from C57BL/6 mice as 
described in section 2.1.1.2.2. 
4.2.3.2 Culture 
BMDMs were cultured and allowed to differentiate as described in section 2.1.1.2.2. 
On the 6
th
 day of culture, normal-serum medium was replaced with serum-stripped 
medium (both prepared as described in section 2.1.1.3) after two washes with PBS. 
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After 24 h, treatments either with LPS alone or in conjunction with steroids were 
started. 
4.2.3.3 Treatments 
Steroidal solutions were prepared as described in section 4.2.1.2. In addition, the GR 
antagonist RU486 was used. The compound was dissolved in ethanol prior to each 
experiment, at a concentration 1000 times higher than the final concentration in the 
culture medium. 
Treatments either with LPS alone or B or 5-THB + LPS were performed as 
described in section 4.2.1.3. Treatments with RU486 (or vehicle) were started one 
hour prior to treatment with steroids (or vehicle in the case of the LPS only-treated 
group), followed by treatment with LPS. 
4.2.3.4 Western blotting 
4.2.3.4.1 Materials 
General materials were obtained as described in section 2.3.3.1.1. Specific primary 
antibodies employed were: monoclonal rabbit anti-NF-B and monoclonal rabbit 
anti-IB from New England Biolabs, Ltd (Hitchin, Hertfordshire, UK); monoclonal 
mouse anti- tubulin and monoclonal mouse anti-GAPDH from Insight 
Biotechnology (Wembley, Middlesex, UK). Secondary antibodies were: IRDye 
800CW Goat Anti-Rabbit IgG (H+L) and IRDye 800CW Goat Anti-mouse IgG 
(H+L) from LI-COR Biosciences Ltd (Cambridge, Cambridgeshire, UK). Protein 
extraction from BMDMs, quantification and Western blotting analysis were 
performed as described in sections 2.3.3.1.2, 2.2.3.1.3 and 2.3.3.1.4. All primary 
antibodies were diluted 1:1000 in BSA (5% w/v in TBST), and all secondary 
antibodies were diluted 1:10000 in Milk (5% w/v in TBST). 
4.2.3.4.2 Procedure 
Protein extraction from BMDMs, quantification and Western blotting analysis were 
performed as described in sections 2.3.3.1.2, 2.2.3.1.3 and 2.3.3.1.4. 
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4.2.3.4.3 Quantification of protein expression 
The abundance of protein was calculated by using the Odyssey® Imaging software 
(LI-COR biosciences, Cambridge, Cambridgeshire, UK). In order to normalise the 
abundance of the proteins of interest to the total amount of proteins present in the 
blots, the intensity values associated with the bands representing NF-B and IB 
were divided by the values of the corresponding bands representing GAPDH and -
Tubulin respectively, and graphed as such. Two different proteins were chosen as 
loading controls in order to avoid interfering signals from the antibodies; this choice 
made it possible to detect the protein of interest and either GAPDH or -Tubulin on 
the same blot, without the necessity for stripping and re-probing.  
4.2.4 Data analysis 
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4.3 Results 
4.3.1 Development of a glucocorticoid sensitive-model of 
inflammation in RAW264.7 cells 
At both 4 and 24 h post LPS stimulation, the abundance of mRNAs of the genes Il6 
and Tnf in the LPS-treated group was higher compared with the vehicle-treated 
cells (Figure 4.1 a, b); for Il6 this increase was more pronounced at 24 h than at 6 h, 
while for Tnf was comparable at both time points. Treatment with B reduced the 
amount of transcripts at both end points (Figure 4.1 a) compared with LPS-treated 
cells, having a bigger effect at 24h. Following these observations it was decided to 
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Figure 4.1 Treatment with lipopolysaccharide (LPS) for 4 and 24 hours (h) increased 
the abundance of transcripts of the genes Il6 and Tnf in RAW264.7 cells; this increase 
was attenuated by corticosterone (B). Real-time PCR analysis of the abundance of 
transcripts of the pro-inflammatory genes (a) Il6 and (b) Tnf after treatment for 4 or 24 h 
with either vehicle (V), LPS (30 ng/mL) alone or B (1 M) + LPS. Data (mean ± SEM) were 
analysed by one-way ANOVA with Tukey’s post-hoc test; ### = p < 0.0001, # p < 0.05 vs 
matched V; *** = p < 0.0001, ** = p < 0.001 vs matched V + LPS; £££ = p < 0.0001; N = 4. 
Tbp = TATA-box binding protein, A.U. = arbitrary unit. 
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4.3.2 Ability of 5-THB to suppress the inflammatory 
response in RAW264.7 cells 
4.3.2.1 Response of the model to 5-THB 
In the initial experiments, treatment for 24 h with B and 5-THB (1 M) reduced the 
abundance of transcripts of Il6, Tnf and Il1 compared with LPS only treated cells 
(Figure 4.2 a-c). In all cases, B had a greater effect than 5-THB. The steroids 
reduced to a similar extent also the basal amount (non-stimulated cells) of transcripts 
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Figure 4.2 5-Tetrahydrocorticosterone (5-THB) lowered the abundance of mRNAs 
of Il6, Tnf and Il1 following stimulation with lipopolysaccharide (LPS). Real-time 
PCR analysis of the abundance of transcripts of the genes (a) Il6, (b) Tnf and (c) Il1 
following treatment with either vehicle (V), corticosterone (B) or 5-THB (both 1M), 
either in presence or absence of LPS (30 ng/mL). Data (mean ± SEM) were analysed by one-
way ANOVA with Tukey’s post-hoc test; ^^^ = p < 0.0001; ## = p < 0.001, # p < 0.05 vs 
matched V; *** = p < 0.0001, ** = p < 0.001 vs matched V; £££ = p < 0.0001, £ = p < 0.05; 
N = 6. Tbp = TATA-box binding protein, A.U. = arbitrary unit. 
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4.3.2.2 Concentration-dependent response of glucocorticoids to 
decrease transcripts of inflammatory genes 
As above, stimulation with LPS for 24 h increased the abundance of transcripts of 
Il6, Tnf and Il1 in comparison with unstimulated cells (Figure 4.3 a-c); treatment 
with B decreased the basal amount of transcripts of all genes, while treatment with 
5-THB decreased only that of Il1 (Figure 4.3 a-c white columns). Pre-treatment 
with B (1 and 3 M) decreased the abundance of mRNAs of all genes in cells 
stimulated with LPS; 5-THB reduced the amount of transcripts in stimulated cells 
only when given at 3 M, and the effect was comparable with that of the same 
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Figure 4.3 5-Tetrahydrocorticosterone (5-THB) decreased lipopolysaccharide 
(LPS)-induced increase of transcripts of inflammatory genes when given at 3 but not at 
1 M. Quantification by real-time PCR of the abundance of mRNAs of (a) Il6, (b) Tnf and 
(c) Il1 following treatment (24 h) with either vehicle (V), corticosterone (B) or 5-THB 
either in the presence or absence of LPS (30 ng/mL) stimulation. Numbers after steroids 
indicate the concentration in M. Data (mean ± SEM) were analysed by one-way ANOVA 
with Tukey’s post-hoc test. ^^^ and £££ = p < 0.0001, £ = p < 0.05; ### = p<0.001; # = p< 
0.05 vs matched V; *** = p < 0.0001, ** = p < 0.001, * = p < 0.05 vs matched V; N = 6. Tbp 






Mechanisms of action of 5-tetrahydrocorticosterone 
  149 
4.3.3 Investigation of the possible causes for the lack of 
reproducibility 
4.3.3.1 Time-dependent variation in the abundance of transcripts of 
inflammatory genes in response to 5-THB and B 
Given the conflicting data regarding the extent of the response with 5-THB 
(compare Figure 4.3 with Figure 4.2), a time course of the abundance of mRNAs of 
Il6, Tnf and Il1 following LPS stimulation, with or without pre-treatment with 
steroids, was conducted. Compared with cells treated with vehicle, treatment with 
LPS increased the abundance of mRNAs of Il6 after 8 and 24 h; of Tnf after 1, 2, 4, 
8 and 24 h and of Il1 after 4, 8 and 24 h (Figure 4.4 a-c, squares vs circles). B (1 
M) reduced this increase after treatment lasting 24 h for Il6; 1 and 2 h for Tnf and 
4, 8 and 24 h for Il1; in addition, B unexpectedly increased transcripts of Il6 and 
Tnf at 16 h (Figure 4.4 a-c, triangles). 5-THB (1 M) only reduced the increase 
caused by LPS of Tnf after 1 h treatment and, like B, increased the abundance of 
transcripts of all genes at 16 h (Figure 4.4 a-c, inverted triangles). 
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Figure 4.4 5-Tetrahydrocorticosterone (5-THB) did not affect the abundance of 
transcripts of pro-inflammatory genes at any time point analysed. Quantification by 
real-time PCR of the time-dependent changes in the abundance of transcripts of (a) Il6, (b) 
Tnf and (c) Il1 following treatment with either vehicle (V), corticosterone (B) or 5-THB 
(both 1 M) of RAW264.7 cells, either in presence or absence of stimulation with 
lipopolysaccharide (LPS, 30 ng/mL). Data (mean ± SEM) were analysed with repeated 
measured ANOVA with Tukey’s post-hoc test. *** = p < 0.0001, ** = p < 0.001, * = p < 
0.05 (steroid) vs (V + LPS); ^^^ = p < 0.0001, ^^ = p < 0.001, ^ = p < 0.05, & = 0.1 < p < 
0.05 (V + LPS) vs (V); N = 4. Tbp = TATA-box binding protein, A.U. = arbitrary unit. 
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4.3.3.2 Influence of 5-THB solutions 
Solutions of 5-THB stored for different times prior to the execution of the 
experiments were analysed for their effects on the abundance of mRNAs of gene 
encoding cytokines after treatment for 24 h. 
None of the 5-THB solutions decreased the abundance of transcripts compared with 
the LPS-stimulated group (Figure 4.5 a, b); the use of 5-THB solutions prepared 1 
month prior to the experiments (A in the graphs) increased transcripts of Tnf when 
given at 1 M (Figure 4.5 b). The effects induced by the 1 month-old solution were 
significantly different from those of the solutions prepared 2 weeks prior to the 
experiments (B in the graphs), and the same day (C in the graphs); there was some 
variation according to the gene investigated (Figure 4.5 a, b). For this reason, it was 
decided that for future experiments the solutions of 5-THB were to be freshly 
prepared each time and, for consistency, this approach was taken also for the 
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Figure 4.5 Solutions of 5-tetrahydrocorticosterone (5-THB) stored for different 
times differently affected the abundance of transcripts for cytokines. Quantification by 
real-time PCR of the abundance of transcripts for (a) IL6 and (b) TNF following treatment 
with either vehicle (V), LPS alone (30 ng/mL) or lipopolysaccharide (LPS) + corticosterone 
(B) or 5-THB for 24 h. A = 1 month-old solution, B = 2 week-old solution, C = solution 
prepared the same day. Data (mean ± SEM) were analysed with one-way ANOVA with 
Tukey’s post-hoc test. ^^^ = p < 0.0001 vs V; *** = p < 0.0001, ** = p < 0.001, * = p < 
0.05, & = 0.1 < p < 0.05 vs V + LPS; £££ = p < 0.0001, ££ = p < 0.001, £ = p < 0.05; N = 4. 







Mechanisms of action of 5-tetrahydrocorticosterone 
  153 
4.3.3.3 Investigation of a new batch of RAW264.7 cells 
4.3.3.3.1 Concentration-dependent production of cytokines in response to 
LPS 
To assess whether the variability in the response to 5-THB was due to variations in 
cell performance following multiple passages, IL6 and TNF production was 
quantified after stimulation with different concentrations of LPS for 24 h in fresh 
cells. As shown in Figure 4.6, the production of both cytokines by the new batch of 
cells increased in a concentration-dependent manner. As the concentration used in 
experiments performed previously (30 ng/mL, arrow in graph) was not causing a 
maximal response, it was decided to continue the investigation on the new batch of 
cells with the same concentration.  
 
Figure 4.6 Lipopolysaccharide (LPS) stimulated the production of IL6 and TNF in a 
concentration-dependent manner in a new batch of RAW264.7 cells. Cells were 
stimulated for 24 hours with increasing concentrations of LPS and the amounts of IL6 and 
TNF quantified by ELISA. Data (mean ± SEM) were analysed with one-way ANOVA with 
Tukey’s post-hoc test. *** and ^^^ = p < 0.0001, * = p < 0.05, & = 0.1 < p < 0.05 vs vehicle 
(0 in the graph); N = 4. Arrow points to the concentration utilised in the experiments (30 
ng/mL). The graph was drawn as a semi-log plot; the log values were substituted with the 
real concentrations of LPS to give a clearer representation. 
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4.3.3.3.2 Abundance of transcripts in response to steroids 
The abundance of transcripts of Il6, Tnf and Il1 increased in LPS-stimulated cells 
after 24 h of treatment compared with vehicle-treated group. B (1 M) lowered this 
increase for each gene compared with LPS-treated cells; 5-THB reduced the 
abundance of transcripts of Il6 at all concentrations tested, but did so for Il1 only at 
10 M; in addition, at 3 M it increased the abundance of mRNAs of Tnf in 
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Figure 4.7 5-Tetrahydrocorticosterone (5-THB) decreased the abundance of 
transcripts of Il6 and Il1 in cells stimulated with lipopolysaccharide (LPS). 
Quantification by real-time PCR of the abundance of transcripts of (a) Il6, (b) Tnf and (c) 
Il1 following treatment with either vehicle (V), LPS (30 ng/mL) or corticosterone (B)/5-
THB + LPS for 24 hours. Data (mean ± SEM) were analysed with one-way ANOVA 
followed by Tukey’s post-hoc test; ^^^ = p < 0.0001 vs V; *** = p < 0.0001, * = p < 0.05 vs 
V + LPS; ### = p < 0.0001, ## = p < 0.001, # = p < 0.05, ns = not significant vs B + LPS; N 
= 4. Tbp = TATA-box binding protein, A.U. = arbitrary unit. 
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4.3.3.3.3 Time-dependent production of pro-inflammatory cytokines in 
response to steroids 
Some concentration-dependent effects of 5-THB were seen employing a new batch 
of RAW264.7 cells. In order to analyse whether these results could be made more 
robust, the time-dependent production of IL6 and TNF in response to treatment 
with LPS alone and in combination with steroids was investigated.   
Production of IL6 increased in a time-dependent manner when cells were stimulated 
with LPS compared with the vehicle-treated group (Figure 4.8 a). Release of TNF 
increased with the addition of LPS at every time point with the greatest increase seen 
at 4 and 8 h (Figure 4.8 b). Pre-treatment with B reduced the LPS-stimulated 
production of cytokines at 8, 16 and 24 h for IL6, and TNF. An effect of 5-THB 
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Figure 4.8 5-Tetrahydrocorticosterone (5-THB), in contrast to corticosterone (B), 
did not reduce the lipopolysaccharide (LPS)-stimulated production of cytokines. Time-
dependent variations in the concentration of (a) IL6 and (b) TNF as quantified by ELISA 
after treatment with either vehicle (V), LPS (30 ng/mL) alone or together with B (1 M) or 
5-THB (1-3 M). Data (mean ± SEM) were analysed with repeated measured ANOVA 
with Tukey’s post-hoc test; ^^^ = p < 0.001 vs matched V; *** = p < 0.0001 vs matched 
LPS; N = 4.  
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4.3.4 Development of an in vitro model of inflammation using 
murine bone marrow-derived macrophages 
The use of RAW264.7 cells proved challenging because of the variability of the 
results regarding the ability of 5-THB to suppress the LPS-stimulated inflammatory 
response, with some evidence of the system/cells becoming less responsive with 
time. As a consequence, primary cells, murine bone marrow-derived macrophages 
(BMDMs) were employed as a complementary model. 
Firstly, the production of IL6 and TNF in response to increasing concentrations of 
LPS was investigated (Figure 4.9). Stimulation with LPS increased the concentration 
of both proteins compared with vehicle-treated cells when administered at a 
concentration equal to or greater than 1 ng/mL. For both cytokines, the greatest effect 
was achieved with a concentration of LPS of 3 ng/mL. 
 
Figure 4.9 Concentration of cytokines by murine bone marrow-derived macrophages in 
response to stimulation with increasing concentrations of lipopolysaccharide (LPS). 
Quantification by ELISA of the concentration of IL6 and TNF following stimulation with 
either vehicle (0 on the graph) or a range of concentrations of LPS. Data (mean ± SEM) were 
analysed by one-way ANOVA followed by Tukey’s post-hoc test; *** and ^^^ = p < 0.0001, 
* = p < 0.05 vs vehicle; N = 6. Arrows indicate the concentrations of LPS chosen for 
subsequent experiments. The graph was drawn as a semi-log plot; the log values were 
substituted with the real concentrations of LPS to give a clearer representation. 
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4.3.5 Ability of 5-THB to suppress the inflammatory 
response 
The response to 5-THB, in comparison with that of B, was investigated using three 
different concentrations of LPS (1, 3 and 100 ng/mL), corresponding to three 
different responses in terms of the abundance of cytokines produced. 
As shown in Figure 4.10, stimulation with every concentration of LPS increased the 
concentration of IL6 and TNF compared with vehicle-treated cells. The largest 
increase was achieved with a concentration of 3 ng/mL for IL6 and of 3 and 100 
ng/mL for TNF. Treatment with B prior to LPS stimulation decreased the 
abundance of both cytokines compared with groups treated with any concentration of 
LPS. Treatment with 5-THB decreased the concentration of IL6 compared with 
cells stimulated with LPS at 3 ng/mL, and reduced the abundance of TNF increased 
by stimulation with LPS at 1 and 3 ng/mL. In both cases the greatest effect was 
achieved at a concentration of 5-THB of 10 M.  
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Figure 4.10 5-Tetrahydrocorticosterone (5-THB) reduced the lipopolysaccharide 
(LPS)-stimulated production of IL6 and TNF in murine bone marrow-derived 
macrophages. Quantification by ELISA of the concentration of (a) IL6 and (b) TNF 
following treatment with either vehicle (V) or a range of concentrations of LPS, with or 
without pre-incubation with either corticosterone (B) or 5-THB. Data (mean ± SEM) were 
analysed by one-way ANOVA followed by Tukey’s post-hoc test; ^^^ = p < 0.0001 vs 
matched V; *** = p < 0.0001, ** p < 0.001, * p < 0.05, & = 0.1 < p < 0.05 vs matched V + 
LPS; N = 8.   
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4.3.6 Mechanisms of action of 5-THB 
In order to investigate the mechanisms whereby 5-THB was reducing the 
production of cytokines in BMDMs, western blotting analysis of the signaling 
molecules IB and NF-B was performed. 
Treatment with LPS alone (1, 3 and 100 ng/mL) increased the abundance of both 
proteins compared with vehicle-treated cells (Figure 4.11 b, c). B decreased the 
abundance of NF-B protein in cells stimulated with any concentration of LPS 
(Figure 4.11 b), while it increased the abundance of IB when cells were stimulated 
with 1 ng/mL of LPS, and decreased it when LPS was given at 100 ng/mL; the 
steroid had no effect in the group treated with LPS at 3 ng/mL (Figure 4.11 c). 5-
THB did not affect the abundance of NF-B at any concentration of LPS (Figure 
4.11 b), and decreased the abundance of IB only when cells were stimulated with 
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Figure 4.11 5-Tetrahydrocorticosterone (5-THB) and corticosterone (B) 
differentially affected the expression of IBa and NF-B in murine bone marrow-
derived macrophages (BMDMs) stimulated with lipopolysaccharide (LPS). (a) 
Representative images of western blotting analysis for NF-B (left-hand side) and IB 
(right-hand side) in BMDMs treated with vehicle (V) or stimulated with LPS (1, 3, 100 
ng/mL) with or without pre-incubation with B (1 M) or 5-THB (10 M); GAPDH = 
glyceraldehyde 3-phosphate dehydrogenase, Tub = Tubulin, kDa = kilo Dalton. (b) and 
(c) Quantification of western blotting analysis for the abundance of NF-B and IB. Data 
(mean ± SEM) were analysed by one-way ANOVA followed by Tukey’s post-hoc test; * = p 
< 0.05 vs corresponding V + LPS; ^^^ = p < 0.0001, ^^ = p < 0.001, ^ = p < 0.05 vs V; N = 
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4.3.7 Are the effects of 5-THB mediated by GR? 
In order to investigate whether the inhibitory effects of the steroids on the LPS-
stimulated production of cytokines in BMDMs were mediated by GR, the  abundance 
of IL6 in response to B and 5-THB, in cells stimulated with LPS, were examined 
after pre-incubation with the GR antagonist RU486. 
As shown in Figure 4.12, treatment with LPS (3 ng/mL) alone increased the 
concentration of IL6 in the medium compared with the vehicle-treated group; pre-
incubation with RU486, followed by stimulation with LPS, decreased the abundance 
of the cytokine in a concentration-dependent manner compared with the LPS only-
treated cells. When B (1 M) was added alone before treatment with LPS, the 
amount of IL6 decreased compared with the group treated with LPS only; this 
decrease was partially reversed by the addition of RU486 at 1 M. Treatment with 
5-THB alone (10 M), before LPS stimulation, reduced the concentration of IL6 
compared with the LPS only-treated group; the addition of increasing concentration 
of RU486 (0.01, 0.1, 1 M) had an additive effect on that of 5-THB. Incubation 
with RU486 alone at concentrations of 0.01, 0.1 and 1 M reduced IL6 concentration 
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Figure 4.12 RU486 decreased the amount of IL6 released by lipopolysaccharide (LPS)-
stimulated murine bone marrow-derived macrophages and this effect added to that of 
5-tetrahydrocorticosterone (5-THB). Quantification by ELISA of the concentration of 
IL6 released after treatment with vehicle (V) or incubation with either LPS alone (3 ng/mL), 
or RU486 (concentrations as indicated) + LPS, or RU486 + B (1 M) + LPS or RU486 + 
5-THB (10 M) + LPS. Data (mean ± SEM) were analysed by one-way ANOVA followed 
by Tukey’s post-hoc test; the dotted lines refer to the comparisons between cells treated only 
with LPS and those treated with LPS + steroids + increasing concentrations of RU486; ^^^ = 
p < 0.0001 vs V; *** = p < 0.0001, ** = p < 0.001, * = p < 0.05 vs LPS alone (first white 
bar); £ = p < 0.05 vs B + LPS (first grey bar); $$$ = p < 0.0001, $$ and ## = p < 0.001, # p < 
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4.4 Discussion 
In Chapter 3, 5-THB was shown to have anti-inflammatory properties in an in vivo 
model of dermatitis in mice; surprisingly, experiments performed with the GR 
antagonist RU486 suggested that this receptor may not be the mediator of 5-THB’s 
effect. In order to explore these findings, simpler in vitro systems, widely in use in 
the literature for testing the anti-inflammatory potential of compounds, were 
employed in the present chapter. The utilisation of the murine macrophage cell line 
RAW264.7 proved challenging because of the lack of reproducibility in the results 
obtained. The employment of an alternative cell model, the culture of macrophages 
derived from bone marrow isolated from mice (BMDMs), gave consistent results, 
and showed that 5-THB decreased the LPS-stimulated production of IL6 and 
TNF. Furthermore, the investigation of possible mechanisms involved highlighted 
some differences between the ways whereby 5-THB and B work. In effect, while 
the latter affected expression of IB and NF-B and its action seemed dependent on 
GR, the former affected only the abundance of IB and its behaviour was not 
antagonised by the GR antagonist RU486. This offers support for the lack of effect of 
this antagonist to attenuate the in vivo effects of 5-THB shown in Chapter 3. 
Macrophages are central players during the inflammatory response, and are capable 
of releasing a wide range of pro-inflammatory molecules which help orchestrate the 
response of the host to a wide range of insults, such as injury, infections and irritants 
(Novak and Koh 2013). GCs affect a broad spectrum of physiological processes, and 
are best known for their potent anti-inflammatory effects, brought about by their 
ability to interact either directly or indirectly with different cell populations of the 
immune system, among which are macrophages. In vitro models, while far from 
being perfectly representative of the complex inflammatory response occurring in 
vivo, are nonetheless useful tools for the investigation of the molecular pathways 
associated with inflammation. They have been used extensively (both in academia 
and industry) for dissection of the mechanisms through which GCs work and for the 
discovery and analysis of new promising anti-inflammatory agents. In addition, they 
allow for the study of pharmacological interventions in a simplified, controlled 
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environment, with the possibility of performing modifications of different 
parameters; this would be difficult in an in vivo setting. The murine RAW264.7 cell 
line has been widely employed as a steroid-responsive in vitro model for the study of 
a variety of putative or established anti-inflammatory compounds (Koo, Lee et al. 
2004; Koo, Song et al. 2004; Rehman, Yoshihisa et al. 2012; Kenny, McCarthy et al. 
2013; Shin, Ryu et al. 2013). In addition, previous studies in my supervisors’ 
laboratory on the properties of 5-THB were performed in this cell line, and to date, 
in vivo data have been obtained only from murine models. B was used as a positive 
control as its inhibitory effects on the production of cytokines are well-established in 
in vivo and in vitro models, including RAW264.7 cells (Xin, Zhang et al. 2011; 
Song, Zhao et al. 2013). 
Initially, 5-THB was shown to reduce the abundance of transcripts of genes 
encoding pro-inflammatory cytokines in RAW264.7 cells, albeit in a weaker fashion 
than B. However, when the same effects were investigated with higher 
concentrations of the compound, the results were not reproduced. As a consequence, 
the protocol used was questioned by testing a variety of experimental conditions; 
while in some of the experiments some effects of the compound were seen, the 
results did not point to one particular factor being responsible for the lack of 
reproducibility. On a technical note, the experiments looking at the time-dependent 
variations of abundance of transcripts for cytokines revealed different kinetics 
according to the gene analysed. These differences indicate that the analysis of 
different cytokines at the same time point may be not the ideal protocol to apply in 
the search for effects of a compound. An unexpected finding of the time-course 
studies was that after 16 hours of stimulation with LPS alone, the abundance of 
transcripts of inflammatory genes was not increased by this inflammatory stimulus. 
This result proved challenging to explain, also after a review of the literature. It has 
been reported that the release of cytokines from alveolar macrophages, and the 
inhibitory effects of dexamethasone, were dependent on culture methodology 
(Higham, Lea et al. 2014), and even though this research pointed to a more 
pronounced difference in unstimulated cells, the finding suggests that macrophages 
may be particularly susceptible to culture conditions. In addition, at the same point in 
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time (16 h), B and 5-THB seemed to have pro-inflammatory effects. A dual role of 
GCs in controlling inflammation has been previously shown (Zhong, Wang et al. 
2013; Cruz-Topete and Cidlowski 2014). In particular, in peritoneal macrophages 
activated with LPS, dexamethasone regulated transcription of pro-inflammatory 
cytokines in an opposite manner depending on its concentration, increasing it at low 
concentration and decreasing it at high concentration (Lim, Muller et al. 2007). 
Despite some of the results with the RAW264.7 cells pointing to a pro-inflammatory 
behaviour of 5-THB, the data were not reproducible, and therefore their 
interpretation is not possible.  
The employment of a new batch of RAW264.7 cells initially provided promising 
results as 5-THB reduced in a concentration-dependent manner the abundance of 
transcripts of Il6, but this did not translate into an inhibition of the release of the 
cytokine in the medium. The demonstration, in subsequent experiments employing 
BMDMs, that 5-THB consistently suppressed the production of IL6 and TNF, 
suggests that the lack of reproducibility in RAW264.7 cells may lie in the overall 
lack of suitability of the model system itself. 
The use of primary BMDMs for the investigation of macrophage biology is an 
excellent tool; cells are freshly isolated and differentiated for each experiment. While 
this may result in a degree of variability due to the intrinsic differences between 
animals, it also has the advantage of providing the researcher with a fresh source of 
macrophages (Weischenfeldt and Porse 2008). Since BMDMs have been employed 
in my supervisors’ laboratory in previous studies analysing 5-THB, a protocol was 
already available (Yang 2009). However, it was decided to investigate the response 
of these cells to different concentrations of LPS in order to determine the best 
experimental conditions, particularly in light of the results obtained with the 
RAW264.7 cell model. The production of TNF was generally lower than that of 
IL6, and they reached different maximal responses. This mirrored results obtained 
previously with RAW264.7 cells after incubation with 30 ng/mL of LPS for 24 
hours. It was decided to study the effects of 5-THB using three concentrations of 
LPS, representing three different aspects of the BMDMs concentration-response 
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curve obtained: 1 ng/mL which induced a low-moderate response, 3 ng/mL which 
stimulated the maximal response and 100 ng/mL which corresponded to a production 
of IL6 in between the two concentrations; in the literature the suggested 
concentration is in the 10-100 ng/mL range, but it is recognised that the response of 
macrophages varies according to the protocol employed, the source of LPS and its 
purity. Consequently, the optimal range must be determined empirically (Mosser and 
Zhang 2008). The ability of 5-THB to suppress the release of IL6 and TNF varied 
according to the cytokine and the concentration of LPS investigated; in contrast, B 
lowered the production of both cytokines under any experimental condition tested, 
indicating the existence of differences regarding the mechanisms whereby the two 
compounds work to reduce pro-inflammatory responses. In Chapter 3, no effects of 
5-THB were seen on the abundance of transcripts for IL6 and TNF in inflamed 
ears. It is possible that the compound may affect the production of the cytokines also 
in the dermatitis model by acting at post-transcriptional level, but this mechanism has 
not been studied yet; however, it also likely that differences between the in vivo 
situation and the in vitro model may account for divergent effects of 5-THB.   
To clarify which mechanisms may be differentially influenced by the two steroids, 
analysis of the expression of the transcription factor NF-B and the signalling 
molecule IB was performed. Stimulation with LPS only increased the abundance 
of NF-B at any concentration, with a pattern resembling that of the production of 
TNFt may well be that TNF was responsible for inducing part of the augmented 
expression of NF-B (De Bosscher, Vanden Berghe et al. 2003; Vandevyver, 
Dejager et al. 2012). The amount of IB was also increased by all concentrations of 
LPS. As mentioned in the introduction to this chapter, inflammatory stimuli activate 
downstream molecules such as NF-B and AP-1 to up-regulate the expression of 
pro-inflammatory mediators. Between the time when the cell encounters a stimulus 
and the activation of such transcription factors, other intermediate events take place. 
They depend on the activity of molecules such as p38 MAPK and IB; the latter 
binds to NF-B in the cytoplasm and impedes its translocation to the nucleus when 
the cell is in a resting state (De Bosscher, Vanden Berghe et al. 2003). Upon 
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inflammatory stimulation, a protein kinase phosphorylates IB inducing its 
degradation, and so freeing NF-B. The results presented here indicate that 
incubation with LPS may promote the release of inflammatory cytokines by 
increasing also the abundance of NF-B protein, in addition to promoting its 
translocation to the nucleus. The increase of IB with LPS may seem contradictory 
given the pro-inflammatory role of LPS and the anti-inflammatory action of IB. 
However, it may represent a negative feed-back to avoid an excessive inflammatory 
response. Indeed, activation of NF-B by TNF is followed by the recruitment of 
co-activators or co-repressors to the IB gene, in a proportion that is cell- and 
situation-dependent (Gao, Chiao et al. 2005). 
The presence of B decreased NF-B in all experimental conditions, and increased the 
abundance of IB when BMDMs were stimulated with LPS at 1 ng/mL, and 
decreased it when LPS was given at 100 ng/mL. In contrast, 5-THB did not affect 
the amount of NF-B, and only decreased IB expression in cells stimulated with 
100ng/mL of LPS. It is thought that GCs mainly affect NF-B by inhibiting its 
binding to DNA regulatory sequences by a tethering mechanism, and de novo protein 
synthesis seems not to play a big role in their ability to suppress the production of 
pro-inflammatory cytokines (De Bosscher, Schmitz et al. 1997; Wissink, van de 
Stolpe et al. 1997). However, this chapter showed that B also affected NF-B at the 
transcriptional level. While no effects of 5-THB on the abundance of NF-B 
protein were revealed, there is still the possibility that it may inhibit the ability of 
NF-B to bind to DNA. Studies investigating the cellular distribution of NF-B in 
response to steroids may help to reveal more about the mechanism of action of 5-
THB. The increase of IB seen with B at the lowest LPS concentration is in 
accordance with its anti-inflammatory properties, and it is an effect that has been 
already documented (Clark 2007; Newton and Holden 2007), while the decrease at 
the highest LPS concentration was unexpected. The phenomenon was seen also with 
5-THB. As puzzling as these results may appear, since they point to pro-
inflammatory behaviour, it needs to be remembered that the mechanisms analysed in 
this chapter represent only a fraction of the processes activated by LPS, and steroids 
Mechanisms of action of 5-tetrahydrocorticosterone 
  169 
work by affecting many of them. Moreover, the possibility that GCs may have pro-
inflammatory properties is not unprecedented. In addition, investigating whether the 
5-reduced steroid affect the abundance of the phosphorylated form of IB, which 
is sensitive to degradation, may shed light on whether the compound modifies the 
extent to which NF-B is freed through alteration of the degradation of the 
sequestering protein. Other signalling molecules such as MAPKs, involved in the 
AP-1 pathway, could also be examined. 
The search for the possible molecular mechanisms underlying the effects of 5-THB, 
and explaining the differences with B, was directed next to the investigation of 
whether the compound acts via GR. Surprisingly, the GR antagonist alone decreased 
the production of IL6 from BMDMs stimulated with LPS – no precedent for this 
could be found in the literature but a clear concentration-response was evident. 
Despite being used mainly as an antagonist of the GR, in in vivo and in vitro models, 
RU486 is known to have also agonist properties, delivered by both its targets, the 
progesterone receptor (PR) and GR (Beck, Estes et al. 1993; Beck, Weigel et al. 
1993; Zhang, Jonklaas et al. 2007; Chien, Lai et al. 2009); in effect, the compound is 
classified as a type II antagonist because it induces a conformation of the receptor 
which resembles that promoted by the binding of the agonist, and so has mixed 
agonist/antagonist characteristics (Moguilewsky and Philibert 1984; Gravanis, 
Schaison et al. 1985; Horwitz 1985; Antonakis, Markogiannakis et al. 1991; Beck, 
Estes et al. 1993; Sartorius, Groshong et al. 1994; McDonnell, Dana et al. 1995; 
Schulz, Eggert et al. 2002). The agonist properties of RU486 have been studied 
mainly regarding trans-activation of genes (Schulz, Eggert et al. 2002; Zhang, 
Jonklaas et al. 2007), but the compound has also been shown to repress some non-
genomic and genomic cellular responses; for instance, when given alone to human T 
cells, it blocked proliferation induced by phytohemagglutinin (PHA), and when 
administered with progesterone, it enhanced its anti-proliferative properties (Chien, 
Lai et al. 2009); in addition, RU486 was shown to inhibit at a pre-translational level, 
and in a concentration-dependent manner, the expression of the interleukin-2 
receptors in HPA-stimulated human lymphocytes, therefore mimicking the effect of 
dexamethasone (Antonakis, Markogiannakis et al. 1991). RU486 bound to GR has 
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also been found capable of inducing transcription of genes synergistically with the 
signalling molecule cAMP, again acting in a similar way to dexamethasone in 
immature murine T cells (Beck, Weigel et al. 1993). An interesting study showed 
that the extent of the agonistic activity of RU486 on induction of the MMTV-Luc 
reporter was determined not by the efficiency with which GR bound to the 
compound interacted with target DNA sequences, but rather by the abundance of the 
co-repressor NCoR (nuclear receptor co-repressor) in the cellular environment 
(Schulz, Eggert et al. 2002). This indicates that RU486 may behave differently in 
different cell types, according to the availability of co-repressors. Thus, it can be 
speculated that in BMDMs the amount of NCoR was such that an agonistic function 
of RU486 was encouraged. 
The results obtained with co-incubation of B and RU486 suggest an antagonist effect 
of the compound. This is what is classically expected, and is consistent with B 
working through GR. An intriguing result was that 5-THB and RU486 together had 
cumulative inhibitory effects on the abundance of IL6. This phenomenon was seen 
before in similar experiments performed in my supervisors’ laboratory using a single 
concentration of RU486 (1 M) (Yang 2009). This may be explainable in different 
ways. First of all, the two steroids may be binding to different populations of the 
same receptor, perhaps GR, and, as a consequence, be having additive effects. In 
support of this possibility is the fact that RU486 binds GR (Lewis-Tuffin, Jewell et 
al. 2007). The fact that 5-THB is a weaker suppressor of cytokine production than 
B, and possibly RU486, may have encouraged this scenario. However, another 
possibility is that the compounds may be targeting different receptors. Nuclear 
receptors such as PR and LXR are present in macrophages, and display anti-
inflammatory features dependent on repression of the activity of transcription factors 
such AP-1 (Hong and Tontonoz 2008; Dressing, Goldberg et al. 2010; Huang and 
Glass 2010; Perissi, Jepsen et al. 2010; Schulman 2010); furthermore, RU486 can 
have PR-dependent agonist properties (Zhang, Jonklaas et al. 2007; Chien, Lai et al. 
2009). These results highlight the importance to include controls in experiments in 
order to correctly interpret the outcomes. They also suggest that a pure antagonist 
may be more suitable for clarifying whether GR is involved in the response triggered 
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by steroids; unfortunately, at the moment such a compound is not available. 
However, another strategy would be to knock down GR expression by siRNA, and 
this is an approach that is planned by the supervisors’ group. 
In summary, in this chapter 5-THB was shown to suppress pro-inflammatory 
cytokine production in BMDMs in a weaker manner than B, and through 
mechanisms that do not seem to entail a strong regulation of the expression of NF-
B and IB, in contrast to B. More importantly, the 5-reduced steroid may not 
work through a conventional interaction with GR, as already suggested by in vivo 
experiments in Chapter 3. 
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Chapter 5: Effects of 5-THB on angiogenesis 
5.1 Introduction 
The effects of GCs on the vasculature are multifaceted. On the one hand, their anti-
inflammatory properties can be explained in part by the fact that they inhibit the 
expression of molecules responsible for the activation and hyper-permeability of the 
vasculature seen during inflammation (i.e. VEGF, TNF, IL6, ICAM1). On the 
other hand, their negative effects on the proliferation of endothelial cells and 
production of extracellular matrix components such as collagen, cause, in the long 
term, inhibition of angiogenesis and wound healing in the skin (Christian, Graham et 
al. 2006; Hengge, Ruzicka et al. 2006; Sanchis, Alba et al. 2012; Tiganescu, Tahrani 
et al. 2013). These aspects make GCs desirable but risky drugs to use, most of all 
when they are applied for a long period of time. As a consequence, the ideal 
compound for the treatment of skin conditions such as eczema or psoriasis would be 
one that, while inhibiting inflammation by affecting also the vasculature (e.g. by 
inhibiting expression of adhesion molecules), would spare other processes such as 
angiogenesis. In Chapter 3, the anti-inflammatory properties of 5-THB, and the 
mechanisms underpinning them, were investigated in a model of skin inflammation. 
The compound was found to decrease the abundance of transcripts of genes involved 
in vascular changes associated with inflammation, and in particular with recruitment 
of inflammatory cells at the site of injury. While this represents a promising 
therapeutic profile, more research is needed in order to unveil the effects of 5-THB 
on the formation of new vessels, and therefore bring to light the potential for vascular 
side effects.  
In this chapter, the effects of 5-THB on angiogenesis were studied using a murine 
in vivo model in which the subcutaneous implantation of a sponge induces the 
development of a granulomatous response including intense formation of new 
vessels and the infiltration of inflammatory cells (Ferreira, Barcelos et al. 2004). This 
model, therefore, allowed the contemporaneous investigation of how two systems 
closely related, the vasculature and the immune system, respond to administration of 
compounds. 
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Previous studies (Small, Hadoke et al. 2005; Logie, Ali et al. 2010) suggested that 
the inhibitory effect of GCs on angiogenesis is dependent on GR. Having 
demonstrated in previous chapters that the anti-inflammatory actions of 5-THB 
were not prevented by the use of a GR antagonist, and taking into account previous 
published and unpublished work which highlighted the lack of side effects caused by 
5-THB on skin thickness and metabolic parameters (Yang, Nixon et al. 2011), the 
hypothesis for this chapter is that: 
- 5-THB does not inhibit angiogenesis in subcutaneously implanted sponges in 
mice but is able to reduce the inflammatory response. 
Objectives 
 
To determine whether 5-THB inhibits: a) the formation of new vessels and b) the 
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5.2 Materials and Methods 
5.2.1 Murine in vivo model of angiogenesis 
5.2.1.1 Preparation of sponges and silastic pellets 
5.2.1.1.1 Materials 
Polyurethane sponge grade XE1700V was used for all experiments and they were a 
kind gift from Caligen Foam Ltd. (Accrington, Lancashire, U.K.). For delivery of 
steroids, silastic pellets were made using SILASTIC® MDX4-4210, BioMedical 
Grade Elastomer, obtained from Dow Corning, MIDLAND, USA. Steroids were 
purchased from Steraloids (Newport, RI, USA). 
5.2.1.1.2 Preparation of sponges 
Cubic sponges (approximately 0.5 cm
3
) were cut manually from a bigger pad. They 
were autoclaved and stored at RT prior to subcutaneous implantation on flanks of 
mice. 
5.2.1.1.3 Preparation of implants of inert silicone elastomer (silastic pellets)  
Silastic pellets have been shown to release steroids at a constant rate for up to 4 
weeks (Cleasby, Livingstone et al. 2003). For the preparation of silastic pellets to use 
as vehicle (control pellets), curing agent was mixed with base elastomer in a ratio of 
1:10 by weight, and subjected to centrifugation (10 s, 16000 x g). For pellets 
containing corticosterone (B) or 5-THB, 250 mg of base elastomer were mixed 
with 100 mg of steroid and subjected to centrifugation (10 s, 16000 x g) prior to 
addition of 25 mg of curing agent followed by another round of centrifugation (10 s, 
16000 x g). The mixture was left to cure (RT, 48 h) before removal from the 
container; the pellet was divided in smaller pellets so that each contained the amount 
of steroids indicated in the “Result” section of this chapter. Pellets were inserted into 
the sponge using fine forceps under sterile conditions in a laminar flow cabinet prior 
to subcutaneous implantation.  
5.2.1.2 Subcutaneous implantation of sponges 
5.2.1.2.1 Materials 
All surgical tools were from Fine Science Tools (Linton, UK). 
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5.2.1.2.2 Surgery 
Surgical instruments were autoclaved prior to surgery and maintained sterile during 
the procedure by using a Novasapa cold steriliser. Male C57BL/6 mice were weighed 
prior to administration of anaesthesia (isofluorane-vet; Merial, Harlow, UK) by 
inhalation; once animals were deemed unconscious, local analgesic (Vetergesic 
multidose, Alstoe, York, UK; 0.05 mg/kg) was given by subcutaneous injection. 
Animal were shaved on the neck region, and a longitudinal incision of about 0.5 cm 
was made using fine scissors. In order to create two subcutaneous pouches where the 
sponges could be implanted, a pair of curved, blunt forceps was passed through the 
neck incision and a tunnel created under the skin on each side of the mouse. Sponges 
were inserted using fine forceps so that two sponges were implanted in each mouse, 
one in each flank. The incision was closed with surgical clips and mice allowed to 
recover from anaesthesia in a clean cage. After recovery, mice were kept in groups of 
three for 21 days, after which they were euthanized by decapitation always between 
8 and 10 a.m. to decrease the variability between outcome measures of experiments 
due to the circadian variations in endogenous corticosterone level. Biological 
materials and implants were recovered as described in section 5.2.1.5.  
5.2.1.2.3 Experimental groups 
The control (or vehicle) group consisted of mice implanted with two sponges, one in 
each flank, containing a pellet without steroids (vehicle pellets). Steroid-treated 
groups consisted of mice implanted with sponges containing pellets loaded with 
steroids; these were always implanted on the right flank of the mouse, while the left 
received sponges containing vehicle pellets as internal control for systemic effects of 
the steroids.  
5.2.1.3 Blood collection and plasma preparation  
Blood was collected at two time points: a) two days prior to euthanasia tail blood was 
collected with the help of Dr. Dawn Livingstone or Tracy Mak in lithium heparin-
treated tubes (Fisher Scientific, Northumberland, UK) in order to analyse the basal 
concentration of corticosterone, and b) at cull trunk blood was collected in tubes 
treated with sterile EDTA solution (0.5M, pH 8). Plasma was recovered as described 
in section 2.2.3. 
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5.2.1.4 Quantification of B in plasma 
The concentration of B in plasma was measured as described in section 2.3.3.4. 
5.2.1.5 Recovery of sponges and biological materials  
Sponges were recovered from their flanks and divided into two halves: one half was 
immersed in RNA later for RNA extraction and real-time PCR (sections 2.3.1.3, 
2.3.1.5, 2.3.1.6) while the other was placed into formalin (10% v/v in PBS; Sigma-
Aldrich, Dorset, UK) and processed for either H&E staining as described in section 
2.3.4, or for immunostaining as described in section 4.2.2.1.   
Thymus and adrenal glands were collected and placed in 10% formalin (RT, 24 h) 
prior to transfer in 70% ethanol; 48 h later their weights were measured using a 
precision scale.  
5.2.2 Analysis of sponges and tissues 
5.2.2.1 Histological analysis 
5.2.2.1.1 Materials 
All materials were provided by the Histology facilities of the Shared University 
Research Facilities (SuRF), Little France Campus, Edinburgh and were purchased 
from Sigma-Aldrich (Dorset, UK) unless otherwise stated. Primary antibodies were: 
rabbit polyclonal anti-CD31 (Abcam, Cambridge, UK), rat monoclonal to F4/80 
(eBiosciences, Hatfield, UK) and mouse monoclonal anti-SMA (Sigma-Aldrich, 
Dorset. UK). Secondary antibodies were included in the Leica Refine Detection Kit 
(Leica biosystems, Milton Keynes, UK) supplied for the Leica Staining Robot. 
Picrosirius solution: Fast Green (0.1%, 50 mL), Direct Red (0.1%, 50 mL), Picric 
Acid Solution (900 mL). 
5.2.2.1.2 H&E staining  
H&E staining of sections of sponge was performed as described in section 2.3.4. 
5.2.2.1.3 Picrosirius (PSR) staining for collagen fibres 
PSR staining was performed by Ms Debbie Mauchline of the Histology Facilities of 
the Shared University Research Facilities (SuRF), Little France Campus, Edinburgh. 
Paraffin was removed and samples were hydrated as described for H&E staining 
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(section 2.3.4). After a wash in running tap water, they were immersed in PSR 
solution (2 h), de-hydrated and mounted as described (section 2.3.4.3). 
5.2.2.1.4 Immunostaining for CD31, SMA and F4/80 
Immunostaining against the antigens CD31, SMA and F4/80 was performed by Ms 
Ruth Hamblin of the Histology facilities of the Shared University Research Facilities 
(SuRF), Little France Campus, Edinburgh. Immunostaining was carried out using a 
Leica Staining Robot, with antigen retrieval for F4/80 performed robotically using 
trypsin solution (0.5 mg/mL in PBS, (Sigma-Aldrich), 10 min, 37 °C), or manually 
using a pressure cooker for SMA under standard conditions (citrate NCL pH6 
buffer, Sigma-Aldrich); no antigen retrieval was performed for CD31. For F4/80 and 
SMA, samples were blocked (5 min) with hydrogen peroxide solution from the 
Leica Refine Detection Kit (Leica biosystems, UK) followed by serum block (30 
min; F4/80, Immpress anti rat (mouse absorbed) kit (Vector Laboratories, 
Peterborough, UK); SMA, Mouse on Mouse Abcam Kit (Abcam, Cambridge, 
UK)). Thereafter, samples were incubated with primary antibody (F4/80 1:300; 
SMA 1:4000; 30min), prior to incubation with polymer (30 min, F4/80 Impress Kit 
as above; SMA Abcam Kit as above). Immunostaining was completed with 
incubation with 3,3’-diaminobenzidine (DAB, 10 min) and counterstaining with 
haematoxylin (5 min), both from the Leica Refine Kit. For CD31 immunostaining a 
Leica Refine Kit (as above) was used, which included a hydrogen peroxide block (5 
min), primary antibody (120 min, 1:200) and polymer incubation (15 min) followed 
by DAB (10 min) and haematoxylin (5 min). 
5.2.2.1.5 Quantification of the number of vessels in sponges 
In order to quantify angiogenesis, the number of vessels present in the implanted 
sponges was counted. The person counting was blinded to treatment. Vessels in 
sections stained with H&E were recognized by their round appearance and the 
presence of erythrocytes in the lumen. The number of vessels positive for CD31 or 
SMA staining was also investigated by counting every tubular structure showing 
reactivity to DAB (brown stain). Three sections from each sponge were examined 
under a microscope (Axioskop, Zeiss, Germany) and vessels counted in the field of 
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vision at magnification of 100X. Analysis of the data was performed taking into 
consideration the mean value of the three cross sections for each sponge. 
5.2.2.1.6 Quantification of cells infiltrating the sponges  
Total cells infiltrating the sponges were quantified by counting under the microscope 
(magnification 200X) the number of blue nuclei present in three different fields of 
vision in sections stained with H&E. Quantification of macrophages was carried out 
with the same method but by using a higher magnification (400X) and by counting 
the number of cells positive for the marker F4/80 and the total number of cells (blue 
nuclei and cells positive for F4/80 staining) in the field of vision. 
5.2.2.1.7 Quantification of collagen staining 
The intensity of Picrosirius staining on pictures taken at a magnification of 100X was 
quantified using the free imaging program ImageJ (NIH, USA). A Macro was kindly 
developed and provided by Mr. James Baily. 
5.2.2.2 Molecular analysis 
5.2.2.2.1 RNA isolation 
Total RNA was isolated from sponges as described in section 2.3.1.3. 
5.2.2.2.2 Real-time PCR analysis 
Production of cDNA and subsequent real-time PCR analysis were performed as 
described in sections 2.3.1.5 and 2.3.1.6. 
5.2.3 Data analysis 
5.2.3.1 General 
Data were represented as mean ± SEM and analysed as described in section 2.4. 
5.2.3.2 Weights of the adrenal glands and thymus 
The weights of the adrenal glands and thymus were represented as absolute weights 
measured at cull.  
5.2.3.3 Real-time PCR analysis 
For quantification of transcripts through real-time PCR, the abundance of each gene 
was represented in relation to the abundance of chosen housekeeping genes. The two 
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housekeeping genes used were Tbp and Gapdh due to the lack of significant changes 
in the abundance of transcripts following treatment with steroids. For each sample 
and each gene studied the values presented in the graphs were calculated as follow: 
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5.3 Results 
5.3.1 Development of an in vivo model of angiogenesis 
5.3.1.1 Qualitative evaluation of angiogenesis in sponges 
Implanted sponges retrieved after 20 days in situ showed clear signs of angiogenesis 
during visual examination (Figure 5.1 A). They appeared to have an intense red 
colour consistent with the growth of vessels and presence of red blood cells. 
Furthermore, they were encapsulated by connective tissue. Staining with H&E 
(Figure 5.1 B) confirmed the presence of vessels (black arrows in the picture) 
surrounded by a fibrous stroma containing cell nuclei (stained pink and purple, 
respectively). Other features visible were pink triangular shapes which represented 
pieces of the sponge (blue arrow in picture). 
 
Figure 5.1 Angiogenesis took place in sponges implanted subcutaneously in mice for 20 
days. (A) Representative macroscopic image of a sponge recovered after 20 days in situ 
from the flank of a mouse. (B) Representative image of a cross-section of a sponge stained 
with H&E. Black arrows point to vessels of different calibre containing visible red blood 
cells; V = vessels. The blue arrow points to a piece of material that constitutes the sponge (S 
= sponge). The vessels and the sponge material are surrounded by tissue and cell nuclei 
(stained pink and purple, respectively). Magnification = 100X. 
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5.3.2 Effects of steroids on angiogenesis using the sponge 
model 
5.3.2.1 Systemic effects of local administration of steroids 
In order to investigate whether the local administration of steroids via pellets inserted 
into the implants had systemic effects, the concentration of B in blood and the 
weights of adrenal glands and thymus were analysed.  
The amount of circulating B was not different between the experimental groups 
(Figure 5.2 a), both at 19 days and at cull. The presence of B in sponges decreased 
the weight of the adrenal glands but not of the thymus compared with the control 










































B  a t  1 9  d a y s B  a t  c u ll
5 -T H B 5 -T H B
a )
 
Figure 5.2 5-Tetrahydrocorticosterone (5-THB) and corticosterone (B) in sponges 
did not affect the concentration of circulating B. Concentration of B (nM) quantified in 
blood taken either at 19 days after implantation of sponges (left-hand side) or at cull after 20 
days (right-hand side). Mice received the treatments indicated; V = control sponges. Data are 
mean ± SEM analysed with One-way ANOVA; n = 6-9 mice/group. 
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Figure 5.3 5-Tetrahydrocorticosterone (5-THB), unlike corticosterone (B), did not 
affect the weight of the adrenal glands. Absolute weights of (a) adrenal glands and (b) 
thymus in mice implanted with sponges containing the indicated treatments. Data (mean ± 
SEM) were analysed with one-way ANOVA followed by Tukey’s post-hoc test. ** = p < 
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5.3.2.2 Ability of 5-THB to inhibit local angiogenesis 
5.3.2.2.1 Macroscopic analysis of sponges 
Visual analysis of control sponges (containing vehicle pellets) collected from 
untreated mice revealed an appearance consistent with growth of vessels and 
presence of red blood cells (Figure 5.4 a, b); the gross appearance was very similar to 
that of sponges not containing any pellet (Figure 5.1 A). A connective tissue capsule 
surrounding the sponge was also present. Control sponges implanted in the left flanks 
of mice receiving steroid treatment on the right also appeared vascularised (Figure 
5.4 c, e, g). However, control sponges from mice receiving B showed a less dense 
external fibrous capsule (Figure 5.4 c). 
A clear difference was noted when sponges loaded with 3 mg B were examined 
(Figure 5.4 d). These sponges were much paler in colour, resembling pre-
implantation sponges, and were lacking the connective capsule; these characteristics 
suggested reduced growth of vessels and tissue. Evaluation of sponges containing 3 
mg of 5-THB (Figure 5.4 f) showed that this treatment did not induce major visual 
changes compared with the control group. A slight discoloration of the sponges, and 
some lack of connective tissue around them, were noted when pellets were loaded 
with 15 mg of 5-THB (Figure 5.4 h) suggesting a dose-dependent effect on the 
growth of vessels and tissue. 
 
Mechanisms of action of 5-tetrahydrocorticosterone 
  185 
 
Figure 5.4 5-Tetrahydrocorticosterone (5-THB) caused visual changes of sponges 
consistent with inhibition of angiogenesis to a lesser extent than corticosterone (B). 
Representative pictures of sponges collected from the flanks of mice after 20 days in situ, 
and containing either vehicle pellets (V) or pellets loaded with either B (3 mg) or 5-THB (3 
mg, 15 mg) as indicated. 
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5.3.2.2.2 Microscopic analysis of sponges 
Microscopic analysis of sections of sponges implanted in control mice, and stained 
with H&E, revealed the presence of a conspicuous number of tubular structures (red 
arrows in Figure 5.5 a, b) containing red blood cells (RBC in Figure 5.5 b), 
indicating that angiogenesis has taken place. These structures were visible mainly on 
the outer edges of the sponges and differed regarding the calibre (see Figure 5.5 b for 
a clearer vision at higher magnification). Purple cell nuclei could be discerned 
throughout the sections (blue arrows) and also inside the blood vessels. Structurally, 
the control sponges appeared to have a looser central part, mainly formed by the 
material constituting the sponge itself (S in Figure 5.5 a) and loose fibrous tissue, 
whilst all around this core, a more dense fibrous capsule was present. 
Qualitative analysis of sponges loaded with B at 3 mg (Figure 5.5 d) showed a 
decreased number of vessels, which also appeared to have a reduced calibre, and a 
looser fibrous structure throughout the sponge. Cell nuclei were still visible, although 
they seemed less abundant compared with the control sponges (a, b). Staining of 
control sponges implanted on the left flank of these mice (Figure 5.5 c) revealed a 
number of vessels comparable with that of the control group. However, the central 
part of these sponges seemed to have a less dense fibrous structure. 
Microscopic analysis of sponges loaded with 5-THB at 3 mg (Figure 5.5 f) showed 
a structure and an abundance of vessels that appeared similar to the control sponges 
(a, b). Sponges containing pellets with 5-THB at 15 mg (Figure 5.5 h) had smaller 
and less abundant vessels compared with the control group. In both cases, a higher 
number of cell nuclei compared with the group treated with B seemed to be present. 
The appearance of sponges implanted in the contra-lateral flank as controls in both of 
these groups (Figure 5.5 e, g) was comparable to the control group. 
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Figure 5.5 5-Tetrahydrocorticosterone (5-THB) affected the microscopic appearance 
of the sponges to a lesser extent than corticosterone (B). Representative pictures of 
sponges loaded with vehicle pellets (V) or with pellets containing either B (3 mg) or 5-
THB (3 mg, 15 mg) as indicated. Red arrows = vessels; blue arrows = cell nuclei; RBC = red 
blood cells; S = sponge matrix. Magnification = 100X except for (b) = 200X. 
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5.3.2.2.3 Quantitative analysis of angiogenesis in sponges 
The number of vessels (Figure 5.6 a) was lower in sponges containing B (3 mg) and 
5-THB at 15 mg compared with the control group (V). In sponges loaded with 5-
THB at 3 mg the number of vessels showed a statistical trend towards significance; 
this was the case also for control sponges from mice receiving B and 5-THB at 
15mg. 
In order to avoid confounding results, and since the main interest of this study was to 
investigate the local and direct effect of steroids, subsequent analyses were 
performed excluding the vehicle contra-later sponges. As a consequence, the effect 
of steroids was statistically re-analysed and represented as a percentage of the control 
group set to 100% (Figure 5.6 b); B was found to decrease angiogenesis by 85.0 ± 
3.3% while both concentrations of 5-THB (3 and 15 mg) decreased the abundance 
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Figure 5.6 5-Tetrahydrocrticosterone (5-THB) reduced angiogenesis in sponges, but 
was less potent than corticosterone (B). (a) Number of vessels in sponges. The quantity (in 
mg) of steroids is reported as number after their names. The last three groups represent the 
contra-lateral control sponges implanted in mice receiving treatment with the indicated 
steroid. (b) Evaluation of angiogenesis as percentage of the control group (mice not 
receiving steroid) set to 100%. V = control group. Data (mean ± SEM) were analysed with 
one-way ANOVA followed by Tukey’s post-hoc test. *** = p < 0.0001, * = p < 0.05, & = 
0.1 < p < 0.05 vs V; ### = p < 0.0001, # = p < 0.05 vs B 3; £ = p < 0.05; n = 8-12 
mice/group. 
5.3.2.3 Effects of 5-THB on different aspects of the angiogenic 
process 
5.3.2.3.1 Analysis of vessels expressing the endothelial marker CD31 
Immunostaining for the endothelial marker CD31 (Figure 5.7) showed the presence 
of vessels of different calibre (orange arrows in the Figure) in each of the 
experimental groups. The staining allowed the recognition of tiny vessels not clearly 
discernible with H&E staining. Furthermore, some of the vessels appeared to be 
undergoing a process of branching or duplication (arrows containing an asterisk in 
Figure 5.7) suggesting that angiogenesis was taking place. The visual examination 
indicated that the abundance and the calibre of the vessels positive for CD31 staining 
were reduced in the sponges containing B and 5-THB at 15 mg (Figure 5.7 (b) and 
(d)) compared with the control group (V, (a)).   
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Figure 5.7 5-Tetrahydrocorticosterone (5-THB, 15 mg) and corticosterone (B) 
appeared to reduce the abundance of vessels expressing the endothelial marker CD31. 
Representative pictures of sections of sponges stained for the endothelial marker CD31. V = 
control group. Orange arrows point to vessels positive for CD31 staining; those with an 
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Quantification of the number of vessels stained for CD31 showed that treatment with 
B (3 mg) and 5-THB at 15 mg, but not at 3 mg, reduced the number of CD31-
positive vessels compared with the control group (Figure 5.8 a). When the amount of 
CD31-positive vessels in each group was represented as a percentage compared with 
the control group set to 100% (Figure 5.8 b), B reduced this amount by 98 ± 0.7%, 
while 5-THB at 15 mg brought it down by 80 ± 5.3%.  
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Figure 5.8 5-Tetrahydrocorticosterone (5-THB, 15 mg) and corticosterone (B) 
reduced the abundance of vessels positive for the endothelial marker CD31. (a) 
Quantification of the number of vessels positive for the endothelial marker CD31; (b) % of 
the number of vessels positive for CD-31 compared with the control group set to 100%. V = 
control group. Data (mean ± SEM) were analysed with one-way ANOVA followed by 
Tukey’s post-hoc test. *** = p < 0.0001, ** = p < 0.001, * = p < 0.05; ### = p < 0.0001, # = 
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5.3.2.3.2 Analysis of vessels expressing alpha smooth muscle actin (SMA) 
Immunostaining for the marker of smooth muscle cells SMA revealed the presence 
of vessels of different calibre (blue arrows), as seen with previous staining. The 
intensity and distribution of the staining, and the abundance of vessels, looked 
similar between the control group (Figure 5.9 a) and the groups treated with 5-THB 
(Figure 5.9 c, d). However, samples of the group treated with B showed reduced 
staining intensity compared with the control group (Figure 5.9 b), and fewer tube-
like structures, indicating a decrease in the number of vessels expressing SMA. 
 
Figure 5.9 5-Tetrahydrocorticosterone (5-THB), unlike corticosterone (B), did not 
appear to reduce the number of vessels expressing the smooth muscle marker SMA. 
Representative pictures of sections of sponges stained for the smooth muscle marker SMA. 
V = control group. Blue arrows point to vessels positive for SMA staining. Magnification = 
100X.  
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Quantification of the number of vessels stained for SMA showed that only 
treatments with B (3 mg) reduced the absolute number compared with the control 
group (Figure 5.10 a). Representation of this analysis as a percentage of SMA-
positive vessels (Figure 5.10 b) revealed that B decreased the abundance by 
approximately 88 ± 3% compared with the control group set to 100%. 5-THB at 15 
mg reduced the number of positive vessels by approximately 44 ± 14%; however, 
this reduction was not statistically significant compared with the control group.    
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Figure 5.10 5-Tetrahydrocorticosterone (5-THB), unlike corticosterone (B), did not 
reduce the abundance of vessels positive for the smooth muscle marker SMA. (a) 
Quantification of the number of vessels positive for the smooth muscle marker SMA; (b) % 
of the number of vessels positive for SMA compared with the control group set to 100%. V 
= control group. Data (mean ± SEM) were analysed with one-way ANOVA followed by 
Tukey’s post-hoc test. ** = p < 0.001, * = p < 0.05 vs V; # = p < 0.05, $ = 0.1 < p < 0.05 vs 
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5.3.2.3.3 Analysis of cell infiltration in sponges 
5.3.2.3.3.1 Total cell number 
The count of the total number of cell nuclei in sponges stained with H&E (Figure 
5.11 a) revealed that treatment with B and 5-THB (15 mg) decreased the number of 
cells compared with the control group. The effect was similar between the two 
steroids, as B reduced the cell number by approximately 40 ± 7.3%, and 5-THB by 
45 ± 3.3 compared with the control group set to 100% (Figure 5.11 b).  
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Figure 5.11 5-Tetrahydrocorticosterone (5-THB) and corticosterone (B) reduced the 
number of total cells infiltrating the sponges to a similar extent. (a) Quantification of the 
total number of cell nuclei in sections of sponges; (b) total number of cell nuclei represented 
as percentage of the control group set to 100%. V = control group. Data (mean ± SEM) were 
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5.3.2.3.3.2 Cell expressing the macrophage marker F4/80 
Immunostaining for cells expressing the protein F4/80 (Figure 5.12, purple arrows) 
revealed that sponges containing B (3mg) and 5-THB (15 mg) (Figure 5.10 b, d) 
appeared to have a reduced amount of cells positive for the marker compared with 
the control group (Figure 5.12 a). Groups treated with 5-THB at 3 mg did not show 
major differences at the visual examination (Figure 5.12 c). Quantification of the 
proportion of cells positive for F4/80 (Figure 5.13) confirmed that the groups treated 
with B and 5-THB, 15 mg, decreased the proportion of macrophages to a similar 
extent compared with the control group. 
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Figure 5.12 5-Tetrahydrocorticosterone (5-THB, 15 mg) and corticosterone (B) 
appeared to reduce the abundance of cells positive for the marker F4/80. Representative 
images of sponges stained for the marker expressed by macrophages F4/80. V = control 
group. Magnification = 100X (a)-(d); 200X (e), 400X (f). Purple arrows point to cells 
positive for the marker; black arrow in (f) indicates a negative cell. 
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Figure 5.13 5-Tetrahydrocorticosterone (5-THB, 15 mg) and corticosterone (B) 
reduced the proportion of macrophages to a similar extent. Quantification of the 
proportion of F4/80-positive cells in different experimental groups; V = control group. Data 
(mean ± SEM) were analysed with one-way ANOVA followed by Tukey’s post-hoc test. * = 
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5.3.2.4 Effects of 5-THB on the abundance of transcripts of a panel of 
genes   
The effects of the administration of B and 5-THB on the abundance of transcripts 
of genes involved in the formation, maturation and established of a new vascular bed, 
and in inflammation and signalling, were investigated. 
5.3.2.4.1 Genes involved in the remodelling of the vasculature  
Transcripts of the genes Vegf-, Vegfr-2, Pecam-1 (also known as CD31), Cdh5 
(Cadherin 5 or VE-cadherin), Pdgf-, Thsb-1, Thsb-2, Vcam-1, Icam-1, E-selectin, 
and Acta2 (SMA) were detectable in all samples (Figures 5.14 and 5.15). 
Administration of B (3 mg) decreased the abundance of mRNAs of Vegfr-2, Pecam-1 
(CD31), Cdh5 (Figure 5.14 a-c), Icam-1, E-selectin and Acta2 (Figure 5.15 d-f), 
while it increased mRNAs of Vegf- and Vcam-1 (Figure 5.14 a and 5.15 c) 
compared with the control sponges. Compared with the same group, 5-THB had 
more limited effects as at 3 mg it decreased transcripts only of Thsb-2 (Figure 5.15 
b), and at 15 mg of Pecam-1 (Figure 5.14 c).  
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Figure 5.14 5-Tetrahydrocorticosterone (5-THB) had limited effects on the 
abundance of transcripts of genes encoding endothelial molecules. Real-time PCR 
analysis of transcripts of (a) Vegf, (b) Vegfr-2, (c) Pecam-1, (d) Cdh5 (Cadherin 5 or VE-
cadherin) and (e) Pdgf-. V = control sponges; Ref = average of two housekeeping genes. 
Data (mean ± SEM) were analysed with one-way ANOVA followed by Tukey’s post-hoc 
test; *** = p < 0.0001, * = p < 0.05 vs V; ### = p < 0.0001 vs B 3mg; n=8-12/group. A.U. = 
arbitrary unit. 
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Figure 5.15 5-Tetrahydrocorticosterone (5-THB) had more limited effects on the 
abundance of transcripts of genes involved in angiogenesis. Real-time PCR analysis of 
transcripts of (a) Thbs-1, (b) Thbs-2, (c) Vcam-1, (d) Icam-1, (e) E-selectin and (f) Acta2. V 
= control sponges; Ref = average of two housekeeping genes. Data (mean ± SEM) were 
analysed with one-way ANOVA followed by Tukey’s post-hoc test; * = p < 0.05, & = 0.05 < 
p < 0.1 vs V; # = p < 0.05 vs B 3 mg; $ = p < 0.05; n=8-12/group. A.U. = arbitrary unit. 
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5.3.2.4.2 Genes involved in inflammation and signalling 
Analysis of transcripts of genes with a role in the inflammatory process and in 
intracellular signalling showed that while B (3 mg) had a broad effect and decreased 
the abundance of mRNAs of Tnf, Il1, Inf and Nos3 (also known as endothelial 
NOS or eNOS) (Figure 5.16 a, c, d, f) compared with the control sponges, the 
administration of 5-THB did not decrease any of them, while at 3 mg it increased 
the abundance of mRNAs of Mcp1 (Figure 5.16 e). 
The analysis was extended also to genes encoding the enzyme responsible for the 
production of 5-THB from B, Srd5a1, and the two receptors known to be targeted 
by glucocorticoids, Nr3c1 (GR) and Nr3c2 (MR). The investigation showed that B 
increased the abundance of transcripts of the former and decreased those of Nr3c1 
and Nr3c2 (Figure 5.17), while 5-THB did not affect the abundance of any of them. 
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Figure 5.16 5-Tetrahydrocorticosterone (5-THB) had limited effects on the 
abundance of mRNAs of genes with a role in inflammation and signalling. Real-time 
analysis of transcripts of (a) Tnf, (b) Il6, (c) Il1, (d) Inf, (e) Mcp1 and (f) Nos3. V = 
control sponges; Ref = average of two housekeeping genes. Data (mean ± SEM) were 
analysed with one-way ANOVA followed by Tukey’s post-hoc test; ** = p < 0.001, * = p < 
0.05 vs V; ### = p < 0.0001, ## = p < 0.001, # = p < 0.05 vs B 3 mg; n=8-12/group. A.U. = 
arbitrary unit. 
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Figure 5.17 5-Tetrahydrocorticosterone (5-THB) did not affect the abundance of 
transcripts of Srd5a1, Nr3c1 and Nr3c2. Real-time analysis of transcripts of (a) Srd5a1 
(encoding 5-reductase type 1 = 5-R1), (b) Nr3c1 (GR) and (c) Nr3c2 (MR). V = control 
sponges; Ref = average of two housekeeping genes. Data were analysed with one-way 
ANOVA followed by Tukey’s post-hoc test; *** = p < 0.0001, * = p < 0.05 vs V; ## = p < 
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5.3.2.4.3 Genes involved in the remodelling of the extracellular matrix  
Analysis of the effects of steroids on genes that control the remodelling of the 
extracellular matrix revealed that the administration of B (3 mg) decreased the 
abundance of transcripts of Mmp10 (Figure 5.18 c) compared with the control 
sponges. 5-THB had no effect on any of the genes analysed; however, at 15 mg the 
decrease seen in the amount of mRNAs of Timp2 showed a statistical trend (Figure 
5.18 d). 
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Figure 5.18 5-Tetrahydrocorticosterone (5-THB) and corticosterone (B) had limited 
effects on genes controlling the composition of the extracellular matrix and migration 
of cells. Real-time analysis of transcripts of (a) Mmp2, (b) Mmp9, (c) Mmp10 and (d) Timp2. 
V = control sponges; Ref = average of two housekeeping genes. Data (mean ± SEM) were 
analysed with one-way ANOVA followed by Tukey’s post-hoc test; * = p < 0.05, & = 0.05 < 
p < 0.1 vs V; ## = p < 0.05 vs B 3mg; n=8-12/group. A.U. = arbitrary unit. 
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Analysis of genes encoding different isoforms of the structural molecule collagen 
showed that the administration of B (3 mg) decreased the abundance of transcripts of 
all of them (Figure 5.19 a-d) compared with the control sponges, while 5-THB, at 3 
and 15 mg, lowered transcripts only of Col1a2 (Figure 5.19 b). A trend for 5-THB, 
at both concentrations, was present for Col31a (Figure 5.19 c). 
 






























5 -T H B
* *






























5 -T H B
* * *
* * * *





























5 -T H B
* * *
&&






























5 -T H B
a ) b )
c ) d )
 
Figure 5.19 5-Tetrahydrocorticosterone (5-THB) affected the transcripts of genes 
encoding different isoforms of collagen to a lesser extent than corticosterone (B). Real-
time analysis of transcripts of (a) Col1a1, (b) Col1a2, (c) Col3a1 and (d) Col4a1. V = 
control sponges; Ref = average of two housekeeping genes. Data (mean ± SEM) were 
analysed with one-way ANOVA followed by Tukey’s post-hoc test; *** = p < 0.0001, ** = 
p < 0.001, * = p < 0.05, & = 0.1 < p < 0.05 vs V; n=8-12/group. A.U. = arbitrary unit. 
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5.3.2.5 Effects of 5-THB on the abundance of collagen in sponges 
The data obtained with the real-time PCR analysis prompted us to investigate the 
abundance of collagen in sponges from the different experimental groups through 
histological analysis. This revealed that administration of B (3 mg) reduced the 
abundance of collagen fibres compared with the control group (Figure 5.20 a-b and 
5.21). In contrast, the treatment with 5-THB did not affect the content of collagen 
(Figure 5.20 c-d and 5.21).    
 
 
Figure 5.20 5-Tetrahydrocorticosterone (5-THB) did not appear to reduce the 
abundance of collagen in sponges in contrast to corticosterone (B). Representative 
images of sponges stained for collagen fibres with picrosirius red staining and implanted 
either with (a) vehicle pellet, (b) B (3 mg), (c) 5-THB 3 mg or (d) 5-THB 15 mg. 
Magnification = 100X. 
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Figure 5.21 5-Tetrahydrocorticosterone (5-THB), unlike corticosterone (B), did not 
reduce the abundance of collagen in sponges. Quantification of the intensity of 3,3’-
diaminobenzidine (DAB) staining in sponges from the different experimental groups. V = 
control group. Data (mean ± SEM) were analysed with one-way ANOVA followed by 
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5.4 Discussion 
In this chapter an in vivo model of angiogenesis in mice was established and 
employed for the investigation of the effects of 5-THB on the formation of new 
vessels and on inflammatory pathways/responses. The main finding was that 5-
THB, when given at equipotent doses to B for the reduction of macrophage 
infiltration, inhibited angiogenesis to a lesser extent than its precursor, indicating a 
dissociated behaviour. Furthermore, while B had systemic effects, in that it decreased 
adrenal gland weights, 5-THB did not. The analysis of different aspects of the 
angiogenic processes revealed also that, while B decreased the abundance of cells 
expressing the endothelial marker CD31 (also known as PECAM-1) and of cells 
positive for the smooth muscle marker SMA, 5-THB only decreased the former. 
The investigation of the effects of the steroidal treatments on the abundance of 
transcripts of a panel of genes showed a substantial difference between the two 
glucocorticoids: B affected a variety of transcripts; by contrast, 5-THB had limited 
effects. In particular, whereas B strongly decreased the transcripts abundance of 
genes encoding different isoforms of collagen, 5-THB only reduced that of one 
isoform. Histological analysis showed that this translated to a lower amount of 
collagen fibres in sponges treated with B, but not with 5-THB. 
In 1987, the model of subcutaneous sponge implantation in rats was first introduced 
in order to study angiogenesis (Andrade, Fan et al. 1987). Since then, a range of bio- 
and non-biodegradable materials to use as matrix for the growth of new vessels has 
been tested. Some of the materials employed as implants included steel mesh 
chambers (Schilling, Joel et al. 1959), synthetic sponge matrix (polyvinyl alcohol, 
polyester or polyurethane) and Matrigel plugs (Kleinman, Graf et al. 1987). For the 
experiments presented in this chapter, polyurethane sponges were used as this 
method was already established in my supervisors’ laboratory (Small, Hadoke et al. 
2005), having being adapted and refined from literature that used mice (Hague, 
MacKenzie et al. 2002; Illanes, Dabancens et al. 2002). Furthermore, it is 
inexpensive, and the number of vessels can be easily and reproducibly quantified by 
employing simple histological techniques. 
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Subcutaneous implants constitute the framework in which the angiogenic process, 
working in concert with the host inflammatory response, can take place and be 
analysed (Leibovich, Polverini et al. 1987). Upon macroscopic analysis, the 
appearance of the “vehicle” sponges was consistent with the growth of fibrous tissue 
around the implant forming a capsule, and the formation of a vascular bed. 
Microscopic analysis was consistent with previous reports in the literature (Xavier, 
Amaral et al. 2010) in that the sponge matrix was filled with fibrovascular tissue 
containing vessels of different calibres, cells and a fibrous stroma. 
This in vivo model has been widely employed for the study of the effects of a diverse 
range of compounds on different aspects of the host response to implants. Different 
methods for the administration of substances have been investigated (Hori, Hu et al. 
1996; Hague, MacKenzie et al. 2002; Illanes, Dabancens et al. 2002). Previous work 
used silastic pellets to deliver glucocorticoids, showing that the release takes place at 
a controlled rate for three weeks (Cleasby, Livingstone et al. 2003). Subsequent 
studies applied this method on the sponge model of angiogenesis with successful 
results (Small, Hadoke et al. 2005), and therefore the same route of delivery was 
used in this chapter. The dose of B chosen reflected the fact that optimisation studies 
performed earlier in my supervisors’ laboratory revealed that a higher dose of B of 
25 mg caused systemic side effects (Small 2006). When this dose was reduced by 
approximately 10 times (2.5-3 mg), the steroid did not affect organs such as the 
thymus and adrenal glands, therefore, it was decided to use a concentration of B of 3 
mg. In initial experiments, 5-THB was used at the same concentration as B. The 
results showed a very small effect of the 5-reduced steroid on vessel count; as a 
consequence, since in the previous chapter significant effects on inflammation were 
robustly obtained with a dose of 5-THB five times higher than B, it was decided to 
administer 15 mg of the compound.  
The results shown here are in contrast to the abovementioned optimisation studies in 
that they show an influence of B on adrenal gland weights, indicating the occurrence 
of systemic effects. In physiological conditions, the HPA axis maintains within 
certain values the concentration of GCs in the circulation by sensing their abundance 
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in the blood (Keller-Wood and Dallman 1984). The concentration of B presented in 
this chapter was within the normal range for C57BL/6 mice (Kotelevtsev, Holmes et 
al. 1997; Livingstone, Di Rollo et al. 2014). The fact that adrenal gland weights were 
reduced in animals treated with B suggests that these normal levels were being 
maintained by the regulatory action of the HPA axis. In effect, if exogenous GCs are 
given to mice, this would reduce the production from the adrenal glands, and induce 
atrophy in the long-term. Another result suggesting systemic effects induce by B is 
the trend towards a significant difference between the number of vessels in control 
contra-lateral implants of mice receiving B and control sponges of untreated mice. 
The use of lower concentrations of B could solve this issue. Regarding 5-THB, in 
previous studies, systemic infusion by mini-pump did not cause systemic effects 
(Yang, Nixon et al. 2011; Livingstone, Sykes et al. 2014), and this chapter suggests 
that this is the case also in the sponge model. However, the analysis of angiogenesis 
in samples stained with H&E indicated a possible effect of the steroid on the contra-
lateral control sponges; therefore, a leakage of 5-THB cannot be excluded. To 
investigate this, its concentration would have to be quantified both in sponges and in 
plasma through mass spectroscopy analysis. As a consequence of these observations, 
and since the aim of the present study was to investigate the localised and direct 
effects of steroids, the decision was to consider as control only the sponges from 
mice not receiving any treatment. 
The present study confirmed the anti-angiogenic properties of B and, for the first 
time, showed that its metabolite, 5-THB, possesses this quality as well, adding 
another angiostatic steroid to the list discovered many years ago (Folkman and 
Ingber 1987). The effects of B given at 3 mg were greater than would have been 
expected using a dose equal to the EC50, indeed the reduction in the abundance of 
vessels was approximately 85%; 5-THB administered at 15 mg caused instead a 
reduction of 55% which is in accordance with a concentration representing the EC50 
in this model. Ideally, titration experiments with the two steroids should be 
performed in order to find/verify the EC50 in this model.   
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During sprouting angiogenesis, endothelial cells lead the formation of new vessels, 
but in order for the vessels to become functional, they must then recruit other cell 
types, comprising pericytes and smooth muscle cells. Endothelial and non-
endothelial cells can be differentially localised by immunostaining of specific 
antigens, such as CD31, also known as Pecam-1, and SMA, or alpha smooth 
muscle actin. CD31 is a trans-membrane protein expressed by early and mature 
endothelial cells, primarily concentrated at the junctions between adjacent cells. It is 
also expressed to a lesser extent by platelets and leukocytes, and plays a crucial role 
in the trans-endothelial migration of the latter (Jackson 2003). The protein SMA is 
found in pericytes and smooth muscle cells, and confers upon them the ability to 
contract (Bergers and Song 2005). The results presented in this chapter showed that 
the absolute number of vessels identified with immunostaining against CD31 in the 
control sponges was higher than the number calculated by using H&E staining. This 
is likely due to the difference in the sensitivity of the two techniques. Tubular 
structures, also of very limited dimensions, were clearly visible in sections 
immunostained for CD31; this allowed for their inclusion in the analysis when they 
were probably overlooked in sections stained with H&E where the only vessels 
counted were those clearly containing erythrocytes, to avoid erroneous evaluation. 
The absolute number of vessels positive for SMA in control sponges was lower 
than the number of CD31-positive vessels. This was to be expected, as the presence 
of SMA suggests that some of the new vessels have matured and become coated 
with pericytes or smooth muscle cells, making them a subset of the total amount of 
vessels. On a technical note, it is worth mentioning that the marker SMA has been 
shown to be occasionally expressed also by fibroblasts (Okada, Ban et al. 2000; 
Inoue, Plieth et al. 2005); the microscopic observation of sponges showed that the 
staining was not only localised on vessels, but it was also scattered among the stroma 
surrounding them. This signal may localise fibroblasts, since they are the main 
producer of fibrous tissue, which can be found in abundance in sponges. To reduce 
the likelihood that non-specific signal was included in the analysis, only tubular 
structure characterised by the presence of a lumen, were counted. This was the case 
also when quantifying the vessels positive for CD31 staining. 
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Both B and 5-THB reduced the number of vessels positive for CD31 compared 
with the control sponges, but only B significantly decreased the abundance of vessels 
expressing SMA. When the reduction in CD31-positive vessels was analysed as 
percentage of the control group, the effects of the steroids were found to be more 
potent than the effects revealed by the analysis of sections stained with H&E; 
furthermore, the effects of B (3 mg) and 5-THB given at 15 mg were comparable, 
indicating that 5-THB was five times less potent than B, as found in the dermatitis 
model (Chapter 3). These observations indicate that because the analysis of sponges 
stained with H&E was restricted to vessels clearly containing erythrocytes (and 
therefore functional vessels), as mentioned above, the potency of 5-THB was 
initially underestimated. These results point also to an interesting difference between 
B and 5-THB, indicating that the former may affect both the initiation and 
maturation phases of angiogenesis, while the latter seems to affect mainly the initial 
steps. 
Angiogenesis is a process dependent on more than one cellular component, as 
already mentioned. Fibroblasts, through the synthesis and maintenance of the 
extracellular matrix, form a stroma that supports old and newly formed vessels; but 
these cells have also more “active” roles; for instance, it has been recognised that 
they secrete factors which are required for lumen formation (Newman, Nakatsu et al. 
2011). On the other hand, cells from the inflammatory system, in particular 
monocytes/macrophages, are central players in determining the initiation and the 
development of the angiogenic process as they are a source of pro-angiogenic 
cytokines such as VEGF and IL-8 (Sunderkotter, Nikolic et al. 2004). For these 
reasons, we have analysed the abundance of total cells infiltrating the sponges and, 
since 5-THB has been shown to be anti-inflammatory in Chapters 3 and 4, also the 
proportion of macrophages. B and 5-THB (15 mg) decreased the total cell number 
to a similar extent. This investigation did not discern between the different types of 
cells being counted, and the tissue found in the implants is formed of a variety of 
cells (Araujo, Rocha et al. 2010), with some of them being precursors of pericytes, 
endothelial cells or smooth muscle cells. A decrease in the cellularity of the sponges 
can, therefore, be attributed to the decrease of any of these different populations. 
Mechanisms of action of 5-tetrahydrocorticosterone 
  213 
Microscopic analysis of sponges containing B showed that the density of the 
fibrovascular tissue was lower than that of control sponges. This was seen also for 
sponges containing 5-THB at 15 mg, even though to a lesser degree. This would 
suggest that perhaps the two steroids reduced the recruitment of cells responsible for 
the deposition of extracellular matrix components. 
The inflammatory response is characterised by the recruitment of circulating 
inflammatory cells at the site of interest, such as neutrophils and monocytes. 
Neutrophils are the first type of cells to migrate to the tissue, and gradually they 
leave space for monocytes, which, once activated, differentiate into macrophages 
(Moura, Lima et al. 2011). Once at the site of inflammation, macrophages proliferate 
and, together with resident cells and other leukocytes, release mediators that attract 
other cell types such as fibroblasts and smooth muscle cells to begin a fibro-
proliferative phase. All this of course applies also to the inflammatory process taking 
place in the sponges; because they were retrieved from mice after 20 days in situ, it 
was evaluated that after such a period of time the main inflammatory cell types 
present would have been macrophages, and therefore decided to analyse this 
population. The marker F4/80 was chosen to stain macrophages because it has been 
shown to be the clearest marker for macrophages. Others, such as Mac-1, Mac-2 and 
CD68, have been found also in fibroblasts isolated from fibrotic tissues (Inoue, Plieth 
et al. 2005), whereas fibroblasts in culture did not react to staining with antibodies 
against F4/80 (Austyn and Gordon 1981). The proportion of macrophages was 
decreased to a similar extent by treatment with B and 5-THB, at 15 mg, compared 
with control sponges. This effect could explain, at least in part, the reduction in the 
total number of cells, and the presence of a less dense stroma, as macrophages have 
been shown to promote fibrosis (Mosser and Edwards 2008; Mosser and Zhang 
2008).  
Angiogenesis is a multi-step process that depends on many different mediators, 
released by a variety of cell types. Any agents that interfere with this process may do 
so by influencing any of the players involved, be they cellular or molecular. Having 
investigated how steroids affect some of the cellular components, next we focused on 
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some of the genes encoding molecules implicated in angiogenesis. Some of the most 
crucial factors during angiogenesis belong to the VEGF family, being potent pro-
angiogenic factors shown to stimulate the proliferation of endothelial cells and their 
motility (Connolly, Heuvelman et al. 1989; Gerhardt, Golding et al. 2003). The 
members of this family exert their actions through two tyrosine kinase receptors, 
VEGFR1 and VEGFR2, with the latter being responsible for the majority of the 
effects of VEGFs on endothelial cells (Zhang, Fang et al. 2004). The expression of 
VEGFs and VEGFR2 seem to be correlated temporally and spatially with the 
proliferation of new vessels during the process of wound healing (Zhang, Fang et al. 
2004). One member of this family in particular plays a central role in angiogenesis, 
VEGF (Hoeben, Landuyt et al. 2004). The increase in the abundance of transcripts 
of Vegf in sponges containing B may seem a paradox, since this is a strong stimulus 
for endothelial cell proliferation and migration, and is considered to be a marker of 
angiogenesis (Xavier, Amaral et al. 2010); in fact, GCs have been shown to reduce 
the production of VEGF and the abundance of mRNAs in human smooth muscle 
cells (Nauck, Roth et al. 1997; Wen, Liu et al. 2003). Furthermore, B decreased the 
amount of transcripts of Vegf in endothelial cells isolated from microvessels of rats 
(Shikatani, Trifonova et al. 2012). However, some research reported increased levels 
of VEGF in the cerebral cortex of mice treated with B (Howell, Kutiyanawalla et al. 
2011). The increase in transcripts seen here may be seen as a compensatory 
mechanism to overcome the marked decrease in vessel growth caused by the steroid. 
The lack of a vascular bed reduces the oxygen supply to the tissue, and this in turn is 
a strong inducer of angiogenesis, through the production of the hypoxia-inducible 
factor (HIF) (Pugh and Ratcliffe 2003). The expression of VEGF itself is induced in 
response to hypoxia (Conway, Collen et al. 2001). GCs have been reported to 
modulate the expression of HIF, though with contrasting results (Klekamp, Jarzecka 
et al. 1997; Fischer, Renz et al. 2001; Yossuck, Yan et al. 2001; Michalopoulos, 
Bowen et al. 2003). It would be interesting to measure the amount of VEGF in 
sponges (e.g. by ELISA), to determine whether it correlates with the variations seen 
in mRNAs; in addition, the expression of HIF in response to steroids could be 
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studied, as this may point to a mechanism of why B increased the amount of 
transcripts of Vegf. 
The reduction of the abundance of mRNAs of the gene encoding the receptor 
VEGFR2 was to be expected since it correlates with inhibition of angiogenesis. This 
phenomenon, through the promotion of a feedback mechanism, may also supply a 
partial explanation for the increase in transcripts of Vegf. This has been seen in vivo 
in cerebral cortex of mice treated with B (Howell, Kutiyanawalla et al. 2011). 
Another GC, dexamethasone, has been shown to reduce the expression of VEGFR2 
in vivo in mice in models of wound healing and allergic dermatitis (Zhang, Fang et 
al. 2004), and in a murine model of melanoma, conjugated dexamethasone gave 
similar results (Sau and Banerjee 2014). 
During the first phases of angiogenesis, endothelial cells go through a complex 
rearrangement process in space and time; they must proliferate, migrate and give rise 
to new tubular structures. During maturation of the newly assembled vessels, the 
endothelial cells must tighten their interactions to form a controlled and functional 
barrier. Intercellular junction remodelling plays a central role in both these processes 
switching between an “inactive” and an “active” mode constantly (Bentley, Franco et 
al. 2014). PECAM-1 and VE-cadherin are expressed by endothelial cells, and both 
are important constituents of intercellular junctions. PECAM-1 has been shown to 
play an important role in the initial formation and stabilisation of cell-cell contact 
between endothelial cells (Jackson 2003), and VE-cadherin has been found to be 
pivotal in determining the dynamics of cell rearrangement, making possible the 
formation of vessels and maintaining their integrity once they are fully formed, so 
influencing greatly vascular permeability (Goddard and Iruela-Arispe 2013; Bentley, 
Franco et al. 2014). The reduction of the abundance of transcripts of Pecam-1 both 
with B and 5-THB (15 mg), provided a causal mechanism for the results obtained 
with immunostaining analysis, and suggest that the two steroids may be reducing the 
number of vessels by disrupting the dynamics of cell rearrangement. PECAM-1 is a 
molecule expressed not only in endothelial cells, in effect it is found also in 
leukocytes and platelets, therefore playing an important role also during the trans-
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migration of leukocytes and regulating platelet function (Jackson 2003). As a 
consequence, the real-time data presented in this chapter may not be only 
representative of the effects of steroids on a single cell population. The analysis of 
transcripts of VE-cadherin showed no effect of 5-THB, but a great decrease 
induced by B. VE-cadherin is a calcium-dependent protein which, once activated, 
triggers different pathways which signal to the actin cytoskeleton (Goddard and 
Iruela-Arispe 2013). While B may be disrupting these pathways, including calcium-
related ones, 5-THB may be acting in a more selective manner. The results on the 
two junction molecules PECAM-1 and VE-cadherin may seem in contrast to the 
literature, which describes GCs as agents able to tighten intercellular connection, 
increasing the barrier function of the endothelium. For instance, dexamethasone has 
been shown to increase expression of VE-cadherin (Blecharz, Drenckhahn et al. 
2008), and GCs strengthen the endothelial barrier, most of all at the level of the 
blood-brain barrier, in conditions characterised by neuroinflammation (Salvador, 
Shityakov et al. 2014). However, the sponge model presented here was different in 
that it investigated de novo angiogenesis instead of the effects of steroids on an 
already established vascular bed. Another result in accordance with immunostaining 
analysis, and providing a molecular mechanism, was the reduction induced by B, but 
not by 5-THB, of the abundance of transcripts of Acta2, encoding SMA. 
Other genes that were found altered by B, but not 5-THB, were Vcam-1, Icam-1 
and E-selectin. These proteins are important in the regulation of vessel permeability 
during inflammation in that they control extravasation of soluble factors and immune 
cells (Frank PG 2008). Studies showed that GCs influence the expression of these 
molecules, and this would explain in part their anti-inflammatory properties 
(Cronstein, Kimmel et al. 1992; Aziz and Wakefield 1996). However, some other 
studies have found no effect, claiming that the effects of GCs may be dependent on 
time, dose and experimental model (Dufour, Corsini et al. 1998). In this chapter, the 
behaviour of B regarding Icam-1 and E-selectin is in accordance with an anti-
inflammatory action. Unexpectedly though, the steroid increased transcripts of 
Vcam-1, an important mediator of the recruitment of leukocytes. It is known that 
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VEGF promote expression of VCAM-1 (Fearnley, Odell et al. 2014), and since B 
increased transcript abundance of Vegf this may provide a causal mechanism. 
One of the few genes affected by 5-THB, at 3 mg, was the anti-angiogenic Thbs-2. 
This may explain the weaker effect on angiogenesis of 5-THB when given at the 
lower dose. The reasons why the higher concentration of compound did not have the 
same, or bigger, effect are not clear. It may be that the higher dose affected other 
molecules and/or processes in such a way that the transcription of Thbs-2 was 
ultimately left unchanged. This protein has been found to affect the remodelling of 
the extracellular matrix in wound healing and during foreign body response 
(Kyriakides, Zhu et al. 2001); it is, therefore, possible that its down-regulation may 
not have had direct and detectable repercussions on angiogenesis as measured by us.  
When the abundance of transcripts of pro-inflammatory genes with a role in 
angiogenesis was investigated, B was found to reduce those of Tnf, Il1 Infand 
Nos3 (eNOS); in contrast, 5-THB had no effects on any of them. The behaviour of 
B is in accordance with its extensively-described anti-inflammatory properties. Since 
these are factors that also stimulate angiogenesis (Leibovich, Polverini et al. 1987), 
the effect of the steroid may explain in part its anti-angiogenic action. eNOS, an 
enzyme responsible for the production of the vasodilator NO, plays a role in 
sprouting angiogenesis by promoting vessel dilation, and its expression is stimulated 
by VEGF (Bir, Xiong et al. 2012). Reduction of transcripts of this gene by B supplies 
another mechanism through which this steroid may be inhibiting angiogenesis. GCs 
have been reported to lower expression of eNOS in endothelial cells (Duckles and 
Miller 2010). The pro-inflammatory molecule INF has been shown to promote 
activation of macrophages through the classical pathway (Bartneck, Peters et al. 
2014). The fact that B decreased accumulation of macrophages in sponges may be 
linked with its effect on INF transcription. 
Interestingly, 5-THB at 3 mg increased the abundance of transcripts of Mcp1, while 
B had no effect. MCP1 is a protein that stimulates the recruitment of monocytes in 
tissues, therefore increasing the abundance of macrophages. Over-expression of 
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MCP1 has been shown to promote vessel growth and functionality in/of infarcted 
hearts, presumably by a mechanism linked with increased infiltration of macrophages 
(Morimoto, Takahashi et al. 2006). 5-THB did not increase the abundance of 
macrophages or improve angiogenesis therefore, this result may seem contradictory. 
This increase may be a reaction to the presence of a constant inflammatory stimulus 
(the implants), which stimulates the recruitment of cells of the immune system. A 
similar result was seen also in a study using a model of sponge-induced angiogenesis 
to test the effects of metformin (Xavier, Amaral et al. 2010), suggesting this may be 
a real compensatory mechanism. As with the result regarding Thbs-2, while the 
lower dose of 5-THB affected abundance of mRNAs of Mcp-1, the higher dose did 
not have any effects. Having encountered this phenomenon twice, it is reasonable to 
believe that it is representative of a real occurrence rather than a chance result. As 
mentioned above, the higher dose of steroid may be influencing a greater number of 
factors and processes, probably not yet investigated, which in turn may keep constant 
the transcription of Mcp-1. 
Cell adhesion, migration and vessel formation during angiogenesis are processes 
closely related to the remodelling of the extracellular matrix (ECM). Central players 
of this remodelling are the metalloproteinase enzymes (MMPs), which promote ECM 
degradation, and tissue inhibitors of MMPs (TIMPs), which counteract the 
destructive actions of MMPs (Pepper 2001; Bellon, Martiny et al. 2004; Sottile 
2004). It is known that GCs influence the expression of both groups of enzyme 
(Perretti and Ahluwalia 2000; Pitzalis, Pipitone et al. 2002; Shikatani, Trifonova et 
al. 2012). For example, decreased expression of MMP2 and increased synthesis of 
TIMP2 cause by GCs have been reported before (Pross, Farooq et al. 2002; 
Shikatani, Trifonova et al. 2012). The data presented here show that B only reduced 
the transcript abundance of Mmp10, while 5-THB had no effect on any of the 
genes. The enzyme MMP10 is known to degrade the basement membrane, together 
with MMP3 and MMP9 (Davis 2010), promoting cell migration. If the decrease in 
transcription induced by B translates into decreased production of MMP10, this 
would point to reduced ECM degradation with consequent reduction in remodelling, 
which is so important in angiogenesis. However, the effect of B on the panel of 
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MMPs tested seemed rather limited, so the functional significance cannot be easy 
judged. Another important component of the ECM that was investigated was 
collagen. B reduced the amount of transcripts of all four isoforms studied, while 5-
THB had a more restricted effect. A plethora of studies have shown that GCs induce 
degradation of the ECM by interfering with production of collagen, and this 
phenomenon is known to cause some of the side effects of GC therapy, such as skin 
thinning and impairment of wound healing. Different kinds of collagen are found in 
different types of extracellular structures, and GCs have been shown to interfere with 
many of these (Maragoudakis, Sarmonika et al. 1989; Grose, Werner et al. 2002; 
Oishi, Fu et al. 2002). Staining of collagen fibres in section of sponges revealed that 
their abundance was reduced in samples treated with B but not with 5-THB. This 
may be due to the fact that 5-THB only affected the abundance of transcripts of one 
type of collagen. When sponges were analysed microscopically, it was clear that the 
fibro-vascular matrix of those treated with B was much less compact that the control 
group. It was also noticed that those treated with the higher dose of 5-THB showed 
a looser structure, even though the effect was less pronounced. The results obtained 
from the staining were therefore slightly unexpected. However, other proteins 
constitute the ECM, and GCs have been shown to have an effect on some of these. 
An example comes from a study conducted almost 30 years ago in which GCs were 
found to decrease, during angiogenesis, two components of the basement membrane, 
laminin and fibronectin, and this phenomenon was thought to explain their anti-
angiogenic properties (Folkman and Ingber 1987). It is possible that 5-THB, while 
not affecting the production of collagen, may affect that of other proteins not yet 
analysed. 
The presence of B in the implants increased the abundance of transcripts of Srd5a1, 
while 5-THB had no effect. This increase indicates that a positive feedback of B on 
its own metabolism may exist, perhaps in order to decrease it deleterious effects on 
angiogenesis. In a model of umbilical cord occlusion in the sheep, hypoxia has been 
shown to increase expression of 5-R2 in the brain (Nguyen, Ross Young et al. 
2004); this may represent a stimulus also for 5-R1 in sponges treated with B. It is 
challenging to make any assumptions about which kind of cells are transcribing the 
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gene in sponges. Some groups found the presence of 5-reductases in human, rat and 
murine vessels and monocytes/macrophages, however, they did not confirm the 
identity of the isoforms (Nixon, Upreti et al. 2011). It has also been shown that 
fibroblasts express 5-R1 (Hoppe, Holterhus et al. 2006). All these cell populations 
are present in the fibrovascular tissues in sponges; as a consequence, more detailed 
studies may have to be performed to clarify this point, perhaps by isolating the 
different cell types by FACS analysis. 
Previous studies using the sponge model of angiogenesis showed that the angiostatic 
effects of GCs are dependent on GR (Small, Hadoke et al. 2005; Logie, Ali et al. 
2010); the former study also confirmed this ex vivo, using the aortic ring model of 
angiogenesis, and showed that MR did not seem important for the sprouting of 
vessels in this experimental set-up. At the same time, GCs are known to bind both 
GR and MR, and some of their effects on the cardiovascular system seem to be 
dependent on MR. This receptor is expressed by cardiac myocytes, where the 
absence of the enzyme 11β-HSD2 makes it a target for activation by GCs (Yang and 
Fuller 2012). Additionally, endothelial cells and vascular smooth muscle cells 
express MR (Meijer 2002; McCurley, McGraw et al. 2013), and a body of literature 
exists suggesting a negative influence of the receptor on angiogenesis (Tiberio, 
Nascimbeni et al. 2013). Interestingly, activation of MR in cell cultures that over-
expressed the receptor correlated with decreased expression of VEGF (Tiberio, 
Nascimbeni et al. 2013). The effect of B on transcripts of Nr3c1 (GR) and Nr3c2 
(MR) suggests a functional interaction of the steroid with the receptors; an 
interaction that may lead also to a mechanism of negative feedback. We could 
speculate that the reduction in transcripts of Nr3c2 may account, at least in part, for 
the increase of Vegf mRNAs, and see this as a compensatory mechanism. This 
effect may also provide a mechanism through which B inhibited collagen deposition, 
as it has been shown that MR is involved in the fibrotic response (Meinel, Gekle et 
al. 2014). The absence of effects with the administration of 5-THB suggests a 
couple of possibilities: the two receptors may not be the targets of this steroid in this 
model, or the action of 5-THB may be not strong enough to alter the two genes. 
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As with any analysis that investigates the abundance of transcripts, the results 
obtained by real-time PCR in this chapter did not provide any information about the 
abundance of the proteins encoded by the genes. It would be, therefore, very 
important to extend the analysis by using techniques such as immunostaining, 
Western blotting and/or ELISA, in order to understand whether the results presented 
here could have functional repercussions. It is well known that GCs can modify 
protein abundance by influencing translational mechanisms (Clark 2003), therefore 
transcript analysis can only give a very partial picture of the potential mechanisms of 
action of B and 5-THB, in this and in any model. 
In conclusion, 5-THB, administered at equipotent doses to B for reduction of 
macrophage infiltration, possessed weaker anti-angiogenic properties. Importantly, 
5-THB affects the abundance of transcripts of a more restricted number of genes in 
comparison with its precursor. One reason for this behaviour may be that 5-THB 
works through a different receptor than B, as suggested by the results presented in 
Chapter 3 and 4 using the GR antagonist RU486. This needs to be verified in the 











Mechanisms of action of 5-tetrahydrocorticosterone 









EFFECTS OF 5-THB ON GLUCOCORTICOID 









Mechanisms of action of 5-tetrahydrocorticosterone 
  223 
Chapter 6: Effects of 5-THB on glucocorticoid 
receptor signalling pathways 
6.1 Introduction 
Classically, the effects of glucocorticoids (GCs) on gene expression have been 
explained by two main types of GR-dependent mechanisms, trans-activation and 
trans-repression. The former has been largely associated with the side effects induced 
by long-term therapy with steroids, while the latter has been suggested as the means 
through which these molecules deliver their beneficial anti-inflammatory effects. As 
a consequence, the search for substitute compounds has focussed on finding 
molecules that work mainly through trans-repressive mechanisms. This, of course, is 
a simplistic picture because GCs have a much more complex behaviour, which we 
have begun to discover only very recently. As reductionist as it may be, the 
simplified division between trans-activation and trans-repression does help to 
identify new more selective anti-inflammatory compounds. Of course, the initial 
screenings must subsequently be refined in order to gain a fuller image of the real 
potential of newly discovered molecules.  
In previous chapters, the anti-inflammatory properties of 5-THB were investigated 
in in vivo and in vitro models; in addition, the compound was tested in vivo for 
effects on angiogenesis, a process which GCs are known to inhibit causing some of 
their most common side effects (i.e. impairment of wound healing). These studies 
provided a preliminary picture of what molecular mechanisms are influenced by the 
5-reduced steroid, and revealed that the compound has weaker effects than B in 
many systems and may work through pathways not requiring GR. In the present 
chapter, the focus will be on delving deeper into these mechanisms and, in particular, 
in understanding how 5-THB affects gene expression mediated by trans-activation. 
This mechanism is also held responsible for some of the anti-inflammatory properties 
of GCs, thanks to induction of anti-inflammatory proteins; therefore, the present 
study will provide a fuller picture of the working mechanisms of 5-THB, and of its 
potential as a new more selective anti-inflammatory drug. Furthermore, it will shed 
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light on how a metabolite physiologically produced, and until recently believed 
inactive, may influence cellular physiology. 
A range of in vitro experimental approaches will be employed, including analysis of 
the induction of luciferase reporters and endogenous genes, and of post-translational 
modification of GR, such as phosphorylation, known to affect transcriptional activity 
of the receptor. 
Hypotheses 
- 5-THB and B differentially affect the phosphorylation state of the glucocorticoid 
receptor 
- 5-THB and B modulate different profiles of signalling pathways regulated by the 
glucocorticoid receptor 
Objectives 
The aims of this chapter were to investigate: 
- the profile of phosphorylation of the GR in response to 5-THB 
- the effect of 5-THB on the expression of GR-driven reporter plasmids and steroid-
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6.2 Materials and Methods 
6.2.1 General 
6.2.1.1 Materials 
Materials for general cell culture and experimental treatments were obtained as 
described in section 2.1.1.1. Steroids, including the GR antagonist RU486, were from 
Steraloids (Newport, RI, USA). The carcinomic human alveolar cell line A549, and 
the mouse hepatoma cell line BWTG3, were sourced and maintained in culture as 
described in sections 2.1.1.2 and 2.1.2. 
6.2.1.2 Preparation of steroids 
Steroids were dissolved in ethanol to obtain solutions 1000 times more concentrated 
than the concentration needed in the experiments. This allowed the addition of 1 L 
of steroid solutions into each mL of medium at the time of treatment. The solutions 
were stored at -20 ºC for a maximum of one month before being discarded and 
replaced with freshly made ones. When needed they were left at RT for 30 min prior 
to usage. 
6.2.1.3 General treatments 
Steroids were added directly to the culture medium into each well, at a concentration 
and for the length of time indicated. Each treatment was always performed in 
triplicate, and each experiment was repeated between three and eight times as 
indicated. 
6.2.2 A549 cells 
6.2.2.1 General treatments 
In all experiments, A549 cells (4x10
5
cells/well) were plated in stripped-FBS medium 
on 12-well plates; 24 h later, cells were treated in triplicate with steroids in ethanol or 
ethanol (vehicle as control) for the time and at the concentration indicated. 
6.2.2.2 Studies on phosphorylation of GR  
6.2.2.2.1 Development of a phosphorylation assay for Ser211 
Western blotting was used to investigate phosphorylation of GR. In order to test the 
responsiveness of the A549 cell line to steroid treatment, cells were incubated either 
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with 5-THB, B or vehicle for 1 h. To confirm the identity of the protein detected, 
GR abundance was suppressed using RNA interference technology.  
6.2.2.2.2 Time course of phosphorylation of Ser211 
Time-dependent phosphorylation of GR was investigated by Western blotting after 
incubation of A549 cells with either steroids or vehicle for 1, 5 and 24 h.  
6.2.2.2.3 Knockdown of GR by RNA interference (RNAi) 
The procedure was performed as described in section 2.1.3.1. 
6.2.2.2.4 Western blotting 
6.2.2.2.4.1 Materials 
General materials were obtained as described in section 2.3.3.1.1. Specific primary 
antibodies employed were: rabbit polyclonal antibody to GR phosphorylated at 
serine 211 (
P-Ser211
GR) from Cell Signalling Technology (Hertfordshire, UK); rabbit 
polyclonal antibody to GR and mouse monoclonal antibody to -tubulin from Insight 
Biotechnology (Wembley, Middlesex, UK); secondary antibodies were: IRDye 
800CW Goat Anti-Rabbit IgG (H+L) and IRDye 800CW Goat Anti-mouse IgG 
(H+L) from LI-COR Biosciences Ltd (Cambridge, Cambridgeshire, UK). Primary 
antibodies were diluted as followed: 
P-Ser211
GR 1:1000, Total GR 1:500, -tubulin 
1:1000 in BSA (5% w/v in TBST), and all secondary antibodies were diluted 
1:10000 in powder cow’s milk (5% w/v in TBST).  
6.2.2.2.4.2 Procedures 
Protein extraction from A549 cells, quantification and Western blotting analysis were 
performed as described in sections 2.3.3.1.2, 2.2.3.1.3 and 2.3.3.1.4. 
6.2.2.2.4.3 Quantification of protein expression 
The abundance of protein was calculated by using the Odyssey® Imaging software 
(LI-COR biosciences, Cambridge, Cambridgeshire, UK). The abundance of 
phosphorylated GR was normalised to the total amount of GR. In order to do that, 
two gels were run at the same time, on the same apparatus, and loaded with the same 
samples; the quantification was performed as followed: the ratios between total GR 
and -tubulin in one gel, and between P-Ser211GR and -tubulin in the other, were 
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calculated; subsequently, phosphorylation was expressed as ratio between these two 
ratios for each treatment. In blots in which 
P-Ser211
GR was detected, two bands were 
visible at the molecular weight predicted; both bands were quantified. Regarding 
knockdown experiments, the percentage of knockdown was calculated by 
considering the ratio for control wells as 100% GR expression. 
6.2.2.3 Studies of transcription of endogenous genes 
6.2.2.3.1 Effects of 5-THB on transcription of endogenous genes 
Cells (4x10
5
cells/well) were treated either with vehicle, B (1M) or 5-THB (1, 3, 
10 M) for 2 h prior to total RNA extraction (described in section 2.3.1.2). 
6.2.2.3.2 Real-time PCR analysis 
Production of cDNA and real-time PCR analysis were performed as described in 
sections 2.3.1.5 and 2.3.1.6 respectively. The details of the human primers and UPL 
probes employed are given below in table 6.1. 
Gene symbol, full name, accession No Primers sequence UPL 
probe 




















Table 6.1 Sequences of the primers and UPL probe numbers used for real-time PCR in 
A549 cells. The reverse primer (3’ → 5’) for each gene is above the separation line, the 
forward primer (5’ → 3’) is below. 
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6.2.2.4 Studies on expression of reporter plasmids 
6.2.2.4.1 Transient transfection 
6.2.2.4.1.1 Material  
General materials were obtained as described in section 2.1.3.2. Two GR-responsive 
luciferase reporter plasmids were employed: MMTV-LTR-Luc reporter (Mouse 
Mammary Tumor Virus-Long Terminal Repeat-Luciferase, abbreviated as MMTV-
Luc) activated by GR-dimer binding (Lefebvre, Berard et al. 1991; Michailidou, 
Carter et al. 2008); rPNMT -998/-446-Luc reporter (rat Phenylethanolamine N-
Methyltransferase -996/-446 Luciferase, abbreviated as PNMT-Luc) activated by 
binding of GR multimers (Adams, Meijer et al. 2003; Michailidou, Carter et al. 
2008). The plasmids were kindly provided by Prof. K.E. Chapman, Centre for 
Cardiovascular Science, University of Edinburgh (rPNMT-998/-466 Luc was 
originally from David Pearce, University of California, Department of Medicine, San 
Francisco, CA, USA). Both plasmids were originated by cloning the appropriate 
regulatory sequence of MMTV or PNMT gene into the pGL3-luciferase reporter 
plasmid. In addition, the following plasmids were utilised: pGEM, plasmid 
containing inert DNA, as negative control; pSV2-Luciferase, plasmid used as 
positive control to confirm success of transfection; pGL3-Luciferase, reporter 
lacking regulatory sequences (promoter/enhancer) used as negative control; pVL342, 
plasmid containing the sequence encoding the murine GR; pKC275, -Galactosidase 
plasmid, used as internal control for transfection efficiency. 
The plasmids pGEM and pGL3-Luciferase were purchased from Promega 
(Hampshire, UK); pVL342 and pKC275 were designed and prepared by Valery 
Kelly (Prof K.E. Chapman’s group), and kindly provided by Dr. K. McInnes along 
with pSV2-Luciferase. The maps of pVL342 and pSV2-Luciferase can be found in 
(Michailidou 2007). The cloning and expression of a plasmid encoding mouse GR 
was first described by (Danielsen, Northrop et al. 1986). 
6.2.2.4.1.2 Transfection procedure 
The amplification of plasmids and their transfection into A549 cells were performed 
as described in section 2.1.3.2. The table below summarises the plasmids used with 
the relative amount of DNA (expressed as g per each well). 
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Table 6.2 Schematic representation of the plasmids, with relative quantities, transiently 
transfected in A549 cells. 
6.2.2.4.2 Experimental conditions and treatments 
6.2.2.4.2.1 Development of an assay to detect expression changes in response to 
steroids 
In order to test that the reporters were responsive to steroids, A549 cells were treated 
with B (1M). To analyse whether their activation was GR dependent two 
approaches were tested: (a) OVER-EXPRESSION OF GR; cells were transfected 
either with the reporters alone or together with a plasmid coding for murine GR 
(mGR) and then treated with B, and (b) PHARMACOLOGICAL GR 
ANTAGONISM; cells were treated with B (1 M) only or with B (1 M) + RU486 
(0.1 and 1 M). RU486 powder was dissolved in ethanol to obtain a concentration 
1000 times greater than that needed in the experiments, and diluted directly by 
addition to the cell culture medium in the wells. The solution was freshly prepared 
prior to each experiment. Treatments were started 1 h before the addition of B.  
Plasmid (μg) 
Transfection 
pGEM pSV2 pGL3 
+ GR - GR 
PMNT MMTV PMNT MMTV 
pGEM 2.2 - - - - - - 
pSV2-luc - 2.2 - - - - - 
pGL3-basic - - 2.2 - - - - 
PMNT-Luc - - - 1 - 1.2 - 
MMTV-Luc - - - - 1 - 1.2 
pVL342 - - - 0.2 0.2 - - 
pKC275 - - - 1 1 1 1 
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6.2.2.4.2.2 Effect of 5-THB on expression of reporter plasmids 
Once the model was tested for responsiveness to steroids and GR-dependency of 
induction, effects of 5-THB on the expression of the two plasmids were 
investigated. To this end, concentration-response comparisons between B and 5-
THB were performed.  
6.2.2.4.3 Luciferase and -galactosidase assays  
The assays were performed, and data recorded, as described in 2.3.3.2. 
6.2.2.4.4 Data analysis 
When the luciferase activity of cells transiently transfected with pSV2-luc was 400 
times higher than that of pGEM, the transfection was deemed successful. Activity 
from pGEM was subtracted from all values as a measure of background activity. 
Quantification of luciferase activity was achieved by calculating the ratio between 
the values of the chemioluminescence generated by luciferase activity and those 
recorded during β-galactosidase assay.  
6.2.3 Gene transcription studies in BWTG3 cells 
6.2.3.1 General treatments 
In all experiments, the murine hepatoma cell line BWTG3 cells (5x10
5
cells/well) 
were plated in stripped-FBS medium on 12-well plates; 24 h later, cells were treated 
in triplicate either with steroids in ethanol or ethanol (vehicle as control) for the time 
and at the concentrations indicated. 
6.2.3.2 Development of an assay to detect gene transcription changes 
in response to steroids 
Cells were tested for responsiveness to steroids by investigating the abundance of 
transcripts of the gene tyrosine aminotransferase (Tat) as representative steroid-
responsive gene following treatment with dexamethasone (dex) and B for 1, 4 and 6 
h.  
6.2.3.3 Effects of 5-THB on endogenous gene expression 
Once the abundance of mRNAs for TAT had been tested, the effect of treatment with 
5-THB for 4, 8, 16 and 24 h was investigated. Subsequently, 16 h was taken as the 
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length of treatment to use in following experiments where the mRNA abundance of 
other endogenous genes was analysed. 
6.2.3.4 Modulation by 5-THB of B-induced effects  
In order to understand if 5-THB was able to interfere with the effects of B on gene 
transcription, cells were co-treated with B (1 M) + 5-THB (0.01-10 M) for 16 h.  
6.2.3.5 Real-time PCR analysis 
Total RNA extraction, cDNA production and real-time PCR analysis was performed 
as described in section 2.3.1. The details of the murine primers and UPL probes 
employed are given below in table 6.3. 
Gene symbol, full name, accession No Primers sequence UPL 
probe 






















Table 6.3 Sequences of the primers and UPL probe numbers used for real-time PCR in 
BWTG3 cells. The reverse primer (3’ → 5’) for each gene is above the separation line, the 
forward primer (5’ → 3’) is below. 
6.2.4 Data analysis 
6.2.4.1 General 
Data were represented as mean ± SEM and analysed as described in section 2.4. 
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6.2.4.2 Real-time PCR 
For quantification of transcripts through real-time PCR, the abundance of each gene 
was represented in relation to the abundance of a chosen housekeeping gene. The 
housekeeping gene used for A549 cells was CyclophilinA (CypA), and for BWTG3 
cells Tbp, due to the lack of significant changes in the abundance of transcripts 
following treatment with steroids. For each sample and each gene studied, the values 
presented in the graphs were calculated as follow: value sample X/value CypA or 
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6.3 Results 
6.3.1 Effects of 5-THB on GR phosphorylation in A549 cells 
6.3.1.1 Development of a phosphorylation assay for Ser211 
As shown in Figure 6.1 a and b, the cell line A549 was responsive to treatment with 
B (1 M) as the steroid increased phosphorylation of GR at Ser211 compared with 
vehicle-treated cells (basal level) after 1 h of incubation. At this time point, 5-THB 
(1 M) did not increase phosphorylation above basal level.  
 
Figure 6.1 5-Tetrahydrocorticosterone (5-THB), unlike corticosterone (B), did not 
induce phosphorylation of serine 211 on the glucocorticoid receptor (GR). (a) 
Representative images of Western blot analysis of total GR (right) and phosphorylated GR 
(
P-Ser211
GR, left) in A549 cells treated for 1 hour either with B, 5-THB (both 1M) or 
vehicle (V). (b) Quantitative analysis of GR phosphorylation after normalisation against -
tubulin. Data (mean ± SEM) were analysed by one-way ANOVA with Tukey’s post-hoc test; 
*** p<0.0001 vs V; N = 4. MW = molecular weight, kDa = kilo Dalton. 
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6.3.1.2 GR knock down 
GR was knocked down by about 40% compared with control treated cells (Figure 6.2 
a). Using this approach, it was confirmed that the correct protein was being studied 
in experiments of phosphorylation of GR on Ser211 (Figure 6.2 b). 
 
Figure 6.2 Glucocorticoid receptor (GR) was knocked down through RNA silencing 
(siRNA). (a) Quantification of the extent of GR knock down; GR amount was normalised 
against -tubulin; CTRL = control, cells treated with vehicle only; N = 3; * = p < 0.05 vs 
CTRL with unpaired t-test. Data are mean ± SEM. (b) Detection of GR (left side) and 
phosphorylated GR (
P-Ser211
GR, right side) upon treatment with vehicle (V) or B for 1 hour. 
MW = molecular weight, kDa = kilo Dalton. CTRL, V and B = cells transfected with mock 
siRNA; GR KD = cells transfected with siRNA for GR. 
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6.3.1.3 Time-dependent phosphorylation of GR at Ser211 in response 
to treatment with 5-THB 
As shown in Figure 6.3, treatment with B of A459 cells increased phosphorylation of 
GR at Ser211 (
P-Ser211
GR) compared with vehicle treated cells at every time point 
studied, with a maximum occurring at 5 h post-treatment and a minimum at 24 h. 
Addition of 5-THB increased phosphorylation compared with the vehicle-treated 
group only at a concentration of 10 M after 1 h of treatment; this effect was weaker 
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Figure 6.3 5-Tetrahydrocorticosterone (5-THB) induced phosphorylation of the 
glucocorticoid receptor (GR) with a different kinetics compared with corticosterone 
(B). (a) Representative image of a Western blotting for phosphorylated GR (
P-Ser211
GR), total 
GR (GR) and -tubulin. MW = molecular weight, kDa = kilo Dalton. (b) Quantification of 
GR phosphorylation performed as described in section 6.2.2.2.4.3. Vehicle group was 
considered as one fold induction at each time point and steroid-stimulated phosphorylation 
was calculated accordingly. N = 8 analysed by one-way ANOVA with Tukey’s post-hoc test. 
*** = p < 0.0001, ** = p < 0.001, * = p < 0.05 vs V; £££ = p < 0.0001, £ = p < 0.05. Data 
are mean ± SEM. 
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6.3.2 Effects of 5-THB on the abundance of transcripts of 
endogenous genes in A549 cells 
Analysis of the effects of steroidal treatment (2 h) on the abundance of transcripts of 
selected steroid-responsive gene (Figure 6.4 a-d) revealed that B (1 M) increased 
that of Gilz, Igfbp1, Fkbp51 and Dusp1 compared with vehicle-treated group, while 
5-THB had a more limited effect in that it up-regulated the abundance of mRNAs 
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Figure 6.4 5-Tetrahydrocorticosterone (5-THB) and corticosterone (B) differentially 
affected the abundance of transcripts of selected genes in A549 cells. Quantification by 
real-time PCR of the abundance of transcripts of (a) Gilz, (b) Igfbp1, (c) Fkbp51 and (d) 
Dusp1 in response to incubation either with vehicle (V), B (1 M) or increasing 
concentrations of -THB (1-10 M) for 2 hours. Data (mean ± SEM) were analysed with 
one-way ANOVA followed by Tukey’s post-hoc test; *** = p < 0.0001, * = p < 0.05, & = 
0.1 < p < 0.05 vs V; N = 6. A.U. = arbitrary unit. 
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6.3.3 Effects of 5-THB on the activation of steroid-
responsive reporters in A549 cells 
 
6.3.3.1 Steroid responsiveness of reporter plasmids  
As shown in Figure 6.5, B (1 M) induced the activation of both reporters. The 
induction was greater when mGR was co-transfected with the plasmids. In the 
absence of mGR, the GR antagonist RU486 was able to significantly block the action 
of B at both concentrations studied for both reporters (a and b), however when mGR 
was co-transfected it could do so only when present at a concentration of 1 M (c 
and d). 
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Figure 6.5 Corticosterone (B) activated the reporters MMTV-Luc and PNMT-Luc in a 
glucocorticoid receptor (GR)-dependent manner. Activation of the reporters (a) and (b) 
MMTV-Luc and (c) and (d) PNMT-Luc by B (1 M), either in the absence (-mGR) or 
presence (+mGR) of co-transfected murine GR and with or without the GR antagonist 
RU486 as indicated. N = 3 analysed by one-way ANOVA with Tukey’s post-hoc test. *** = 
p <0.0001, * = p < 0.05 vs V; £££ = p < 0.0001, £ = p < 0.05, ns = not significant. Data are 
mean ± SEM. -Gal = -Galactosidase activity, A.U. = arbitrary unit. 
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6.3.3.2 Effect of 5-THB on activation of reporter plasmids 
MMTV-Luc 
As shown in Figure 6.6, in the absence of co-transfected mGR, B increased the 
expression of the MMTV-Luc reporter, compared with cells treated only with vehicle 
(represented as 0 on the x axis), in a concentration-dependent manner at a 
concentration equal or greater than 0.1 M; in the presence of mGR, B induced the 
expression of the reporter at any concentration tested (0.01-10 M). 5-THB 
increased the expression compared with the vehicle group only at 10 M in absence 
of mGR, and at 3 and 10 M in presence of co-transfected mGR. 
PNMT-Luc 
As shown in Figure 6.7, B activated the PNMT-Luc reporter when given at a 
concentration equal or greater than 1 M in the absence of co-transfected mGR, 
compared with vehicle (represented as 0 on the x axis); in the presence of mGR, the 
minimal concentration that increased expression of PNMT-Luc was 0.01 M. 5-
THB did not have any effect. 
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Figure 6.6 5-Tetrahydrocorticosterone (-THB) only activated the MMTV-Luc 
reporter at 3 and 10 M, whereas corticosterone (B) did so in a concentration-
dependent manner. Quantification of luciferase activity (normalised to -galactosidase (-
Gal) activity) in response to increasing concentration of steroids, either in the absence (a, -
mGR) or presence (b, +mGR) of co-transfected murine GR (mGR). N = 6 analysed by one-
way ANOVA with Tukey’s post-hoc test; *** = p <0.0001, ** = p < 0.001, & = 0.1 < p < 
0.05 vs V (0 in the x axis). Data are mean ± SEM. A.U. = arbitrary unit. 
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Figure 6.7 5-Tetrahydrocorticosterone (-THB), unlike corticosterone (B), did not 
activate the PNMT-Luc reporter. Quantification of luciferase activity (normalised to -
Galactosidase  (-Gal) activity) in response to increasing concentration of steroids, either in 
the absence (a, -mGR) or presence (b, +mGR) of co-transfected murine GR (mGR). N = 6 
analysed by one-way ANOVA with Tukey’s post-hoc test; *** = p <0.0001 vs V (0 in the x 
axis). Data are mean ± SEM. A.U. = arbitrary unit. 
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6.3.4 Effects of 5-THB on abundance of transcripts of 
endogenous genes in BWTG3 cells 
6.3.4.1 Evaluation of the model 
The murine hepatoma cell line BWTG3 was responsive to dexamethasone (dex, 100 
nM) and B (1 M) in that they increased abundance of mRNAs of the Tat gene after 







































Figure 6.8 Dexamethasone (dex) and corticosterone (B) increased the abundance of 
transcripts of the gene encoding the metabolic enzyme tyrosine aminotransferase (Tat). 
Quantification by real-time PCR analysis of transcripts of Tat in BWTG3 cells treated either 
with vehicle (V) or steroids (dex, 100 nM; B, 1 M) as indicated. N = 3 analysed by one-
way ANOVA with Tukey’s post-hoc test. *** = p < 0.0001 vs V. Data are mean ± SEM. Tbp 
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6.3.4.2 Effects of 5-THB on abundance of transcripts of endogenous 
genes 
6.3.4.2.1 Time-dependent effect of 5-THB on Tat  
In BWTG3 cells B increased abundance of mRNAs of Tat in a time-dependent 
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Figure 6.9 5-Tetrahydrocorticosterone (5-THB) did not affect the abundance of 
mRNAs of tyrosine aminotransferase (Tat), whereas corticosterone (B) increased it in a 
time-dependent manner. Quantification by real-time PCR analysis of transcripts of Tat in 
BWTG3 cells treated either with vehicle (V) or steroids as indicated for increasing period of 
time. N = 6 analysed by one-way ANOVA with Tukey’s post-hoc test. *** = p < 0.0001, * = 
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6.3.4.2.2 Effects of 5-THB on Gilz, Igfbp1 and Ggt1  
As shown in Figure 6.10, analysis of the effect of steroidal treatments on selected 
steroid-responsive genes revealed that B (1 M) increased the abundance of 
transcripts of Gilz, Igfbp1 and Ggt1 compared with the vehicle-treated group, while 









































































b )G ilz Ig fb p 1
G g t1
 
Figure 6.10 5-Tetrahydrocorticosterone (5-THB), unlike corticosterone (B), did not 
increase the abundance of transcripts of steroid-responsive genes in BTWG3 cells. 
Quantification by real-time PCR analysis of abundance of transcripts of (a) Gilz, (b) Igfbp1 
and (c) Ggt1 in BWTG3 cells treated either with vehicle (V) or steroids for 16 hours as 
indicated. Data (mean ± SEM) were analysed with one-way ANOVA followed by Tukey’s 
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6.3.4.2.3 Effects of 5-THB on the modulation of transcripts abundance by B  
As shown in Figure 6.11, increasing concentrations of 5-THB reduced the up-
regulation induced by B (1 M) of the abundance of transcripts of Tat in a 
concentration-dependent manner; the maximal effect was seen at the concentrations 
of 1, 3 and 10 M, at which the 5-reduced steroid decreased it by approximately 
50% compared with cells treated only with B. An effect was also seen on the B-
induced increase of the abundance of mRNAs of Ggt1, which was reduced by 
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Figure 6.11 5-Tetrahydrocorticosterone (5-THB) affected the modulation of selected 
steroid-responsive genes by corticosterone (B) in BWTG3 cells. Quantification by real-
time PCR of the effects of the presence of 5-THB on the modulation of the abundance of 
transcripts of (a) Tat, (b) Gilz, (c) Igfbp1 and (d) Ggt1 by B after 16 hours of treatment. Data 
(mean ± SEM) were represented as relative transcription compared to B-treated group set as 
100%, and were analysed by one-way ANOVA followed by Tukey’s post-hoc test; ** = p < 
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6.4 Discussion 
In the present chapter, the effects of 5-THB on molecular signalling pathways 
involving GR were analysed, and it was shown that the 5-reduced steroid is a 
weaker direct modulator of these pathways compared with B. Indeed, 5-THB 
induced phosphorylation of GR, expression of steroid-responsive reporters, and 
affected the abundance of transcripts of endogenous genes in A549 cells only 
weakly. Furthermore, it did not affect the abundance of transcripts of selected genes 
in the hepatic cell line BWTG3, in contrast to B. However, when cells were treated 
with 5-THB and B simultaneously, 5THB reduced the effects of B on the 
metabolic gene tyrosine aminotransferase (Tat), and to a lesser extent also of -
glutamyltransferase 1 (Ggt1).  
Previous chapters suggested that GR may not be the principal target of 5-THB, as a 
consequence, in this one, a more direct approach to understanding if and how the 
compound affects GR has been employed. When applying this kind of strategy, 
common read-outs used in the literature are phosphorylation of GR and expression of 
endogenous or transfected genes known to contain glucocorticoid responsive 
elements (GREs) and respond to GCs; therefore, the present investigation aimed to 
analyse these processes. 
GR undergoes a variety of post-translation modifications, which in turn modulate its 
activity. Phosphorylation was the first covalent modification identified, and at least 
six serine residues (Ser113, Ser141, Ser203, Ser211, Ser226 and Ser404) are 
subjected to phosphorylation on human GR, and these sites are conserved in rats and 
mice. GR displays a basal level of phosphorylation and becomes hyper-
phosphorylated once bound to the ligand, with the extent of phosphorylation 
depending on the nature of the ligand (Avenant, Kotitschke et al. 2010; Avenant, 
Ronacher et al. 2010; Oakley and Cidlowski 2010). Phosphorylation of GR often 
changes its transcriptional activity in a gene-selective manner, and it is thought to 
influence the interaction with co-regulators (Chen, Dang et al. 2008). A study 
reported that the transcriptional activity of GR is correlated with a 10-fold increase in 
the phosphorylation state of Ser211 in the N-terminus of the receptor (Ismaili and 
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Garabedian 2004), while phosphorylation of Ser226 seems to induce cytoplasmic GR 
retention and increase its degradation (Wang, Frederick et al. 2002; Blind and 
Garabedian 2008). Since these links have been made, in the quest for alternative 
GCs, often the ability of candidates to induce phosphorylation of Ser211 has been 
investigated as read-out for their ability to promote activation of gene transcription, 
such as in the study of Compound A (CpdA). This molecule has been shown not to 
promote phosphorylation of Ser211, and this behaviour has been correlated with the 
absence of induction of promoters such as that present in MMTV-driven reporters 
(De Bosscher, Vanden Berghe et al. 2005). As a consequence, molecules inducing no 
phosphorylation or a differential pattern of post-translational modifications of GR 
may also be more likely to have a more selective and safer pharmacological profile. 
For this reason, the effects of 5-THB on phosphorylation of Ser211 were 
investigated. Other phosphorylation sites were also analysed, namely Ser203 and 
Ser226; however, the antibodies used returned a high non-specific signal and, after 
extensive unfruitful trials aimed at improving the results, it was decided that the best 
approach was to focus only on Ser211. 
Phosphorylation is a rapid process that has been shown to reach a peak at 1 h upon 
stimulation with steroids in COS-1 cells (Lynch, Rajendran et al. 2010). 
Consequently, the study presented in this chapter initially analysed this event at the 
same time point, confirming that indeed B strongly induced phosphorylation of 
Ser211. In contrast, treatment with an equivalent concentration of 5-THB did not. 
This was not entirely unexpected. 5-THB has been shown to possess anti-
inflammatory properties and reduced metabolic side-effects in previous studies 
(Livingstone, Sykes et al. 2014), and the investigation on which this thesis is based 
has revealed that the compound affected in vivo and in vitro signalling pathways 
classically associated with steroids in a weaker, more restricted manner than B. This 
suggested also a potential weaker action on post-translational modifications of GR, 
since they have been linked to activation of downstream signalling pathways (Plumb, 
Robinson et al. 2013). From a technical point of view, there are a few experimental 
caveats to address. First, it would be of interest to investigate the nature of the double 
band obtained in the Western blot experiments. This is perhaps due to the presence of 
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multiple GR isoforms carrying other post-translational modifications, as shown also 
in another cell type (Lynch, Rajendran et al. 2010). Second, the quantification 
analysis performed on the data presented here decreased the reliability of the results, 
since calculating the ratio between ratios increases the variability of the data, 
requiring greater numbers of replicates. However, it has not been possible to quantify 
both GR and its phosphorylated form on the one gel. 
Despite the above-mentioned findings, we were prompted to deepen the investigation 
into the phosphorylation of Ser211 because of a recent published study which 
showed that two potent non-steroidal ligands of GR caused delayed phosphorylation 
and induction of gene expression in comparison with classical agonists such as 
dexamethasone (Trebble, Woolven et al. 2013). As a consequence, a time-course 
study of Ser211 phosphorylation in response to increasing concentrations of 5-THB 
was performed. While this analysis did not reveal a time-dependent phosphorylation 
pattern caused by the 5-reduced steroid, it did show that the compound caused 
phosphorylation after 1 h treatment at 10 M. B was confirmed to strongly induce 
phosphorylation, which was time-dependent. This result reinforced the idea that 5-
THB is a weaker modulator of GCs-responsive signalling pathways compared with 
classical steroids. In order to understand if the weak effect on phosphorylation had 
any functional consequences, the abundance of transcripts of steroid-responsive 
genes was analysed after 2 h of treatment. The products of the two genes Gilz and 
Dusp1 are important proteins that mediate part of the anti-inflammatory effects of 
GCs (Clark 2003; Yang, Zhang et al. 2008; Ayroldi, Cannarile et al. 2012; Plumb, 
Robinson et al. 2013; Lim, Park et al. 2014). As expected, B strongly increased the 
amount of transcripts of these two genes. In accordance to a weak effect on 
phosphorylation, 5-THB did not significantly increase the abundance of mRNAs of 
the genes, even though a trend was seen at the highest concentration (10 M). 
Recently, work by a collaborator using microarray analysis showed increased 
expression of Dusp1 in response to 5-THB (1 M) in unstimulated human blood-
derived monocytes (Dr. Alistair Jubb, personal communication), suggesting that the 
behaviour of the compound may be cell-specific. However, it would also be of 
interest to study the effects of the two steroids on the expression of these genes upon 
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stimulation of the A549 cells with inflammatory stimuli, as it is plausible that the 
results will be different since both genes are actively involved in inflammation. A 
strong effect of B was also seen on the abundance of transcripts of another two 
classical targets for steroidal hormones, the genes Fkbp51 and Igfbp1. Also in this 
case, 5-THB had a weaker, albeit significant, effect at 10 M. The protein FKBP51 
is an immunophilin that binds to the GR complex in the absence of ligand by 
interacting directly with the molecule HSP90. Upon ligand binding, a correlated 
protein, FKBP52, switches position with FKBP51 promoting the activation of GR 
and its translocation to the nucleus (Guess, Agrawal et al. 2010). The expression of 
Fkbp51 is known to be up-regulated by GCs and it is seen as a negative feedback for 
attenuating the responses induced by exposure to steroids (Plumb, Robinson et al. 
2013). Therefore, 5-THB may induce, to a small extent, this kind of feedback. 
Trans-activation by GR of the other gene investigated, Igfbp1, is known to be reliant 
on phosphorylation of Ser211 (Trebble, Woolven et al. 2013), and therefore it is not 
surprising that B increased the transcripts in a stronger manner than 5-THB.  
Modulation of GR phosphorylation by ligands is an important factor in determining 
the functional properties of the receptor, in that it alters the ability of the receptor to 
bind co-regulators, such as MED14, which in turn determine its effects on 
transcription. However, post-translational modifications are only one of the ways in 
which the function of GR is controlled. Indeed, the extent to which receptor ligands 
affect gene transcription depend also on the number of GREs found on the target 
genes, and on their sequences; and it is becoming more evident that the majority of 
them are not simple, canonical GREs as previously thought (So, Chaivorapol et al. 
2007; Kaur, Chivers et al. 2008). This entails a further layer of complexity regarding 
how GR controls gene expression. The genes analysed in A549 cells have been 
shown to contain different types of GREs, with Gilz, for example, having four 
consensus GREs and Igfbp1 harbouring instead non canonical GREs at which GR 
occupancy is lower compared with Gilz (Chen, Dang et al. 2008). In addition, also 
Dusp1 does not appear to contain simple GREs (Kaur, Chivers et al. 2008). 
Interestingly, studies of the GREs contained in the Igfbp1 gene have concluded that 
the strongest GRE for GR binding in response to dexamethasone is found in the first 
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intron rather than in the promoter region (Luo, Lu et al. 2013); on the one hand, the 
fact that 5-THB increased the transcription of this particular gene, and not of 
others, may be due to a preference of the receptor through which it acts for this 
specific strong GRE, perhaps not present on other genes; on the other hand though, 
the fact that 5-THB is less effective compared to B, may be due to receptor binding 
to the less strong GREs, or to a less effective binding to the strong one. Furthermore, 
the transcriptional up-regulation induced by GCs of Gilz and Igfbp1 relies on a 
different type of co-regulator, making the latter, but not the former, dependent on the 
presence of MED14 (Chen, Dang et al. 2008). This complexity is further increased 
by the fact that the co-regulators vary also in a cell-dependent manner. Therefore, 
while it is reasonable to try to find a correlation between the degree of 
phosphorylation of Ser211 induced by 5-THB and its transcriptional effects, other 
factors may be playing an important role in determining the behaviour of the 
compound, for example, the availability of co-regulators in A549 cells; the picture 
needs to be completed with further investigations.   
In order to clarify if one of the determining factors of the behaviour of 5-THB was 
the types of GREs in the promoter regions of target genes, the transcriptional 
responses to the compound of reporters containing different GREs were analysed. 
The cell line A549 was chosen as it expresses GR, however, because the effect 
induced by 5-THB may have been weak, two approaches for investigating the 
dependency on GR were tested on the system: over-expression of GR and utilisation 
of the antagonist RU486. Both methods were efficacious in showing that the effects 
of B were GR-dependent, as expected. These results suggested that the model was 
suitable for the investigation of 5-THB as a modulator of GR-activated signalling 
pathways, and provided two options for studying this relationship. While B strongly 
induced the expression of both reporters, 5-THB selectively increased the 
expression of MMTV-Luc but not of PNMT-Luc reporter; furthermore, the induction 
was very weak in the absence of co-transfected hGR, and became stronger when the 
receptor was over-expressed, but in both cases was not comparable to that of B 
administered at the same concentrations. The findings point to a GR-dependent effect 
of 5-THB, and the decision to test this possibility by over-expressing hGR instead 
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of using the antagonist RU486 was made because the effect in the absence of co-
transfected hGR was of a very limited amplitude, making the over-expression 
approach more suitable. Had 5-THB displayed a stronger effect, the experiments 
would have been repeated using the antagonist. 
In line with a role of phosphorylation of Ser211 in promoting GR transcriptional 
activity, it has been shown that phosphorylation of Ser211 is necessary for maximal 
activation of the GR dimer-dependent synthetic promoter MMTV (Avenant, 
Kotitschke et al. 2010). It is therefore not surprising that the two steroids differed in 
their efficiency. In addition, while the promoter found on the MMTV-Luc reporter 
requires dimerisation of GR, the one found in PNMT-Luc reporter requires a more 
complex interaction between GR and other proteins (Adams, Meijer et al. 2003). 
Indeed, studies done employing a murine model harbouring a dimerisation-deficient 
GR (GR
dim
) showed that the receptor is likely to induce the formation of so-called 
non-conventional dimers, or even of multimers, involving other transcription factors 
and/or hormone receptors. The MMTV-driven luciferase reporter contains a 
consensus palindromic GRE which is highly induced by the wild type GR, but not by 
GR
dim
, while the PNMT-driven luciferase reporter achieves greater activation by the 
GR
dim
 than the wild type GR, suggesting alternate binding of GR to the promoter. It 
can be hypothesized that while B is able to induce conformational changes of GR in 
accordance with the formation of both classical dimeric structures and alternative 
complexes, and therefore induces both reporters, 5-THB is only capable of 
inducing the formation of the former. The fact that this happened more strongly 
when GR was over-expressed indicates that the physiological level of GR found in 
A549 cells is not sufficient for gene induction by this compound. This may be due to 
the fact that 5-THB is not as potent as B, and therefore the concentration used was 
too low for the drug to mediate strong effects. However, higher concentrations within 
the medium can induce toxicity and so maximal efficacy cannot be reliably tested. In 
corroboration, the response seen with the highest concentration was lower than with 
B. 
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The data presented in this chapter are somehow in contrast with some earlier studies 
in which 5-THB was shown to induce MMTV-Luc reporter with a comparable 
potency to B (McInnes, Kenyon et al. 2004). The difference between the two 
investigations is the cell type used for the experiments. McInnes et al. worked with 
HeLa cells, while the results described in this chapter were obtained by using A549 
cells. GR transcriptional activity is largely determined by the presence of co-factors, 
which are often expressed in a cell- and gene-specific manner (So, Chaivorapol et al. 
2007; Zhang, Jonklaas et al. 2007). The cell system used in this chapter may have 
fewer of the important co-regulators required by 5-THB to activate the MMTV 
promoter, or be devoid of them inducing the compound to use alternative ones not as 
efficiently. Nonetheless, the results presented here showed a clear difference between 
the behaviour of B and 5-THB, with the latter seemingly lacking the ability to 
strongly induce GRE-driven expression. 
In order to investigate what kind of transcriptional changes 5-THB may promote in 
metabolic tissue, the changes in the abundance of transcripts of selected genes in 
response to the steroid were studied in a metabolic cell line. The mouse hepatic cell 
line BWTG3 was chosen in order to follow previous studies of the properties of 5-
THB in a mouse model (Yang, Nixon et al. 2011); in addition, this cell line expresses 
GR, and has been used for the investigation of the properties of another putative 
selective GR modulator, Cpd A (Robertson, Allie-Reid et al. 2009; Visser, Smith et 
al. 2010). The gene Tat was chosen as a model gene to analyse because it contains 
GREs, is induced by GCs, and, catalysing a crucial step in gluconeogenesis (Grange, 
Roux et al. 1991), is responsible for the onset of some of the side effects seen during 
treatment with anti-inflammatory steroids. Its transcription is promoted by the GR 
binding to the DNA as a homodimer, a mechanism that can be seen as a 
representation of the classical trans-activation way through which GR works. In the 
present chapter, the analysis of the abundance of transcripts of Tat after treatment 
with B and 5-THB showed that the latter did not affect it, while it was confirmed 
that a classical GC (B) was able to significantly increase it and did so in a time-
dependent manner. Investigation of other GC-responsive genes revealed a similar 
scenario in that treatment for 16 h with B up-regulated the amount of transcripts of 
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Gilz and Igfbp1, as shown in A549 cells, and Ggt1, while 5-THB did not. These 
results suggest that 5-THB does not promote binding of GR on endogenous 
“positive” GREs involved in potentially deleterious metabolic pathways, unlike B. 
While this scenario suggests a potential positive absence of stimulation of GRE-
driven transcription by 5-THB, one needs to remember that induction of 
transcription accounts also for some of the anti-inflammatory properties displayed by 
the conventional GCs. A compound that lacks this ability is also likely to have more 
limited anti-inflammatory effects.  
This work is in accordance with the results obtained previously in mice by Yang et 
al. (Yang, Nixon et al. 2011), in which acute administration of 5-THB did not 
increase Tat expression in liver, contrary to B. However, the results presented here 
are in contrast with those obtained by another study which showed that 5-THB 
could significantly increase transcription of Tat in a rat liver cell line (H4IIE), after a 
16-hour treatment (McInnes, Kenyon et al. 2004). As in the case of the discrepancies 
seen with the MMTV-Luc reporter, the explanation for these dissimilarities may lie 
in the different cell lines used. The co-regulators necessary for transcription of Tat in 
H4IIE cells may not be present in the BWTG3 cell line. The same phenomenon may 
account also for the contrasting results regarding the effects of 5-THB on transcript 
abundance of Igfbp1 in A549 and BWTG3 cells. However, it is worth noting that 
there is a certain degree of consistency between the two models regarding the 
promoters not targeted by 5-THB; indeed, the lack of effects of the compound on 
PNMT-Luc activation in A549 cells, and on the abundance of mRNAs of Tat in 
BWTG3 cells, may be explainable by the fact that both promoters contain 
palindromic GREs, whilst, for instance, the MMTV-Luc reporter, which is activated 
by 5-THB, contains GRE ½ sites. Therefore, 5-THB could regulate preferentially 
genes harbouring these types of GREs which are considered non-canonical. In 
addition, and interestingly, a study showed that the efficiency with which different 
steroidal compounds trans-activate the same GC-responsive gene (in this case Gilz) 
is regulated by different parameters in different cell types. In effect, while in A549 
cells the transcriptional activation was dependent on the extent of promoter 
occupancy by a given compound, in U2O cells the determinant factor for the same 
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compound was the extent to which nuclear localisation of GR was induced (Hadley, 
Louw et al. 2011). This is to remark on the fact that a compound is not only likely to 
behave differently from another that has intrinsic divergent properties, but also from 
itself when studied in different cellular environments. It is therefore not surprising 
that 5-THB did not show exactly the same behaviour in different cell types, also 
considering that being a weak agonist regarding certain responses, it may be more 
susceptible to the changes in different factors. Nonetheless, the fact that the results 
presented in this chapter are in accordance with results obtained in vivo, indicates 
that they are likely to be relevant. 
In pharmacology, a partial agonist is defined as a compound that binds and activates 
a given receptor inducing a response which is less efficacious than that of a full 
agonist acting on the same receptor. When partial and full agonists are present 
together, the former may behave like a competitive antagonist, competing for the 
occupancy of the receptor and reducing its activation by the full agonist (Zhu 2005). 
5-THB has shown properties of a weak agonist throughout the experiments 
presented in this thesis, and with this in mind, it was decided to co-incubate B and 
5-THB with BWTG3 cells in order to analyse the possibility that the latter may 
behave like a competitive antagonist, and therefore show some of the characteristics 
of a partial agonist. Interestingly, 5-THB did indeed antagonise the up-regulation of 
transcript abundance of Tat induced by the full agonist B, reducing it by 
approximately 50%. To a lesser extent, the phenomenon was also seen for the gene 
Ggt1. This result may provide a mechanism explaining the phenotype seen in mice 
harbouring a genetic disruption for the 5-THB-producing enzyme 5-reductase 
type 1 (5-R1), which displayed a worse hepatic metabolic profile than wild type 
mice (Livingstone, Barat et al. 2014). Indeed, it may be possible that physiological 
concentration of 5-THB, mainly produced in the liver, are able to decrease the 
metabolic effects of B as suggested form the experiments in BWTG3 cells. It would 
be of interest to perform a similar experiment analysing the effect of co-incubation of 
B and its metabolite on the reporters previously mentioned; this would provide 
information on whether the phenomenon is a broad one. 
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Exactly through which mechanism 5-THB may accomplish the above-mentioned 
effects is an open question. The compound may affect any of the steps and processes 
involved in the cellular response to B, from ligand binding to nuclear translocation, 
to the binding to GREs. Indeed, 5-THB may act directly by binding to GR and, as a 
consequence, reduce the amount of GR available to bind B; otherwise, 5-THB may 
also reduce B-induced translocation of GR to the nucleus as seen with the antagonist 
ORG 34517 (Peeters, Ruigt et al. 2008). In addition, 5-THB may work at the level 
of the DNA impeding the binding of GR to GREs, or disrupting fundamental 
changes required for initiation of transcription. Recently, it has been reported that 
proteins belonging to the negative elongation factor (NELF) complex are capable of 
reducing the trans-activation induced by GR of GRE-containing genes, such as Gilz 
and Igfbp1; this is achieved by binding of NELFs to the LBD of the activated 
receptor, therefore reducing its recruitment to GREs (Luo, Lu et al. 2013). A 
fascinating speculation would be that 5-THB may recruit some of these factors to 
reduce the amount of GR bound to B reaching target genes. The fact that these 
molecules also differ in their inhibitory potential according to the type of GREs, and 
the type of cells, is a fact that make them even more interesting from the perspective 
of this study. A further possibility is that the 5-reduced steroid is acting through a 
different isoform of GR, for example GR which is known to have inhibitory effects 
on GC-induced gene transcription (Zhang, Clark et al. 2008; Guess, Agrawal et al. 
2010). Regardless of the reasons behind the antagonistic behaviour of 5-THB, the 
experiments in BWTG3 cells revealed both an intriguing and promising mode of 
action of the compound, which, if confirmed relevant in other models, may be 
exploited for the reduction of the metabolic side effects induced by classical steroids. 
Some of these mechanisms, along with the results presented in Chapter 3 and 4, 
suggest the possibility that 5-THB may act through a receptor which is not GR. 
Liver X receptors (LXRs) are important receptors controlling metabolism, and have 
been shown to bind to GREs and, when activated or over-expressed, to repress the 
activity of GR on metabolic genes (Demerjian, Choi et al. 2009; Nader, Ng et al. 
2012); furthermore, another receptor important in regulating hepatic functions, 
pregnane X receptor (PXR), has been shown to bind to steroids (Banerjee, Robbins et 
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al. 2013; Gerbal-Chaloin, Iankova et al. 2013). This evidence makes the two 
receptors reasonable candidates for 5-THB. Another putative receptor is the 
progesterone receptor (PR); PR has high homology with GR, in that the two are 90% 
identical in their DBD and 55% in the LBD, and despite being bound to different 
hormones, they can bind to and activate transcription from the same hormone 
responsive elements (HREs). One of the factors that determines the efficiency with 
which PR would induce a gene versus GR is the presence of certain co-regulators 
(Szapary, Song et al. 2008); it is possible that 5-THB may activate transcription 
through PR, and do so in a less efficient manner than B because the genes studied 
here may require the presence of regulators which do not efficiently interact with PR. 
A broader investigation of gene expression in response to 5-THB may be helpful to 
gain a clearer and fuller picture.    
In summary, in this chapter the effects of 5-THB on signalling pathways controlled 
by GR were investigated. The compound appeared to be a weak agonist, and despite 
the results obtained with the MMTV-Luc reporter suggesting an action through GR, 
the involvement of other receptors is not to be excluded. Repeating some of the 
experiments presented here by using siRNA technology against GR, or by employing 
the antagonist RU486, may clarify at least in part this aspect. Furthermore, studies 
that investigate other post-translational modifications of GR in response to 5-THB 
treatment may be useful; in effect, some of them are important in determining the 
receptor transcriptional activity because they work in concert with the most 
commonly studied Ser211 (Avenant, Ronacher et al. 2010; Oakley and Cidlowski 
2010). If 5-THB does indeed bind to GR to deliver its effects, a lower affinity for 
the receptor in comparison with B may explain is weaker agonistic properties. This 
may be better clarified with molecular modelling or crystallography analyses aimed 
at studying the possible characteristics of an interaction between the compound and 
GR; this would also shed light on which co-regulators may or may not bind to the 
complex, increasing the understanding of which genes and cells may be targeted by 
5-THB.  
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Chapter 7: Summary and future work 
The research presented in this thesis was born out of the necessity to deepen the 
understanding of the molecular mechanisms whereby 5-THB works to reduce 
inflammation, and to investigate how molecular pathways associated with beneficial 
outcomes and deleterious side effects are affected by the compound. Since previous 
in vivo and in vitro published and unpublished studies showed that this compound is 
a more selective anti-inflammatory agent than both B, from which it derives, and the 
clinically used glucocorticoid hydrocortisone (HC) (Yang, Nixon et al. 2011; 
Livingstone, Sykes et al. 2014), the hypotheses being tested were that 5-THB 
preferentially modulates inflammatory signalling pathways, and that it does so 
through GR.  
7.1 5-THB is an effective anti-inflammatory 
compound that may not work through GR 
First of all, the work of this thesis confirmed previous in vivo and in vitro findings in 
that it showed that 5-THB decreases inflammatory swelling associated with irritant 
dermatitis (Livingstone, Sykes et al. 2014), and suppresses the release of pro-
inflammatory cytokines in primary cultures of murine bone marrow-derived 
macrophages (BMDMs) (Yang, Nixon et al. 2011), but in a weaker manner than B. 
Most importantly, original contributions towards the understanding of the molecular 
mechanisms whereby 5-THB works to resolve inflammation in vivo have been 
provided here. Indeed, for the first time, it has been shown that the compound acts 
more slowly than B, being effective after 24 but not 6 h of treatment in a model of 
irritant dermatitis. While the work focussed on analysing how 5-THB 
mechanistically reduced inflammation at 24 h, some preliminary studies at 6 h 
showed that the compound is unable to decrease the infiltration of inflammatory 
cells. The reasons behind this phenomenon were not investigated, but they may relate 
to less efficient modulation, compared with B, of signalling pathways associated with 
the early phases of the response to the insult (croton oil in this case); for instance, 
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5-THB may not be able to prevent the release of inflammatory mediators from the 
cells (such as endothelial cells, keratinocytes and fibroblasts) responsible for the 
initiation of the host response. Alternatively, the compound may be unable to prevent 
the activation of the microvasculature (that leads to vasodilation and increased 
permeability) that plays a pivotal role in the onset of swelling and infiltration of cells 
(Lee, Stieger et al. 2013). This and other processes may be instead controlled 
efficiently and rapidly by B; as an example, in Chapter 5 it is demonstrated that B, 
but not 5-THB, reduced the abundance of transcripts of eNos, a gene encoding an 
enzyme that promotes vasodilation through the production of NO during both 
inflammation and angiogenesis. Another important mediator common to the two 
processes is VEGF, which in the case of skin inflammation is released from 
damaged keratinocytes, and is a strong inducer of vascular remodelling 
(Huggenberger and Detmar 2011); Vegf transcripts were decreased in inflamed ears 
by both compounds after treatment lasting 24 h; it would be of interest to analyse the 
same gene at the earlier time point to understand whether it is affected by B but not 
by 5-THB. Investigation of the effects of 5-THB on specific cell types present in 
the skin, such as keratinocytes and fibroblasts, would also help. 
When the model was analysed for the molecular changes associated with the anti-
inflammatory effects of 5-THB at 24 h, the picture that emerged was one in which 
B and its 5-reduced metabolite influenced similar pathways, in a similar way. The 
data suggested that the two compounds act mainly by down-regulating the abundance 
of transcripts of genes involved in the modulation of vascular permeability. 
Nonetheless, three major differences between the two were revealed: 
- 5-THB was more effective than B in reducing the infiltration of neutrophils 
- 5-THB increased the abundance of transcripts of Dusp1 in inflamed ears, 
but B did not 
- The GR antagonist RU486 prevented the effect of B on swelling but not that 
of 5-THB 
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Whether these differences are sufficient for explaining the behaviour of 5-THB is 
not yet known, but they pave the way for planning further research targeted to 
answer specific questions, related also to other models employed in this thesis.  
Question 1: Which cell population represents the principal target of 5-THB, and 
how is it affected by the compound? 
Part of this question may be answered by an extended analysis (e.g. through FACS) 
of how the populations of inflammatory cells infiltrating the auricular tissue change 
in response to 5-THB, in comparison with B, after administration for 6 and 24 h. 
While in the in vivo model of inflammation the effects on macrophages were not 
investigated, the data obtained with primary culture of murine BMDMs and the in 
vivo model of angiogenesis showed that 5-THB also affects these cells. This 
population plays a vital role in inflammation, by releasing cytokines and 
chemokines; furthermore, it has been shown that, in in vivo models of psoriasis, 
macrophages are required for neutrophil recruitment (Stratis, Pasparakis et al. 2006; 
Wang, Peters et al. 2006). Despite the fact that irritant dermatitis and psoriasis are 
different dermatological conditions, macrophages are also recruited to the tissue after 
contact with an irritant, and play a pivotal role during the acute and reparative phases 
of the inflammatory response (Tang, Schlapbach et al. 2010); it is therefore a 
possibility that 5-THB may be affecting neutrophil infiltration in part by 
modulating macrophage activity. Regarding the mechanisms whereby the compound 
may affect this cell population and others, this is still an open question. It is known 
that classical steroids work by influencing a broad range of cellular mechanisms, 
either genomic or non-genomic, and the overall picture emerging from the data of 
this thesis is one in which 5-THB affects fewer of those tested than B. In Chapter 4, 
some preliminary data on how 5-THB may interfere with one of the classical 
pathways with a central role in inflammation, NF-B, have been obtained through 
Western blot analysis, and, in contrast to B, they show only a marginal effect of the 
compound. One possibility is that 5-THB may be interfering in a stronger manner 
with the transcription factor AP-1 rather than NF-B. A study suggested that the GR-
mediated repression of the two factors is dependent on different domains of the 
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receptor (Bladh, Liden et al. 2005); it is therefore possible that 5-THB may 
preferentially induce a conformation of GR, or another receptor, more suitable for 
the inhibition of AP1 than NF-B. As an example, a new selective glucocorticoid 
receptor modulator, Compound A, has been shown to preferentially repress NF-B-
driven transcription rather than AP-1, showing that new selective compounds may 
not only be able to discern between GR-dependent gene activation and repression, 
but also between different types of repressive mechanisms (De Bosscher, Beck et al. 
2013). Studies analysing the differential ability of 5-THB to suppress transcription 
of AP-1-dependent versus NF-B-dependent genes may be useful to clarify this 
point. Some preliminary experiments regarding this aspect have been previously 
conducted by my supervisors’ group, and they provided surprising results; indeed, 
they showed that in human embryonic kidney (HEK) cells 5-THB potentiated, in a 
GR-independent manner, the NF-B- and AP-1-mediated expression of the 
luciferase gene induced by phorbol ester (Nixon 2011). While the lack of a 
dependency on GR is in accordance with the results presented in Chapter 3 and 
Chapter 4 of this thesis, more extensive investigations (analysing different cell types 
and inflammatory stimuli) are required to shed light on the potential mechanisms 
involving NF-B and AP-1, and explain the anti-inflammatory properties of 5-
THB. Furthermore, GCs have been shown to suppress the production of pro-
inflammatory cytokines at a post-transcriptional level (Clark, Dean et al. 2003), 
adding another putative mechanism whereby 5-THB may work. In effect, GCs have 
the ability to induce the expression of tristetraproline (TTP), which binds to mRNAs 
of pro-inflammatory genes destabilising them (Kadmiel and Cidlowski 2013). The 
production of some cytokines has been shown to be dependent on post-
transcriptional mechanisms, adding a layer of complexity that compounds controlling 
the inflammatory response may target (Zuckerman, Evans et al. 1991). 
Question 2: To what extent are the anti-inflammatory properties of 5-THB 
dependent on DUSP1? 
GCs are known to suppress pro-inflammatory pathways, activated for instance by 
LPS, by stimulating the expression of DUSP1, which in turn inhibits p38 MAPK and 
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therefore the activation of AP-1 (Bhattacharyya, Brown et al. 2007). In addition, and 
as mentioned before, new selective regulators of GR have been found to act in this 
way (Joanny, Ding et al. 2012). In accordance with the findings presented in Chapter 
3, whereby 5-THB increased the abundance of transcripts of Dusp1 in inflamed 
ears, previous results from my supervisors’ group also showed increased abundance 
of DUSP1 protein in LPS-stimulated RAW264.7 cells after treatment with 5-THB 
(Nixon 2011), and another preliminary study employing human blood-derived 
monocytes found that the compound did increase the abundance of transcripts of this 
gene (Dr. Alisdair Jubb, personal communication). Despite the fact that a broader 
investigation of the many signalling pathways involved in inflammation is necessary 
to gain a more complete picture of the differences between 5-THB and classical 
steroids such as B, the employment of Dusp1 -/- mice would be a good starting point. 
This would also allow the analysis of specific cell populations (e.g. BMDMs) 
isolated from these mice in order to determine the cellular target of the compound 
(for instance macrophages vs neutrophils). 
Question3: Are the anti-inflammatory properties of 5-THB independent of GR? 
In Chapter 3, it was shown that the attenuation of ear swelling upon application of 
5-THB was not affected by the GR antagonist RU486. In addition, in Chapter 4 the 
same antagonist was shown not to prevent the reduction in the release of IL6 from 
BMDMs induced by 5-THB. These results must be confirmed by using an 
alternative method to the pharmacological antagonism with RU486, both in vivo and 
in vitro. Mice in which GR is knocked down would be a useful tool, although it 
needs to be taken into consideration that only heterozygous mice can be used, as the 
total knock out of GR is lethal with mice dying hours after birth because of 
respiratory failure (Cole, Blendy et al. 1995). This would mean employing a model 
in which GR is still expressed, albeit to a lesser extent than in wild type animals. 
Another possibility would be to generate a conditional knock out mouse model 
where GR expression could be switched off whenever deemed appropriate. If 
contrary to what is suggested in this thesis, the effects of 5-THB are found to be 
dependent on GR, targeted disruption of the receptor in difference cell populations of 
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the skin or the immune system, such as keratinocytes and macrophages/neutrophils, 
may be the strategy to employ. Previous in vitro studies showed that 5-THB did 
bind GR (McInnes, Kenyon et al. 2004), and translocate it to the nucleus (Yang 
2009). Interestingly, the translocation was slower than that induced by B, and after 
24 h did not reach the same level. This could explain why 5-THB acted more 
slowly, and was less potent than B, in the dermatitis model. If GR is indeed involved 
in the responses induced by 5-THB, the lack of antagonism by RU486 in the 
dermatitis model would need to be explained. One possibility could be that the 5-
reduced steroid binds to a different site compared with RU486, or that perhaps its 
displacement is not possible because of strong interactions with the receptor. The 
former would perhaps also explain the additive effect of RU486 and 5-THB on the 
release of IL6 from BMDMs. Molecular modelling and crystallography analysis 
would be useful tools that would provide potential explanations. However, a 
dependency on GR, most of all in vivo, must be first robustly proved, and if instead 
the anti-inflammatory effects are found not to be consistently dependent on GR, the 
investigation needs to move into the search for alternative receptors. Some possible 
targets are outlined below. 
In addition to GR, other nuclear receptors have been shown to play a major role in 
skin homeostasis. Among them are the liver X receptor (LXR) and the pregnane X 
receptor (PXR) (Schmuth, Moosbrugger-Martinz et al. 2014). Both receptors have a 
role in controlling skin inflammation and keratinocyte function. LXR modulates 
numerous metabolic pathways, and some of its ligands are products of the oxidation 
of cholesterol, namely oxysterols, and other lipids (Nader, Ng et al. 2012). The 
isoform LXR beta is expressed in mouse epidermis, white blood cells and 
neutrophils, making it relevant to skin inflammation (Komuves, Schmuth et al. 2002; 
Chang, Shen et al. 2008; Man, Barish et al. 2008). Agonists of LXR have been 
shown to lower inflammatory cytokines and metalloproteinases (Mohan and Heyman 
2003; Schmuth, Moosbrugger-Martinz et al. 2014), while LXR- null mice show 
thinner epidermis than control animals due to decreased proliferation of 
keratinocytes (Chang, Shen et al. 2008). Topical activation of the receptor 
suppressed irritant and allergic contact dermatitis by lowering the production of 
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TNF and IL1 (Schmuth, Moosbrugger-Martinz et al. 2014). Interestingly, 
application of LXR ligands with GCs prevented side effects induced by GCs such as 
atrophy of skin (Demerjian, Choi et al. 2009). Furthermore, activation/over-
expression of LXR repressed the transcriptional activity of GR on metabolic genes, 
and it was found that endogenous LXR bound GRE (Nader, Ng et al. 2012). All this 
suggests a crosstalk between the GR and LXR, and it is tempting to speculate that the 
latter may be responsible for the anti-inflammatory effects of 5-THB. It would be 
interesting to investigate what happens when 5-THB is co-applied with other 
steroids known to cause dermal side effects such as skin thinning. Previous studies 
(Livingstone, Barat et al. 2014) showed that mice with a genetic disruption of 5-R1 
have a worse hepatic metabolic phenotype than wild type littermates. This may 
indicate a physiological role of 5-THB in repressing the action of endogenous GCs, 
a role that may be played out through LXR, which is highly abundant in the liver.  
Another interesting and important nuclear receptor found in the skin and immune 
cells is PXR, which regulates the metabolism of endogenous hormones and 
exogenous xenobiotic compounds by modulating cytochrome P450 enzyme 
expression. Together with the constitutive androstane receptor (CAR), PXR belongs 
to the group of xenobiotic receptors. These receptors have promiscuous ligand-
binding properties (Banerjee, Robbins et al. 2013) and bind structurally different 
molecules. Indeed, they are activated by a broad range of compounds, among which 
are steroids, bile acids, dietary lipids, drugs such as antibiotics, progesterone and 
RU486. PXR is involved in the control of steroid hormone pathways as it is activated 
by C21 steroids. Interestingly, the phorbol ester phorbol-12-myristate-13-acetate 
(PMA), in combination with other inflammatory stimuli, has been found to greatly 
activate PXR (Gerbal-Chaloin, Iankova et al. 2013), and this is one of the 
compounds found in croton oil. PXR may have a role in KC proliferation in that it 
may suppress NF-B, over-expression of which has been shown to decrease KC 
proliferation. Furthermore, repression of the NF-B pathway suggests an anti-
inflammatory role for this receptor (Gerbal-Chaloin, Iankova et al. 2013). Despite the 
fact that much still needs to be investigated about the role of PXR in skin 
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homeostasis and inflammation, data available so far point to it as an interesting drug 
candidate and as a potential receptor for 5-THB.  
More work is clearly needed to gain a clearer understanding of how 5-THB works 
to resolve inflammation, and the availability of mice lacking the expression of 
receptors such as LXR and PXR, and of inhibitors of these two potential targets, 
offers good tools to expand our knowledge, either in in vivo or in vitro models. 
Furthermore, another important issue to address is about how far 5-THB penetrates 
into the dermal layers. This would inform about potential systemic effects in cases of 
long-term topical administration. In order to address this, a plan is already in place to 
carry out mass spectrometry tissue imaging experiments in pig models, using a 
protocol developed in my supervisors’ laboratory (Cobice, Mackay et al. 2013).  
7.2 5-THB possesses weaker anti-angiogenic and 
trans-activation properties in comparison with B 
In an effort to try to understand whether 5-THB inhibits angiogenesis, and activates 
molecular signalling pathways associated with side effects induced by GCs, an in 
vivo model of angiogenesis and in vitro cell systems were interrogated. 
The sponge model of angiogenesis revealed that 5-THB, at equipotent doses to B 
for anti-inflammatory properties (reduction of macrophage infiltration), inhibits 
angiogenesis in a weaker manner than B. The overall picture that emerged is one in 
which B and 5-THB affect a smaller number of common molecular pathways than 
in the dermatitis model. For this reason, I would like to draw attention to those 
aspects of this model not significantly affected by the 5-reduced steroid, and 
instead strongly perturbed by B. 
5-THB, unlike B, did not: 
- reduce the number of vessels expressing SMA (mature vessels) 
- affect the abundance of transcripts of the majority of genes analysed, 
including genes involved in angiogenesis and the inflammatory response 
- reduce the amount of collagen in sponges 
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The fact that 5-THB had more limited effects than B suggests important functional 
differences. First of all, and as mentioned in Chapter 5, the lack of strong effects on 
the expression of SMA, a marker of late-stage angiogenesis, indicates that 5-THB 
may specifically not interfere with processes (e.g. migration of pericytes and pruning 
of the newly formed vascular network) that are characteristic of the final phases of 
new vessel formation. In contrast, the strong effects of B both on CD31 and SMA 
expression point to a broader action of the compound. This suggests that B may be 
targeting more than one cell type, while 5-THB may be more selective and acting 
mostly on endothelial cells, which have an active and central role in the early phases 
of angiogenesis. These results are promising, in terms of developing a safer therapy. 
Indeed, inhibition of the angiogenic process may represent a negative outcome when 
steroids are used to treat inflammatory conditions, and in particular topical ones such 
as dermatitis. A compound like 5-THB that modulates fewer signalling pathways, 
and reduces only weakly the number of functional vessels, may have a lesser impact 
on the functionality of the tissue treated. This may be even more likely considering 
the dose of the 5-THB necessary to inhibit angiogenesis was much higher than the 
dose displaying topical anti-inflammatory properties in the dermatitis model. In 
effect, this would suggest that the two effects may be dissociated. 
From the aforementioned results, a question, that ought to be answered in future 
research, arises: which cells are targeted by 5-THB during angiogenesis? 
It is known that glucocorticoids suppress endothelial (Longenecker, Kilty et al. 1984; 
Sakamoto, Tanaka et al. 1987) and smooth muscle cell proliferation through 
mechanisms that are not completely clear, and may be both direct and indirect 
(Radke, Weber et al. 2004). In addition, dexamethasone has been shown to induce 
apoptosis of rat microvascular pericytes in vitro (Katychev, Wang et al. 2003). In the 
past decade the importance of these cells in angiogenesis has become increasingly 
evident (Bergers and Song 2005); for example, they can release VEGF. Studies 
suggest that apoptosis of pericytes may be linked with vascular regression 
(Katychev, Wang et al. 2003), and GCs have been known to induce the latter since 
the first experiments performed by Folkman et al. (Folkman, Langer et al. 1983). 
Although proliferation or apoptosis were not analysed in the work presented in this 
Mechanisms of action of 5-tetrahydrocorticosterone 
  268 
thesis, we could hypothesize that one of the mechanisms by which B, but not 5-
THB, decreased angiogenesis, and in particular the expression of SMA, may be 
through induction of apoptosis of pericytes which express this protein. The effect of 
B may have been also indirect though, through modulation of the inflammatory 
response. In effect, inflammation has been shown to stimulate expression of SMA 
in pericytes (Nehls and Drenckhahn 1993; Armulik, Genove et al. 2011). 
 
Angiogenesis and inflammation are two processes that share many mediators. As an 
example, molecules such as IL6, TNF, VEGF and NF-B promote angiogenesis 
(Conway, Collen et al. 2001), are released during inflammation, and are also 
suppressed by GCs (Barnes 1998; Wallerath, Witte et al. 1999; Beer, Fassler et al. 
2000; Hasan, Tan et al. 2000; Grose, Werner et al. 2002; Blomme, Chinn et al. 
2003). As a consequence, the inhibition of angiogenesis seen with B and 5-THB 
may be due, in part, to their anti-inflammatory properties. However, the mechanisms 
through which they deliver this effect may be be very different, since B down-
regulated the abundance of transcripts of pro-inflammatory genes while 5-THB did 
not. 
 
While one of the cellular targets of 5-THB may be the endothelial cell population, 
it may also affect angiogenesis by modulating cells of the immune system. Indeed, 
5-THB and B decreased the proportion of macrophages in sponges to a similar 
extent, and this effect may provide a potential mechanism explaining the reduction in 
the number of vessels as macrophages have also pro-angiogenic properties. Whilst 
until a few years ago these cells were considered a homogeneous population 
secreting pro-inflammatory mediators and displaying phagocytic behaviour, 
compelling evidence has now emerged for the existence of at least two types of 
macrophages (Nahrendorf, Swirski et al. 2007; Bartneck, Peters et al. 2014). These 
are classified as either classically- or non-classically activated macrophages. The first 
group includes a population of cells that are pro-inflammatory, and that are activated 
by bacterial toxins such as LPS or stimuli such as INF produced by other 
leukocytes; the second population, by contrast, is anti-inflammatory and is able to 
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secret pro-angiogenic molecules such as IL4, TGF, IL8 and TNF (Loke, Nair et 
al. 2002; Mosser and Edwards 2008; Mosser and Zhang 2008). It is possible that the 
inhibitory effect of B and 5-THB on the formation of new vessels is explainable by 
a dual mode of action. By decreasing the proportion of classically-activated 
macrophages, the steroids may decrease inflammation and, thus, angiogenesis; on the 
other hand, by decreasing the alternatively-activated population, they may lower the 
release of pro-angiogenic mediators. It would be of interest, therefore, to investigate 
whether B and 5-THB differentially affect the two groups of macrophages. One 
way would be to immuno-stain the alternatively-activated macrophages using an 
antibody against the antigen YM1, a protein that is specifically secreted by this 
population (Loke, Nair et al. 2002; Mosser and Edwards 2008). Interestingly, these 
cells do not convert the amino acid arginine into NO in order to kill bacteria, as done 
by classically-activated macrophages, but instead they transform it into ornithine, 
which is a precursor of collagen. This explains their participation in wound healing 
(Hesse, Modolell et al. 2001; Mosser and Zhang 2008). Understanding whether 5-
THB affects this population would also provide information about the likelihood that 
the compound may disrupt wound healing. To improve understanding of the cell 
types present in sponges, and how they are affected by steroids, more in-depth 
studies could be attempted. For instance, FACS analysis would be a useful tool to 
discern between different populations of inflammatory cells. However, this technique 
has not been extensively applied to this model, and optimisation studies may have to 
be performed beforehand. Measurement of the enzymatic activity of MPO and NAG 
(N-Acetylglutamate synthase), enzymes associated with active neutrophils or 
macrophages respectively, is an alternative method that has been widely used to 
quantify the two populations in a variety of implants in the sponge model of 
angiogenesis. This could be applied to the model presented here in future 
experiments. 
 
The fact that 5-THB, unlike B, did not decrease the amount of collagen in sponges, 
has potentially important functional consequences. Indeed, skin thinning induced by 
GCs is thought to be caused in part by reduced deposition of this protein in the 
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presence of topical steroids. Furthermore, and relevant to the angiogenesis model, 
this may be one of the reasons why the 5-reduced compound is a weaker inhibitor 
of vessel growth than B, as the ECM plays a crucial role in the process by supporting 
and guiding the formation of the new vascular bed. Collagen production and 
deposition is also central in wound healing (Christian, Graham et al. 2006), 
suggesting that 5-THB may not interfere with this process.  
 
In the dermatitis model, 5-THB had broader effects than in the model of 
angiogenesis; in effect, it regulated the abundance of transcripts for molecules 
involved in vascular permeability and many others. The intrinsic differences between 
the two models may account for the difference in behaviour. The dermatitis model 
represented an acute inflammatory response, whereas the sponge model represents a 
more complex setting where new tissue and vessels need to be built over a longer 
period of time. Experiments analysing shorter implantation times could shed more 
light on the role of 5-THB in the early phases of the body response to the implants, 
when inflammation is particularly strong. Furthermore, in vitro studies, for example 
the ring aortic assay, ought to be a priority in order to investigate the mechanisms of 
action of 5-THB in a more limited and controlled environment; indeed, this would 
allow testing of a wider range of concentrations of the compound, over a greater 
number of time points, and to quantify more easily a variety of soluble cytokines and 
factors involved in angiogenesis in response to 5-THB. In addition, other in vivo 
models analysing angiogenesis in other contexts, such as wound healing, will have to 
be performed to gain a more comprehensive picture of the potential effects of 5-
THB on processes which are commonly disrupted by topically applied 
glucocorticoids, and are of clinical relevance. 
 
The in vitro experiments analysing the trans-activation properties of 5-THB also 
produced promising results, as the compound had very weak effects. More 
importantly, in the hepatic cell line BWTG3, 5-THB did not increase the abundance 
of transcripts of any of the genes analysed. Interestingly, it antagonised some of the 
responses induced by B, being effective at concentrations as low as 10 and 100 nM 
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for the metabolic gene Tat. This may have important functional and 
pathophysiological consequences since both compounds are found in abundance in 
the liver, a major site where some of the adverse metabolic effects of GCs are 
triggered. In order to explain this phenomenon, GR does not necessarily need to be 
involved, as another receptor, LXR has been shown to repress GR transcriptional 
activity when activated both in vivo and in vitro in hepatoma cells (Nader, Ng et al. 
2012). Indeed, whilst the experiments presented in the last chapter suggest the 
existence of an interaction between 5-THB and GR, this needs to be confirmed. As 
mentioned above and in section 7.1, other receptors are interesting candidates and 
could explain the behaviour and selectivity of 5-THB. One approach would be to 
perform chromatin immunoprecipitation analysis (ChIP), perhaps also combined 
with next-generation sequencing (ChIP-seq), in order to clarify if and to what extent 
the compound modifies the pattern of DNA sequences to which GR binds. However, 
these being expensive and elaborate methods, a good strategy may be to perform 
some preliminary experiments aimed to knock down GR in BWTG3 cells. 
More experiments are needed to complete the work presented in this thesis, and to 
definitely verify the hypotheses presented. However, it can be concluded that 5-
THB is a new, promising, more selective, topical anti-inflammatory agent; indeed I 
have shown that: a) it is an effective anti-inflammatory compound in vivo, b) it is a 
weak inhibitor of angiogenesis and c) it weakly activates pathways linked with the 
onset of side effects. 
 
I would like to conclude by highlighting one of the many things I have learnt from 
this work. I understood that the word “weaker” does not necessarily mean worse 
since, whatever causes this weakness, either the involvement of a different receptor 
than GR or a different interaction with GR itself, this characteristic may well be the 
reason behind 5-THB being an effective and safer compound. Most importantly, I 
am excited that this thesis has opened new directions of research that we did not 
expect, and that is the beauty of scientific enquiry. 
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